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ABSTRACT 
 
Molecular modelling techniques have been extensively applied to the elucidation of 
glycan-protein interactions at the atomic level of several systems with biological and 
therapeutic interests, and have provided new insights for the understanding of the 
molecular recognition events underlying the biological functions of these systems. In 
this Thesis, the general objective is to elucidate the carbohydrate-protein interactions at 
the atomic level through computational techniques. In particular, the following systems 
have been studied: human galectins -1, -3, and -7, Pisum sativum lectin, Maackia 
amurensis seed lectin, and glycosyltransferase GalNAc-T2. The final aim is to provide 
new insights for the understanding of the molecular recognition events underlying the 
biological functions of these proteins.  
 
Chapter 2: A pluridisciplinary approach, in a collaborative work with experimental 
groups, has been carried out for the study of carbohydrate-protein interaction. In 
particular, we seek the elucidation of the binding modes of a fluorinated trimannoside 
α1→3 and α1→6 linked and its fluorinated disaccharide derivatives with a model lectin 
from Pisum sativum, combining computational studies with 
19
F-NMR experimental data. 
This combined study has required the use of synthetic fluorinated complex glycan 
mimics to provide detailed structural and binding information for every sugar ring, 
allowing the elucidation of the interacting ligand epitope and the bound conformations, 
not available when using non-fluorinated sugars. Computational techniques have been 
proved to assist the 
19
F NMR experiments and to provide the necessary 3D perspective 
for the elucidation of this example of molecular recognition of high complexity. 
Specifically, the combination of the modelling and NMR experimental data indicates the 
co-existence of two different binding modes for the trifluorinated trimannoside when 
interacting with the plant lectin from Pisum sativum. This example accounts for the 
complementarity between these techniques for the elucidation of complex molecular 
recognition problems where experimental techniques cannot provide a full response. 
 
x 
 
Chapter 3: Computational study of the binding mode of several β-galactoside ligands 
(lactose, LacdiNAc, and three glycans containing the LacNAc motif: blood group A type 
II tetrasaccharide, and two compounds derived from the important xenoantigen α-Gal 
epitope) towards human galectin-3 has been carried out. These ligands contain the 
epitopes LacdiNAc and α-Gal, proposed as molecular patterns for galectin-3 mediated 
immune response. We seek the characterization of the key interactions required for the 
distinct recognition by galectin-3, pointing out to the subtle differences in the 
recognition event, by means of combined molecular modelling and NMR techniques. 
Using this combined approach, we here report the ligand-receptor interactions 
accounting for the gal-3 recognition of the important xenoantigen α-Gal epitope, 
showing the important role of gal-3 in the initial recognition and adhesion of human 
monocytes to porcine aortic endothelial cells which may contribute to delayed xenograft 
rejection. Our findings have unraveled important details at atomic level of the gal-3 
recognition. 
 
Chapter 4: Computational design of novel selective galectin binders with predicted 
improved affinity has been performed. In particular, we have focused our efforts in 
adhesion/growth-regulatory galectins -1, -3, and -7, whose functions have been shown to 
be correlated among them in several tumoral processes. Our computational studies have 
been focused on the pocket adjacent to the CRD as additional anchorage point, and have 
provided structural basis for a fragment-based design of novel galectin binders with 
predicted selectivity and high affinity. With this approach, we identified the appropriate 
fragments/moieties able to be anchored to this pocket. In collaboration with other 
groups, selected compounds have been synthesized and preliminary NMR and ITC 
results are very promising. These selective ligands may contribute to the understanding 
of the highly relevant biological functions of galectins, and their role in cancer.  
 
  
xi 
 
Chapter 5: A computational model for the interaction of the podoplanin (PDPN) epitope  
(Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc) and Maackia amurensis seed lectin 
(MASL) isoforms has accounted for the protective action of these lectins against 
cartilage degradation in osteoarthritis (OA). We explored the binding site of the two 
MASL isoforms, Maackia amurensis leukoagglutinin (MAL) and Maackia amurensis 
hemagglutinin (MAH), and the possible recognition by the epitope of the glycoprotein 
podoplanin. The ability of MASL to target sialylated glycoproteins such as PDPN, 
which is also induced during OA and rheumatoid arthritis, and to protect chondrocytes 
from insults leading to cartilage degradation might offer further possibilities for 
therapeutic interventions and novel arthritis treatments that may include the regulation of 
sialylation during acute disease stages. In particular, the docking of the tetrasaccharide 
(Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc) shows the preference of this ligand to bind 
the MAH isoform, due to the presence of disialyl-core and the specific Galβ1-3GalNAc 
glycosidic linkage. The experimental results indicate that MASL preserves the structure 
and function of cartilage under diverse arthritic insults by interfering with the function of 
-2,3-sialylated transmembrane receptors, such as the mucin-type transmembrane 
glycoprotein PDPN. Moreover, these findings suggest that MASL inhibits the activation 
of signal transduction pathways that lead to progressive cartilage destruction during the 
pathogenesis of arthritis by increasing reactive oxygen species, inflammatory cytokines, 
and metalloproteinases. We propose the direct interaction of MASL with PDPN as a 
plausible mechanism for this protective activity of the lectin, and our computational 
studies have provided a 3D molecular model for such interaction. 
 
  
xii 
 
Chapter 6: We have studied the binding mode of a series of synthetic nucleoside 
mimetics as inhibitors of a model glycosyltransferase, the GalNAc-T2. These less-polar 
nucleotide sugar analogues, derived from uridine only containing the -phosphate, could 
be efficient ligands for the enzyme, as deduced from the experimental data. We have 
proposed a computational 3D model for the binding mode of these ligands to provide 3D 
clues regarding the mechanism of the catalytic cycle of this family of enzymes. In 
particular, from the docking studies, it is inferred that the β-phosphate is required for 
binding to the Mn
+2
, and thus the replacing of the β-phosphate while keeping the 
phosphate or alike groups in the α position should maintain the binding of these 
compounds. The docking study suggests that the less polar uridyl-sugar analogues are 
putative GalNAc-T2 binders where the uridine moiety plays a major role in the binding 
in agreement with the crystallographic binding poses, while the phosphonate group and 
the sugar moiety provide additional interactions, not finding differences among the type 
of sugar. Additionally, the tMD simulation has given us an approximation to the binding 
pose changes that the UDP-GalNAc suffers in the closing/opening process when bound 
to the GT. The specific interactions for the GalNAc in the closing/opening process may 
be useful to understand the catalytic mechanism cycle of this enzyme, and to help for the 
designing of selective GT binders. In fact, we provide a plausible explanation for the 
role of the N-acetylamido group in the binding, which supports its higher affinity to the 
enzyme in comparison to UDP-Gal. 
 
Summarizing, molecular modelling techniques have been extensively applied to the 
elucidation of glycan-protein interactions at the atomic level of several systems with 
biological interest, and have provided new insights for the understanding of the 
molecular recognition events underlying the biological functions of these systems. 
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RESUMEN 
 
En esta Tesis Doctoral, se han empleado técnicas de modelado molecular para la 
elucidación a nivel atómico de las interacciones carbohidrato-proteína de varios sistemas 
con interés biológico y terapéutico. Estos estudios han permitido aportar nuevas 
perspectivas para la comprensión de los procesos de reconocimiento molecular 
implicados en las funciones biológicas de estos sistemas. En particular, se han estudiado 
los siguientes sistemas: galectinas humanas -1, -3 y -7, lectina de Pisum sativum, lectina 
de semillas de Maackia amurensis, y la glicosiltransferasa GalNAc-T2. El objetivo final 
es proporcionar nuevas perspectivas para la comprensión de los eventos de 
reconocimiento molecular que subyacen en las funciones biológicas de estas proteínas. 
 
Capítulo 2: Se ha llevado a cabo un estudio pluridisciplinar, en colaboración con grupos 
experimentales, abordándose el estudio de los modos de unión de una trimanosida 
trifluorada, con enlaces α1 → 3 y α1 → 6, y sus derivados disacáridos fluorados, con 
una lectina modelo de Pisum sativum, combinando los estudios computacionales con 
datos experimentales de 
19
F-RMN. Para llevar a cabo este estudio combinado, se han 
necesitado glicómiméticos fluorados sintéticos para la elucidación de detalles 
estructurales y detalles de la interacción de cada manosa fluorada con la proteína, 
identificando el epítopo y las conformaciones de unión. Este tipo de estudio no hubiera 
sido posible sin la presencia del flúor. Las técnicas computacionales han ayudado de 
forma importante a los experimentos de 
19
F-RMN, y han proporcionado la perspectiva 
3D necesaria para la elucidación de este ejemplo de reconocimiento molecular de gran 
complejidad. Específicamente, la combinación de los datos experimentales de modelado 
y los datos de RMN ha indicado la coexistencia de dos modos de unión diferentes para 
la trimanosida trifluorada cuando se une a la lectina de Pisum sativum. Este ejemplo 
ilustra la complementariedad entre estas dos técnicas para la elucidación de problemas 
complejos de reconocimiento molecular donde las técnicas experimentales no pueden 
proporcionar una respuesta completa. 
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Capítulo 3: Estudio computacional de la unión de varios ligandos de β-galactósido 
(lactosa, LacdiNAc y tres glicanos que contienen el motivo LacNAc: tetrasacárido del 
grupo sanguíneo A tipo II, y dos compuestos derivados del importante epítopo α-Gal de 
xenoantigeno) hacia la galectina-3 humana. Los epítopos LacdiNAc and α-Gal contienen 
el motivo LacNAc, que ha sido propuesto como patrón molecular para la respuesta 
inmune mediada por galectina-3. Se han caracterizado las interacciones clave necesarias 
para el reconocimiento distinto por la galectina-3, señalando las sutiles diferencias en el 
evento de reconocimiento, mediante técnicas combinadas de modelado molecular y 
RMN. Utilizando este enfoque combinado, aquí presentamos las interacciones ligando-
receptor que representan el reconocimiento gal-3 del epítopo importante de 
xenoantógeno α-Gal, mostrando el importante papel de gal-3 en el reconocimiento 
inicial y adhesión de monocitos humanos a endotelio aórtico porcino, que pueden 
contribuir al rechazo tardío del xenoinjerto. Nuestros estudios han aportado importantes 
detalles a nivel atómico del reconocimiento gal-3. 
 
Capítulo 4: Se ha realizado el diseño computacional de nuevos ligandos selectivos de 
galectinas con afinidad mejorada predicha. En particular, hemos centrado nuestros 
estudios en las galectinas -1, -3 y -7, involucradas en la adhesión, crecimiento y 
regulación celular.  Además se ha demostrado que las galectinas -1, -3 y -7 tienen 
diferentes papeles en varios procesos tumorales. Nuestros estudios computacionales se 
han dirigido al bolsillo de unión adyacente al dominio de reconocimiento de 
carbohidratos, y nos han proporcionado una base estructural para llevar a cabo un diseño 
basado en fragmentos de nuevos ligandos de galectina con selectividad y alta afinidad. 
Con esta aproximación, identificamos los mejores fragmentos capaces de anclarse a este 
bolsillo en cada una de las galectinas. En colaboración con otros grupos, se han 
sintetizado algunos compuestos seleccionados y los resultados preliminares de RMN e 
ITC son muy prometedores. Estos ligandos selectivos pueden contribuir a la 
comprensión de las funciones biológicas de las galectinas, altamente relevantes, y su 
papel en el cáncer. 
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Capítulo 5: Se ha propuesto un modelo computacional para la interacción del epítopo de 
podoplanina (PDPN) (Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc) con las isoformas de 
lectina de semilla de Maackia amurensis (MASL), explicando la acción protectora de 
estas lectinas en la degradación del cartílago en la osteoartritis (OA). Hemos explorado 
el sitio de unión de las dos especies moleculares de la MASL, la leucoaglutinina de 
Maackia amurensis (MAL) y la hemaglutinina de Maackia amurensis (MAH), y el 
posible reconocimiento por el epítopo de la glicoproteína podoplanina. La capacidad de 
MASL de unirse a glicoproteínas sialiladas como la podoplanina, que se inducen durante 
la osteoartritis y la artritis reumatoide, protege a los condrocitos de insultos que 
conducen a la degradación del cartílago. Este mecanismo puede suponer nuevas formas 
de intervención terapéutica y nuevos tratamientos para la artritis que incluyan la 
regulación de sialilación durante estadios agudos de la enfermedad. En particular, la 
unión del tetrasacárido (Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc) muestra la 
preferencia de este ligando para unirse a la isoforma de la MAH, debido a la presencia 
de dos unidades de acido siálico y a la presencia del enlace glucosídico específico 
Galβ1-3GalNAc. Los resultados experimentales indican que la MASL preserva la 
estructura y la función del cartílago bajo diversos insultos artríticos interfiriendo con la 
función de los receptores transmembrana α-2,3-sialilados, tales como la glicoproteína 
transmembrana podinaplanina de tipo mucina (PDPN). Por otra parte, estudios sugieren 
que MASL inhibe la activación de las vías de transducción de señales que conducen a la 
destrucción progresiva del cartílago durante la patogénesis de la artritis mediante el 
aumento de las especies de oxígeno reactivo (ROS), citoquinas inflamatorias y 
metaloproteinasas. Proponemos la interacción directa de MASL con PDPN como un 
mecanismo plausible para esta actividad protectora de la lectina, y nuestros estudios 
computacionales han proporcionado un modelo molecular 3D para dicha interacción. 
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Capítulo 6: Se ha estudiado el modo de unión de una serie de miméticos sintéticos de 
nucleósidos como inhibidores de una glicosiltransferasa (GT) modelo, la GalNAc-T2. 
Estos análogos de nucleótidos son compuestos menos polares derivados de la uridina que 
contiene sólo el β-fosfato y podrían ser ligandos eficaces para la inhibición de la enzima, 
como se deduce de los datos experimentales. Hemos propuesto un modelo 3D 
computacional para el modo de unión de estos ligandos para proporcionar más 
información sobre el mecanismo del ciclo catalítico de esta familia de enzimas. En 
particular, a partir de los estudios de modelado molecular se deduce que el β-fosfato no 
es necesario para la unión al Mn
+2
, y por lo tanto la sustitución del α-fosfato, 
manteniendo el fosfato o grupos similares en la posición β, debe mantener la unión de 
estos compuestos. Los estudios de docking sugieren que los análogos menos polares del 
azúcar uridilo son posibles ligandos de GalNAc-T2, donde la parte de la uridina 
desempeña un papel principal en el enlace, de acuerdo además con los modos de unión 
observados en las estructuras cristalográficas. El grupo fosfonato y el azúcar establecen 
interacciones adicionales, no encontrándose diferencias al estudiar otros tipos de azúcar. 
Además, la simulación de tMD nos ha dado ha permitido estudiar los cambios en la pose 
de unión a la GT que el UDP-GalNAc sufre en el proceso de cierre/apertura. Las 
interacciones específicas de GalNAc en este proceso de cierre/apertura pueden ser útiles 
entender el ciclo del mecanismo catalítico de esta enzima y para el diseño de ligandos 
selectivos de GT. De hecho, nos han proporcionado una explicación plausible para el 
papel del grupo N-acetilamido en el enlace, que apoya su mayor afinidad a la enzima en 
comparación con la UDP-Gal. 
 
Resumiendo, se han empleado técnicas de modelado molecular a la elucidación a nivel 
atómico de las interacciones glicano-proteína de varios sistemas con interés biológico. 
Estos estudios han proporcionado nuevos conocimientos para la comprensión de eventos 
de reconocimiento molecular subyacentes a las funciones biológicas de estos sistemas. 
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CHAPTER 1 
 
INTRODUCTION 
 
In biological systems, cells communicate each other and transmit signals to other 
cells through mediators of different chemical nature. During the years, the most studied 
molecules were the nucleic acids and proteins. However, this view has changed and also 
lipids and carbohydrates have been included in this scenario.
1
 Carbohydrates (named 
also sugars or saccharides) are the most abundant biomolecules in nature and they are 
often conjugated with proteins (glycoproteins) or lipids (glycolipids). These molecules 
play different roles in the cells, and for this reason recent studies are focused on 
carbohydrates as selective mediator in the molecular recognition processes. They are 
involved in physiological and pathological events and in a variety of intra- and extra-
cellular events. In most of the cases, the initial contacts of saccharides with cells take 
place at cell-cell and cell-matrix level.
2
 An important and rather complex process is the 
glycosilation. The glycosilation, the enzymatic process that links glycans with proteins 
or lipids, is usually rather heterogeneous and it strictly depends on the activity and/or 
availability of specific enzymes, such as glycosyl transferases and glycosyl hydrolases 
(glycosidases). Modifications on the regular cell glycosylation pattern are often observed 
during pathological conditions, for example in inflammation and cancer development. 
Therefore, glycans have become a topic of major interest to develop diagnostic tools or 
therapeutic drugs.
3
 To date, several sugar-based drugs have already been developed and 
currently employed as therapeutics, diagnostics, and vaccines and many more are 
expected to come in the next few years.  
  
CHAPTER 1 
2 
 
1.1 Carbohydrates 
As mentioned above, carbohydrates are very abundant in nature and they play 
numerous biological roles. They are the fundamental source of metabolic energy, in fact 
they represent an important element in our diet; some insoluble carbohydrate polymers 
serve to lubricate skeletal joints and provide adhesion between cells and others serve as 
structural and protective elements in the cell walls of bacteria and plants and in the 
connective tissues and cell coats of animals. Sugars can exist in nature as single entities 
or as a forming part of glycoconjugates, essentially glycolipids and glycoproteins. 
Chemically, carbohydrates are polyhydroxy aldehydes or ketones, and their chemical 
formula is usually Cn(H2O)n (carbon “hydrates”), but some “natural” carbohydrates can 
also contain nitrogen, phosphorus, sulphur. Their chemical variability is enormous, due 
to the possibilities of branching at either hydroxyl group as well as the possible presence 
of pendant substituents, either neutral or charged.
1, 4
 In turn, this variability generates a 
huge possibility of constitutional isomers and a plethora of conformations. Moreover, 
their chemical properties in terms of the presence of polar and non-polar patches make 
them to exhibit peculiar stability and, acting as ligands for receptors, to be fairly 
adaptable to a variety of environments. They may adopt different shapes and display 
rather distinct conformational and dynamic properties. Glycan diversity depends on the 
monosaccharides (basic unit of saccharide) which are made by, on the linkages that 
connect monosaccharides (glycosidic linkage), and on other factors such as the anomeric 
effects, the orientation of all the torsional angles,
5-6
 and the intramolecular hydrogen 
bonding between adjacent OH groups.
7
 Therefore, it is of paramount importance to 
predict and characterize their conformational and structural properties in a systematic 
manner. Computational techniques have proven to be essential in this aspect.
8
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1.1.1 Monosaccharides 
Carbohydrates are made by small constituents, named monosaccharides (or 
simply sugars). Monosaccharides are composed of a single polyhydroxy aldehyde or 
ketone unit and may have different number of carbons normally from five to nine. The 
most abundant monosaccharide in nature is D-glucose. Usually the carbons of a 
monosaccharide have hydroxyl groups attached and they are normally stereogenic 
centres.  
Monosaccharides of six carbons (pyranose) usually adopt chair conformations 
and the substituents can be found either in the axial or equatorial position. In pyranose 
sugars, if there is a hydroxyl group at the anomeric carbon (the hemiacetal/acetal 
carbon) the monosaccharide could assume α or β configuration (Figure 1.1-right). α and 
β Isomers are both optically active and usually present similar physical properties. If the 
substituent on the anomeric carbon is electronegative (like a methoxy group) there is a 
preference of the substituent to adopt an axial configuration rather than an equatorial 
one. This phenomenon is called anomeric effect that is contrasted by steric factors, 
reason why D-sugars present more stability as α isomer (Figure 1.1-left). If the hydroxyl 
group is attached to a different carbon from the anomeric one the effect of the different 
position leads to a different monosaccharide (epimer) with completely different 
properties. For example, glucose and mannose differ on the position of the OH group in 
position 2 (in equatorial position in glucose and in axial in mannose) and glucose and 
galactose on the OH of position 4 (in equatorial position in glucose and in axial in 
galactose) (Figure 1.1-left).  
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Figure 1.1. Left: α and β configuration of glucose and epimers of the β-glucose 
on C2 (mannose) and C4 (galactose). Right: anomeric effect is shown. The presence of a 
methoxy group on the anomeric carbon determines the preference of the axial position 
(α). 
Moreover, simple monosaccharides may adopt distinct three-dimensional shapes. 
The most common shape for a pyranose is the chair conformation that minimizes steric 
congestion and includes the anomeric effect. However, also other shapes are allowed, 
depending on the orientation, nature and number of substituents. The most prevalent 
alternative shapes for a pyranose are the boat, the skew and the envelope (Figure 1.2). 
  
 
Figure 1.2. Conformational shapes of the monosaccharide β-D-glucopyranose.  
Top: regular chair conformations. Bottom: other prevalent conformers. 
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Regarding the conformation of the dihedral angle (ω) around C5-C6 in a 
pyranose ring (ω formed by O5C5C6O6, see Figure 1.1), a combination of solvation, 
steric, and stereoelectronic (gauche effect) effects drive the observed geometries. It has 
been monitored that for glucose-type sugars, a combination of gauche-gauche (gg) and 
gauche-trans (gt) rotamers coexists, while for galactose-type, ω prefers gauche-trans 
(gt) and trans-gauche (tg) geometries. This experimental behaviour has also been 
validated using computational protocols (Figure 1.3).
9
 
   
 
Figure 1.3. Possible conformation of ω (O5C5C6O6) in α-glucose. 
1.1.2 Disaccharides  
Monosaccharides are attached among them through glycosidic linkage. The 
anomeric oxygen of one particular monosaccharide is attached to a secondary (or 
primary) hydroxyl group of a second sugar moiety to build one disaccharide. The 
glycosidic linkage is an acetal linkage with particular chemical properties (sensitive to 
strong acid and basic conditions) and conformational features.  
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If the substituent at the anomeric carbon shows lone pair electrons, as an alkoxy 
group, retrodonation can proceed from the exocyclic oxygen to the sigma anti-bonding 
orbital of the intracyclic bond C-O. This is known as the exo-anomeric effect. In this 
case, the lone-pair orbital has to be anti-periplanar to the antibonding orbital of C-O, and 
consequently the alkyl substituent at the glycosidic oxygen adopts a syn-type orientation. 
This molecular orbital theory is able to predict also the modification of the bond length. 
In fact, for equatorially substituted pyranosides, the intracyclic C-O bond is longer than 
the exocyclic C-O bond (Figure 1.4).  
 
Figure 1.4. Representation of the anomeric effect and the exo-anomeric effect. 
Actually, these preferences lead to a syn-type conformation, although it has been 
observed that a minor proportion of anti- conformation may co-exist in β-glycosides 
(e.g. in 1→2, 1→3 and 1→4 linkages) provided that the contiguous OH-2 displays an 
equatorial orientation (i.e., glucose or galactose). The anti-type geometry is also 
favoured by the exo-anomeric effect. Combined modelling/Nuclear Magnetic Resonance 
(NMR) approaches are mandatory to characterize the glycosidic linkage of a particular 
disaccharide or oligo-saccharide (either α and β, either 1→2, 1→3, 1→4, or 1→6).9-10 
All the particular features mentioned above for saccharides, besides their intrinsic 
dynamic properties require the synergy combination of rigorous experimental and 
theoretical protocols.
11
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1.1.3 Oligosaccharides, polysaccharides and others 
Oligosaccharides are composed of a small number of monosaccharides. Their 
conformational properties, adaptability and recognition features have been, and still are, 
deeply analysed.
12
 Chemical methods have been employed to provide stable chemical 
analogues of oligosaccharides, with increased resistance to glycosyl hydrolases. 
Typically, either the glycosidic (inter-unit) or the endocyclic oxygen within the ring is 
substituted by other chemical element. Therefore, C-,
13
 S-,
14
 Se-,
15
 and N-
16
 glycosyl 
analogues have been synthesized to provide chemical probes for interaction studies or to 
prepare enzyme inhibitors. Given the different chemical properties of these analogues, 
their conformational properties have been carefully analysed and compared to those of 
their parent O-glycosides.
17
 Computational studies have been directed towards the 
analysis of the flexibility of these new linked glycosides, and the preferences of the 
binding proteins to select the proper “binding pose” from the conformational assemble, 
not always being the most stable conformer in terms of potential energy.
18-21
  
1.1.4 Glycoproteins and glycolipids 
In glycoproteins, oligosaccharides are present as N-glycans attached to an 
asparagine of the protein or as O-glycans attached to a threonine or a serine. The 
different substitution patterns make them to be named as displaying antennas. In fact, 
depending of the degree of branched substituents, they are bi-antennary, tri-antennary 
and even tetra-antennary. The different substitutions provide these molecules with 
different conformational and dynamic features,
22
 which can be exploited for recognition. 
Additional core substitutions at certain positions might modify the dynamics of the 
different arms in a rather dramatic way. These aspects have been addressed in 
computational studies of N-glycans
22-23
 in parallel with novel NMR methods to deduce 
their conformational behaviour.
24-27
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Glycolipids are amphiphilic molecules composed by a polar sugar part attached 
to lipophilic lipid chains. They display rather distinct structural and conformational 
properties. In this regard, the conformational properties of different lipooligosaccharides 
(LOS) and lipopolysaccharides (LPS) from different sources can be accessed by 
modelling protocols, in combination with NMR methods.
28-29
 For example, nodulation 
(Nod) factors are lipochitooligosaccharides incorporing N-acetylglucosamines that 
mediate the recognition between Rhizobium bacteria and their legume symbionts. 
Further modifications, such as methylations, sulfations, and fatty acids, account for the 
specific recognition between the interacting partners. The structure of Nod factors and 
their recognition properties by receptors have been exhaustively modelled in silico.
14, 30-
31
  
Among the class of polysaccharides the most known are the glycosaminoglycans 
(GAGs). They are widely spread in nature and they encompass a variety of sulphated 
saccharides. GAGs are involved in several molecular recognition and signalling events. 
The relevancy of GAGs is owed to their recognition by different receptors, triggering a 
plethora of biological responses, including inflammation, cell adhesion, and regulation 
of cell growth and proliferation.
32-33
 They are composed of different monosaccharide 
residues, either positively (rarely) or negatively charged (sulfate or carboxyl groups) or 
neutral and aminosugars, frequently acylated. Within this extensive family, heparin and 
heparan sulfate have been employed as therapeutic agents. Heparin and heparin sulfate 
are linear polysaccharides consisting of a glucuronic or iduronic acid, fragment that is 
1→4 linked to a glucosamine moiety.34 The structure of these molecules has been 
extensively studied using a variety of experimental (preeminently in the shape of NMR 
restraints) and modelling methods.
35-36
 Special mention should be given to the “heparin 
pentasaccharide” one of the carbohydrate-based drugs in clinic, used as anti-thrombotic 
agent.
37-38
 The study of the conformational properties of this molecule is one 
paradigmatic example of the employment of computational methods and NMR, both in 
its free and bound state to a variety of receptors.  
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As a token, the application of both protein- and ligand-detected NMR methods, 
assisted by computational protocols have allowed for the assessment of the binding 
mode of the heparin pentasaccharide and related GAGs to fibroblast growth factors,
39
 as 
well as the conformation of the GAGs in the bound state.
40
 These studies permitted to 
identify the bioactive structure of the complex, and to reveal a receptor-driven 
conformational selection of particular iduronic acid ring puckers. Also plant 
polysaccharides have many possible geometries, shapes and therefore, physical and 
chemical properties. Many of them have been extensively studied, such as pectins, 
which contain L-rhamnose and arabinose and have complex branched structures,
41-42
 and 
others, such as chitin (GlcNAcβ1-4GlcNAc)n, which display a linear shape.
43
 
1.1.5 Glycans in medicinal chemistry 
Several carbohydrate-based drugs are currently being used to treat several 
diseases, the most illustrative examples are antibiotics and antivirals.
44
 For decades, 
aminoglycosides, inhibitors of bacterial protein synthesis, have been used as antibiotic 
especially for infections by aerobic Gram-negative bacteria.
45
 Streptomycin (Figure 1.5) 
was the first to be discovered and it was used for the treatment of tuberculosis.
46
 
Chemically, it contains an aminocyclitol moiety that is linked to a carbohydrate 
skeleton. Other chemically related molecules have been discovered/synthesized, among 
them framycetin, employed for the treatment of ophthalmic infections, paromomycin 
used for the treatment of acute and chronic intestinal amebiasis, kanamycin and its 
derivative amikacin, for short-term treatment of serious infections, gentamicin,
47
 
tobramycin, specially indicated for Pseudomonas aeruginosa lung infections, septicemia 
or used in combination with other antibiotics and/or anti-inflammatory glucocorticoids 
for the treatment of different Pseudomonas spp., ophthalmic, and respiratory infections, 
including those associated with cystic fibrosis (Figure 1.5).  
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Streptomycin Framycetin 
  
 
 R1 R2 
Kanamycin A NH2 OH 
Kanamycin B NH2 NH2 
Kanamycin C OH NH2 
Amikacin 
 
 
 
 
 
 
 
 R1 R2 
Gentamicin C1 CH3 CH3 
Gentamicin C2 CH3 H 
Gentamicin C1a H H 
Tobramycin 
 
 
 
 
 
Figure 1.5. Chemical structure of several aminoglycosides. 
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Also lincosamides contain a sugar moiety (1-thio-D-erythro-α-D-
galactopyranoside). They are also inhibitors of protein synthesis of bacteria, binding to 
the 50S ribosomal subunit of the bacteria. The first lincosamide to be discovered was 
lincomycin (Figure 1.6), isolated from Streptomyces lincolnensis, but it was afterward 
replaced by its semisynthetic derivative, clindamycin (Figure 1.6). Clindamycin 
improved lincomycin side effect profile and gave the possibility of topical or systemic 
treatments. It is effective for the treatment of serious infections caused by susceptible 
anaerobic bacteria as well as in poly-microbic infections such as intra-abdominal or 
pelvic infections, respiratory infections, vaginosis, and topically to treat acne.
48
  
 
  
Lincomycin Clindamycin 
Figure 1.6. Chemical structure of several lincosamides. 
Although the chemical diversity, also macrolides contain one or more deoxy 
sugars, usually cladinose and desosamine, attached to a large macrocyclic lactone ring. 
These antibiotics also interfere with the proper translocation of the aminoacyl t-RNAs, 
thus inhibiting the bacterial synthesis of the protein by interfering with the proper 
translocation of the aminoacyl t-RNAs. Erythromycin, and its semi-synthetic derivatives 
dirithromycin, clarithromycin, and azithromycin, belong to this class of antibiotics 
(Figure 1.7). They possess a wide spectrum of activity including many Gram-positive 
and Gram-negative aerobic bacteria, and they are used to treat infections of the 
respiratory system.
49
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Erythromycin Dirithromycin 
 
 
Clarithromycin Azithromycin 
Figure 1.7. Chemical structure of several macrolides. 
There also are glycan-based antifungal agents, like amphotericin B (Figure 1.8), 
used for the treatment of systemic mycosis. Amphotericin B is an amphipathic molecule: 
the hydrophobic macrolide is connected with a hydrophilic sugar portion (3-amino-3,6-
dideoxy-β-D-mannopyranose). It binds ergosterol in the fungus cell membrane, creating 
a transmembrane channel. Due to the important alterations in the cell permeability, the 
fungal cell dies.
50-51
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Figure 1.8. Chemical structure of amphotericin B. 
The glycans also form part of the glycoproteins present on the viral surface and 
they are produced by the regular glycosylation machinery of the host cell, and thus 
trigger the immune system tolerance of the host. Human Immunodeficiency Virus (HIV) 
generally infects CD4+ cells employing a molecular mechanism in which the viral 
envelope gp120 glycoprotein interacts with a particular receptor (CD4) and a co-receptor 
(CXCR4 or CR5) located on the host cells. Then, the subsequent insertion of the viral 
envelope gp41 glycoprotein into the cell membrane causes the fusion and the entry of 
the virus.
52
 Different approaches have been proposed to combat HIV.  
Within the field of glycan-based drugs the discovery of a series of glycan-
dependent broadly neutralizing antibodies (bNAbs) from HIV-infected individuals laid 
the foundations for designing better antigens for innovative HIV vaccines. In particular, 
the so called 2G12 monoclonal antibody (mAb) exquisitely recognizes a conserved and 
unusual dense cluster of oligomannose residues formed by terminal α-D-Manp-(1→2)-
Man residues on the envelope glycoprotein gp120. Another approach could be the 
competition with the corresponding glycoproteins and antibodies,
53
 using a variety of 
natural and glycomimetic ligands.  
For instance, a family of small-size non peptide molecules, dubbed as 
carbohydrate-binding agents (CBAs), have been devised to target the highly 
mannosylated gp120 glycoprotein of the HIV envelope. These molecules have shown 
potent antiviral activities via interfering the interaction between this protein and 
CD4+.
54-55
 Among CBAs, pradimicin A, a non-peptidic antibiotic, as well as its more 
soluble analogue, pradimicin S, also block the virus entry by inhibiting the fusion of the 
HIV virions with their target cells (Figure 1.9).
56-57
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Pradimicin A Pradimicin S 
Figure 1.9. Chemical structure of several carbohydrate-binding agents. 
The knowledge of the capsular polysaccharides (CPS),
58
 exposed antigens on 
bacteria surfaces, has allowed to develop glycan-based vaccine.
59-60
 However, vaccines 
formulated exclusively with saccharides have regularly presented some limitations, such 
as the duration of the protection effect (one or two years), due to the absence of memory 
stimulating effects.
61-63
 In fact, polysaccharides are able to stimulate specifically B cells, 
without the active participation of helper T-cell, and for this reason they are considered 
T-cell independent type 2 (TI-2) antigens. This fact precludes the existence of a 
significant immunity memory stimulation.
64-65
  
Also cancer is not strange to glycans and aberrant glycosylation patterns either.
66
 
Abnormal protein/lipid glycosylation is diagnostic and a proper biomarker for a number 
of diseases. Recently, several glycosyl processing enzymes have been recognized as 
important targets for therapeutic intervention, leading to the design and development of 
distinct relevant classes of drugs.
67
 In the early stages of cancer, there is an incomplete 
synthesis process of the complex glycans normally expressed in healthy epithelial cells. 
This event provides the biosynthesis of truncated structures, as sialyl Tn antigen (STn) 
expression in gastrointestinal and breast cancers.
68-69
 On the other hand, in advanced 
stages of cancer, a neo-synthesis and expression of peculiar antigens take place, due to 
the cancer-associated induction of certain genes that control the expression of the 
carbohydrates.  
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This is, for instance, the case for the presence of sialyl Lewis a (SLea) and x 
(SLex) in many cancers.
70
 In order to address a wide variety of tumours, different 
vaccines have been designed, aiming to target these different carbohydrate antigens, 
such as Globo-H, GM2, STn, TF, and Tn, on a particular peptide backbone. These 
molecules are then conjugated to a carrier protein, as the keyhole limpet hemocyanin 
(KLH) or the diphtheria toxin mutant (CRM197).
71
 Also an overexpression of mucin 
glycoproteins, abnormal branching of N- and O-glycans, as well as significant 
modification of the fucosylation and sialylation levels have been identified.
72-74
 For this 
reason, Tumour-Associated Carbohydrate Antigens (TACAs), such as the mucin-related 
epitopes, have been proposed as key targets for the development of anti-tumour 
vaccines.
67
 To date, different TACAs-targeted vaccines are already in preclinical and 
early clinical settings,
75
 such as VAXIL.
76
 There are also anti-neoplasic drugs with a 
saccharide in their structure. For example, etoposide (Figure 1.10), a semi-synthetic β-D-
glucopyranoside derivative of podophyllotoxin, inhibits DNA synthesis by forming a 
complex with topoisomerase II and DNA.
77
 Another example is pentostatin (Figure 
1.10), an inhibitor of adenosine deaminase and ribonucleotide reductase, particularly 
active for the treatment of lymphoproliferative malignancies.
78
 
 
 
Etoposide Pentostatin 
Figure 1.10. Chemical structure of several antineoplastic drugs. 
As mentioned above, malignancy is often related to glycosylation changes, and 
these variations can be used as cancer diagnosis and prognosis. 
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 In fact, different antigens are used as diagnostic tools, such as the Carcino-
Embryonic Antigen (CEA) in the colorectal cancer,
79
 MUC16 (CA125) for the detection 
of ovarian tumor,
80-81
 the prostate-specific antigen
82
 for the prostate tumours, and the 
carbohydrate antigen 19-9 (CA19-9) for pancreatic, colorectal, gastric or biliary 
cancer.
83-84
 
Glycans are also related to metabolic drugs. The metabolic syndrome (MetS) is 
associated with a variety of interconnected physiological, biochemical, clinical, and 
metabolic factors that directly increase the risk of a pro-inflammatory state that could 
end up into a chronic condition. The most known diseases associated to the MetS are 
atherosclerosis, cardiovascular disease, and type 2 diabetes mellitus. Since a wide 
variety of factors could cause the MetS, there are many treatments addressing the 
dysfunctions associated to the MetS.
85
 Inhibitors of -glucosidase have been extensively 
used to prevent the presence of high glucose concentrations in blood after food 
ingestion.
86-87
 -glucosidase is an enzyme present in the brush border of the small 
intestines, hydrolyzing oligosaccharides into glucose and other monosaccharides in the 
postprandial state. High glucose levels lead to the activation of kinases causing 
endothelial disfunction,
88
 with cardiovascular effects. To prevent these events, some of 
the most used drugs are α-glucosidase inhibitors,67 which have also been demonstrated 
to be useful in patients with diabetes mellitus type 1.
89-90
 Among them, acarbose (Figure 
1.11) is a synthetic tetrasaccharide glycomimetic, displaying one carbamino sugar 
moiety. This molecule has diverse activities, since not only inhibits membrane-bound α-
glucosidases, but also blocks pancreatic α-amylase.91 Acarbose is orally administered to 
non-insulin dependent diabetes mellitus patients, whenever diet modifications or oral 
hypoglycemic agents are not able to control their condition. In the context, voglibose 
(Figure 1.11), also a glycomimetic displaying one carbamino sugar fragment, is 
frequently used for the treatment of type II diabetes.
92
 A variety of sugar mimics, 
including iminosugars and piperidine-containing saccharide mimetics, also inhibit 
various glycosidases in a reversible and competitive manner. In fact, there are mimics of 
the ground state conformation of the natural sugars, as a consequence because of their 
structural resemblance to the terminal saccharide moiety of the natural neutral 
substrates.  
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Acarbose Voglibose 
Figure 1.11. Chemical structure of several α-amilase inhibitors. 
A large number of iminosugars have been discovered from plants and 
microorganisms.
93-95
 For example, miglitol (Figure 1.12), an analogue of 1-
deoxynojirimycin, is used for the treatment of type II diabetes. Iminosugars are also 
employed in the treatment of lysosomal storage disorders (LSDs), rare diseases with 
terrible consequences for normal life. Among them, the most important drug is miglustat 
(Figure 1.12), which is used for the treatment of Gaucher’s disease. In this disease, the 
normal activity of the ceramide glucosyltransferase is altered, leading to the 
accumulation of glucosylceramide. This glycolipid causes the enlargement of the liver 
and the spleen, changes in the bone marrow and blood, and bone disease.
96
 Miglustat has 
also been approved for the treatment of progressive neurological complications in 
patients with Niemann–Pick disease type C, another LSD characterized by the 
progressive accumulation of cholesterol in the lysosomes. Different basic research 
studies have permitted to disentangle the mechanism of action of these inhibitors. In 
particular, they are able to resemble the cationic hydrolase transition state in glycoside 
hydrolysis.
97
 This knowledge can be exploited to develop new strategies based on 
molecular design coupled to the development of efficient screening protocols for the 
identification of novel chemical entities. The final aim would be to develop more 
selective inhibitors with minimized side effects versus the currently employed drugs.
98
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Miglitol Miglustat 
Figure 1.12. Chemical structure of several iminosugars. 
Nowadays, glycoproteins are also well introduced in the drug market as 
therapeutics. Recombinant expression of the glycoproteins may lead to isoforms with 
null or incomplete glycosylation patterns, which may modify their therapeutical 
properties. Since the efficacy of biopharmaceuticals proteins critically depends on their 
specific glycoforms, different synthetic, bioengineering, chemoenzymatic, and chemical 
biology-mixed strategies have been applied for the production of improved therapeutic 
glycoproteins. One of the most representative cases is the erythropoietin (EPO), a 
blockbuster anti-anemia drug. This hormone regulates the production of red blood cells, 
other human hormones, interferon-β, interleukin-6, and glycan-containing monoclonal 
antibodies.
99
 Recombinant EPO can be safely discriminated from endogenous EPO due 
to the glycosylation pattern characteristic of mammalian cells. Nevertheless, the current 
success in the synthesis of glycosylated EPO poses a challenge for the discrimination of 
the endogeneous and the exogenous hormone. 
Also glycolipids are very abundant in nature especially on the surface of Gram-
negative bacteria (i.e., lipopolysaccharides, LPS, and lipooligosaccharides, LOS). In 
particular, LPS (Figure 1.13) are responsible for acute sepsis and septic shock,
100
 and its 
chemical structure has served as inspiration for rational drug design studies. The LPS 
structure comprises a lipid A moiety, which contains a β-1→6 linked disaccharide of N-
acetylglucosamine linked by either ester or amide bonds to five or six hydroxylated fatty 
acids (FA), plus a polysaccharidic core.
101-103
 The toxic action of LPS is due to a 
complex cascade of extracellular protein-LPS and protein-protein interactions, leading 
finally to the activation of the membrane-bound Toll-like receptor 4 (TLR4),
104
 with the 
subsequent intracellular signalling process, and the synthesis of pro-inflammatory 
cytokines.  
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TLR4 activation requires the participation of the myeloid differentiation factor 2 
(MD-2), and the dimerization of two TLR4/MD-2 single complexes. LPSs are able to 
bind this TLR4/MD-2 system, in the so-called antagonist conformation, by inserting the 
FA chains into the lipophilic pocket of MD-2. The global 3D geometry is also stabilized 
by the establishment of polar interactions with both TLR4 partners.
105
 
 
 
Figure 1.13. Representation of the X-ray crystallographic structure of 
TLR4/MD-2 in complex with Escherichia coli LPS (PDB ID 3FXI). On the right (top), 
detail of the X-ray crystallographic structure of MD-2 in complex with eritoran 
extracted from PDB ID 2Z65. On the right (bottom), the chemical structure of eritoran 
is depicted. 
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1.2 Carbohydrate-protein interaction 
Proteins that bind carbohydrates are called GBPs (Glycan Binding Protein) and 
in this group lectins, receptors, toxins, microbial adhesins, antibodies and enzymes, 
among others
106
 are included. In the framework of cellular recognition, non-enzymatic 
proteins are the most important proteins that bind carbohydrates without drastic 
conformational changes. Between them, lectins are widely distributed in nature since 
they can be found in almost all living organisms. The recognition process between a 
lectin and a carbohydrate usually occurs through: 
 Hydrophobic interactions, such as CH-π interaction (between the sugar 
moiety and residues such as tryptophan, tyrosine and phenylalanine). 
 A net of hydrogen bonds between the OH group of the sugar and the 
polar group of the protein. Frequently a water molecule is also involved 
in this net.  
 Metal coordination (usually with calcium or manganese) present in the 
binding site of the lectins.  
These characteristic interactions occur in a specific region of the protein 
normally named Carbohydrate Recognition Domain (CRD). Unconventional sugars 
binding sites have been observed, as for the C-type lectin-like receptor 2 (CLEC-2).
107
 
The specificity of a lectin to recognize selectively some epitopes is due to the diversity 
of the CRD. Actually lectins have been classified based on their CRD, the sugar 
specificity and their expression patterns. In particular, human lectins are divided into 
two classes: C-type (or calcium-dependent) lectins and S-type (sulfhydryl-dependent or 
calcium-independent) lectins. Their main functions are the cellular recognition, cellular 
adhesion regulation, as well as immunological functions such as recognition of sugars 
from pathogen organisms (Figure 1.14).
108
 Lectins also play an essential role in the 
infection process. One of the most studied players in this event is the Dendritic-Cell 
Specific ICAM-3 Grabbing Nonintegrin (DC-SIGN). DC-SIGN is a C-type lectin that 
has been demonstrated to spread and evade the immune system by the HIV virus. 
Fittingly, this lectin seems to be involved in several infections by pathogens, such as 
Ebola virus and Mycobacterium tuberculosis.
46, 109
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Figure 1.14. Schematic representation of the main function of glycans (figure 
from reference 110). 
Plant lectins are accumulated in seeds or other tissues and mainly have a storage 
function but also they seem to play an important role in plant defence. Twelve families 
of lectins have been identified, although they commonly share some features. Plant 
lectins are usually found as dimers or tetramers, in which each monomer has a CRD 
with two metal binding sites for calcium and manganese. In the dimer there is a side-side 
protein-protein interaction forming 12-strandeed sheet. Plant lectins are very interesting 
because due to their easy availability are extensively used as spy molecules due to their 
high glycans specificity. For example, it is very well known that Pea lectin and 
Concanavalin A selectively bind mannose or glucose, while Maackia amurensis lectins 
bind sialic acids. To date, more than 132 crystal structures of legume lectins have from 
18 different plants are available from the Protein Data Bank.
111
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1.2.1 Pea Lectin 
Pisum sativum lectin (also named Pea lectin) is a dimeric protein 
mannose/glucose specific with agglutinating activity.
112
 To date, there are five 3D 
structures of Pea lectin in complex with glucose, mannose and sucrose available at the 
PDB ( Table 1.1). In chemical glycobiology, Pea lectin is usually used as a model lectin 
for the study of carbohydrate-protein interactions, especially in the case of studying 
mannose or glucose-based glycomimetics.
113
 
 Table 1.1. Pea lectin X-ray crystallographic structures available at the PDB. 
PDB ID Resolution (Å) Ligand 
1OFS 1.86 sucrose (α-D-glucopyranosyl-1-2-β-D-fructofuranoside) 
1HKD 2.09 α-methyl-D-glucopyranoside 
2BQP
114
 1.9 α/β D-glucopyranoside 
1BQP
115
 2.1 α/β D-mannopyranose 
1RIN
116
 2.6 trimannose 
 
In the carbohydrate binding site, manganese and calcium ions are present. The 
specificity for mannose and glucose is due to the fact that the hydroxyl group present in 
the position 2 either in axial or in equatorial position of each sugar is not involved in any 
interaction (Figure 1.15).
116
  
  
Figure 1.15. Left: X-ray crystallographic structure (PDB ID 1RIN) of the Pea 
lectin (cyan) in complex with the mannoside (magenta). Magnesium (purple) and 
calcium (green) are shown as spheres. Right: Details of the carbohydrate recognition 
domain. Aminoacids involved in the binding are depicted (shown in sticks). 
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1.2.2 Galectins 
A special type of lectins evolutionary-conserved
117
 is galectins (abbreviation of 
galactose binding lectins). Galectins constitute a family of β-D-galactoside binding 
proteins. They are localized in cytoplasm, nucleus, cell surface, and extracellular 
matrix,
118-119
 and present a S-type sequence motif. To date 15 members of this family 
have been identified in mammals (gal-1 to -15), but only 10 of them are present in 
humans (gal-1, -2, -3, -4, -7, -8, -9, -10, -12, -13).
120
 They are soluble proteins with a 
molecular weight around 14-36 kDa
121
 and they lack of enzymatic activity.
6
 Among the 
physiological processes in which galectins have an important role, there are regulation of 
the immune response, cell cycle, cell growth and apoptosis.
122-127
 Due to these functions, 
an alteration in these proteins can trigger various pathological processes, depending on 
which galectin is affected. Thus, it has been demonstrated that galectins are involved in 
processes like cancer, metastasis, inflammation, hypersensitivity and atherosclerosis, 
among other pathologies.
128-137
 Therefore, in the last years the interest in these proteins 
as therapeutic targets has increased since the development of selective galectins 
modulators could improve the prognosis of many diseases.
138-142
  
Based on the structural features, mammalian galectins have been classified in 
proto, tandem-repeat, and chimera types (Figure 1.16). Proto-type galectins (gal-1, -2, 
-5, -7, -10, -11, -13, -14, and -15) are usually dimers containing only one type of CRD 
(homodimers) non-covalently joined. Tandem-repeat-type galectins (gal-4, -6, -8, -9, 
and -12) have two different CRDs, almost homologous, that are covalently joined. 
Chimera-type galectin (only gal-3) has a carboxyl-terminal CRD associated to an amino-
terminal peptide which is rich in tyrosine, proline and glycine (collagen-like 
sequence),
143
 forming a tail that intervenes in the oligomerization of this unique 
galectin.
144
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Proto 
Two identical CRDs 
Tandem-repeat 
Two different CRDs 
Chimera 
One CRD and one  
non-lectin domain 
Galectin-1, -2, -5, -7, -10,  
-11, -13, -14 and -15 
Galectin-4, -6, -8, -9 and -
12 
Galectin-3 
Figure 1.16. Classification of galectins depending on their CRD. 
The activity of galectins is ligand-concentration dependent and it can be both 
stimulatory and inhibitory.
145
 These proteins recognize carbohydrates through the CRD, 
which consists of 130 amino acids approximately,
146
 and it folds into a β-sandwich 
structure comprising two anti-parallel β-sheets (the F-sheet and S-sheet).147 The CRD 
that is different among the galectins family, establishes a net of interactions selectively 
with the β-galactoside moiety through the formation of hydrogen bonds and hydrophobic 
interactions with tryptophan (Trp), histidine (His), and arginine (Arg) residues (Figure 
1.17).
148
 Apart from the CRD, galectins differ in other aspects, such as chain length or 
number of domains in their structure. To date, more than one hundred X-ray structures 
of human galectins are available at the Protein Data Bank (PDB).
111
 For the studies 
performed for this Thesis, we selected one or two X-ray crystallographic structures for 
each human galectin (PDB ID codes are shown in  Table 1.2).  
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 Table 1.2. X-ray crystallographic structures of human galectins used in this 
Thesis. 
Galectin PDB ID Resolution (Å) Ligand 
Galectin-1 1GZW
149
 1.7 lactose 
Galectin-2 5DG2
150
 1.61 lactose 
Galectin-3 
3ZSJ
151
 
1KJR
152
 
0.86 
1.55 
lactose 
2,3,5,6-tetrafluoro-4-methoxy-lactose 
Galectin-4 4XZP
153
 1.48 no ligand 
Galectin-7 4GAL
154
 1.95 lactose 
Galectin-8 4BMB
155
 1.35 lactose 
Galectin-9 3NV4
156
 1.99 sialyllactose 
Galectin-10 1G86
157
 1.8 N-ethylmaleimide 
 
 
 
Figure 1.17. Left: X-ray crystallographic structure (PDB ID 1GZW) of human 
galectin-1 (green) in complex with lactose (magenta). Details of the carbohydrate 
recognition domain. Aminoacids involved in the binding are depicted (shown in sticks). 
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1.2.3 Maackia amurensis lectins 
In the early 1970,
158
 it was described the hemoagglutinating activity from the 
seeds from Maackia amurensis, and it was discovered that it was due to the presence of 
two different lectins able to agglutinate different blood cell types: Maackia amurensis 
leukoagglutinin (MAL) and Maackia amurensis hemagglutinin (MAH). These lectins 
selectively recognize sialylated oligosaccharides. In particular, MAL preferentially binds 
sialylactosamine (αNeu5Ac-(2-3)βGal1-4βGlcNAc) and N-linked glycans and MAH 
disialylated tetrasaccharide (αNeu5Ac2-3βGal1-3(αNeu5Ac2-6)αGalNAc) and O-linked 
glycans. Although the high identity sequence (more than 86%), the presence of an 
alanine (Ala219) in MAH instead of a tyrosine (Tyr250) in MAL in the binding site 
determines the different recognition process. The X-ray crystallographic structure of 
MAL is available at the PDB (PDB ID 1DBN) and for MAH a homology model has 
been already reported.
159
 The binding site of the MAL consists in a deep pocket that can 
accommodate up to three sugar moieties. The peculiarity of these lectins are related to 
the fact that normally all the legume lectins conserve polar interactions with one 
aspartate, one glycine and one asparagine. Instead, MAL and MAH have one lysine 
(Lys136 in MAH and Lys105 in MAH) instead of the glycine, and one aspartate 
(Asp166 in MAL and Asp135 in MAH) instead of the asparagine (Figure 1.18). 
Mutagenesis studies on MAH demonstrate that the replacement of the Lys105 with a 
glycine, or the Asp135 with an asparagine, abolish the ability to bind the ligand.
160
 
  
Figure 1.18. Left: Superimposition of the X-ray crystal structure of MAL (in 
magenta, PDB ID 1DBN), and the X-ray crystal structure of a lectin from Ulex 
europaeus (in yellow, PDB ID 1QNW) as representative lectin. Right: Differences in the 
aminoacids between a model legume lectin and MAL are shown.  
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1.2.4 Glycosyltransferases 
Glycosyltransferases (GTs) are key enzymes responsible of the incorporation of 
carbohydrates into a variety of acceptor biomolecules, including proteins, lipids, 
oligosaccharides and different metabolites.
161-163
 The resulting glycoconjugates mediate 
a wide range of functions from structure and storage to signalling and, in consequence, 
they are related with important diseases, non-alcoholic fatty liver disease.
164
 Therefore, 
chemical manipulation of GTs activity could lead to the development of useful 
therapeutic drugs.
165
 Because of it, considerable synthetic efforts have been directed 
toward the preparation of efficient GT inhibitors.
166-172
 Transfer of the sugar residue 
occurs from an anionic nucleotide sugar donor to the acceptor substrate; it can take place 
with retention or inversion of configuration at the anomeric centre of the sugar 
residue.
173
 Only nine sugar donors are known to be involved in protein glycosylation in 
mammal organisms,
174
 which is the most abundant post-translational modification in 
nature. Six of these sugar donors (glucose, glucosamine, glucuronic acid, galactose, 
galactosamine, xylitol) contain the uridine moiety that is in line with the existence of 
GTs employing UDP sugars as the most predominant in nature.
175
 In particular, 
GalNAc-T2 a member of the N-acetylgalactosaminyl transferase family (GalNAcTs E.C. 
2.4.1.41) is involved in mucin biosynthesis,
176-177
 so it is involved in aberrant 
glycosilation in pathological condition such as cancer.
178
 To date, there are 20 X-ray 
crystallographic structures of GalNAc-T2 available at the PDB. For the present Thesis, 
we used the structures shown in  Table 1.3. The peculiarity of this protein is the 
conformational change associated to a loop which determines the binding of the 
substrate. For this reason, in this Thesis two different crystal structures were used, one in 
closed conformation (PDB ID 4D0Z) and one in open conformation (PDB ID 2FFV). 
 Table 1.3. X-ray crystallographic structures of GalNAc-T2 used for this Thesis. 
PDB ID Resolution (Å) Ligand Conformation 
2FFV 2.75 UDP Open 
4D0Z 2.2 UDP-5SGalNAc Closed 
5FV9 2.07 Compound 16d Open 
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1.3 Computational techniques in drug design 
Given the difficulty of getting proper crystals of carbohydrates beyond a 
particular size, molecular modelling has proven to be very useful for the elucidation of 
their structural and conformational characteristics, either alone or in combination with 
experimental techniques, usually solution state NMR spectroscopy methods. In fact, the 
combination of modelling/NMR protocols has been extremely useful to deduce the 
conformational and dynamic properties of free and bound carbohydrate molecules.
13, 179-
180
 Molecular modelling of carbohydrates can be performed at different levels of 
complexity. Specific structural properties of carbohydrates can be extracted from 
quantum mechanics (QM) methods, especially those related to electronic features, to 
study chemical reactions (for instance, by using hybrid quantum mechanics/molecular 
mechanics QM/MM approaches), and to calculate force constants and atom charges to 
be used as force field parameters.
181-183
 These methods can nowadays be employed even 
to deal with molecular recognition details. The most employed protocols for the study of 
carbohydrates are based on force fields, to perform molecular mechanics (MM) and 
molecular dynamics (MD) simulations (Figure 1.19). Research in force field 
development has been very active in recent years, yielding several high quality force 
fields able to reproduce dynamic and electronic properties of carbohydrates. In 
particular, MD simulations are one of the most useful tools to have insights into the 
conformational dynamics of the system, combined, if available, with NMR experimental 
information. The interaction of carbohydrates with their receptors can also be performed 
at different levels of complexity, also using force-field based methods (MM and MD 
simulations) or quantum mechanics (QM) methods (Figure 1.19).
184-185
 Choosing the 
appropriate computational method is a key decision in a given study, and it will depend 
on the properties under investigation, and also on the starting experimental information 
we have in our hands. 
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Figure 1.19. Computational methodologies employed for the study of 
carbohydrates. 
1.3.1 Ab initio calculations and semi-empirical approaches 
Ab initio quantum mechanical (QM) calculation is a very useful tool to 
investigate molecular properties or describe chemical reaction. This calculation is not 
based on experimental data but it takes information from the electronic properties of 
each atom. Depending on the size of a molecule or a system (receptor-ligand) this type 
of calculation has a very high computational cost, reason why with this technique it is 
not possible to analyse system with more than few hundred atoms. QM calculations are 
based on the solution of Schrödinger equation (Equation 1).
186
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ħ
2𝑚
(
𝜕2
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(Eq. 1) 
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This equation describes the probability of a single electron of mass m that is 
moving in a three-dimensional space with a vector r = x+y+z during the time t. V 
represents an external field such as the electrostatic potential due to the presence of the 
nuclei in a molecule. i is the unity imaginary number (the square root of -1) and ħ is the 
Plank constant divided by 2π. Several mathematical approximations have been proposed 
to approximate a solution to the Schrödinger equation.  
The most known approximation is the Hartree Fock (HF) method, in which 
electronic correlation (the Coulombic electron-electron repulsion) is not taken in 
consideration. The limitation of this method is that the resulted energy is usually higher 
than the exact one. Moreover, in HF calculations electrons must be described by some 
functional form, which is only known for a single-electron system.
187
 The set of one 
particle functions employed to assemble molecular orbital are defined as basis sets. 
Among them the linear combinations of Slater type orbitals (STO) or Gaussian type 
orbitals (GTO) are the most popular. Also other functions can be added such as the 
polarization function, which takes in consideration the possible shift of an atom’s 
orbital, and the diffuse function, in which the electron is considered far away from the 
nucleus. The diffuse function is very important for anions and van der Waals complexes.  
Quantum Monte Carlo (QMC) is a very time consuming method, which avoids 
HF limitations. This method explicitly correlates wave functions and evaluates integrals 
numerically using a Monte Carlo integration. QMC is probably the most accurate 
method known today.
188
  
Density Functional Theory (DFT) is another QM method, in which the total 
energy is related to the total electron density instead of the wavefunction. In the 
Chemical Biology field, DFT methods are very widely used since they combine low 
computational cost with high accuracy.
189
 
Semiempirical calculations are based on HF assumption but the parameters or 
numbers are fitted with experimental data. The advantages of this method are the lower 
computational cost, compared with ab initio calculations and the velocity of the 
calculation. The disadvantage of this technique is related to the lack of experimental data 
for particular systems.  
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Widely used semi-empirical methods include AM1, PM3, and MNDO.
190
 More 
recently, also PM5 and PM6 have been used for carbohydrates.
191
 DFT has also been 
employed for conformational studies of carbohydrates using different basis sets,
192-195
 
and also solvation models.
196
 To tear down the computational costs a reasonable 
approach can consist on preliminary calculations by means of semi-empirical methods 
followed by more precise studies at ab initio level or DFT calculation.
197-198
 
1.3.2 Docking 
Molecular docking is the most common method applied in structure-based 
design. It provides a model of interaction between two proteins or between a small 
molecule and a protein at the atomic level. Computational docking protocols are usually 
adopted to explore the possible binding poses (and therefore the putative ligand-receptor 
interactions) of a given ligand within a particular receptor, and to estimate the binding 
affinity of the resulting complex. The availability of the 3D structure of the receptor (by 
means of, commonly, X-ray crystallography, NMR spectroscopy, electron microscopy 
or homology modelling) is required and previous information about the binding site is 
preferable. The knowledge of the binding site could be deduced by comparison of other 
related target proteins or through complementary computational studies. For decades, 
the interaction between protein and ligand has been thought as key-lock system. This 
model is very easily reproducible with a rigid docking in which both ligand and protein 
are treated as rigid. With the advent of the induced-fit theory by Koshland, in which a 
mutual conformation change of both ligand and protein occurs at the moment of the 
interaction, the global vision of this model evolved.
199
 However, these two theories are 
now better substituted by the concept of conformational ensembles. In a dynamic 
context, a biomolecule indeed does not have only a fixed conformation. The real three-
dimensional structure will be represented by an ensemble of structures which 
interconvert through dynamic processes. Thus, the study of dynamics and its impact in 
conformation and molecular recognition is of paramount importance within this field.  
So, it has to take in consideration that ligands are usually faced with several 
receptor microstates rather than with a unique structure, as is usually assumed for 
simplification.  
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Karush defines this phenomenon as a configurational adaptability in which the 
best-fitting configuration for a biomolecule after interacting with a ligand would become 
selected from the whole structural ensemble.
200
 Moreover, Weber suggested that the 
binding with a ligand shifts the conformational equilibrium of the receptor in favour of 
those conformers in the dynamic ensemble that are most complementary to the ligand.
201
 
In order to reproduce this event, flexible docking is needed. Nowadays, current 
docking methods incorporate ligand flexibility with high efficiency, and receptor 
flexibility is becoming incorporated in several docking programs, although with 
limitations.
202
 The flexibility of a protein can be included into the binding site before the 
docking or afterward, for example, it is possible to generate different ensembles 
structures from MD simulation or from Normal Mode Analysis (NMA). Some programs 
use different strategy to include the flexibility in the receptor. For example, AutoDock4 
program allows the selection of some bonds of the side chain of several residues as 
rotatable bonds when performing the docking of the ligand.
203
 Another strategy is to 
perform a conformational search and a refinement of some side chains of selected 
residues or in the region of the binding site while docking the ligand (e.g. protocol used 
by Glide program).
204-205
 Obviously this technique has an higher computational cost than 
considering the receptor as rigid.
206
  
A docking calculation is basically characterized by two main steps: in the first 
step, a conformational search is performed to predict possible conformations of the small 
molecule (ligand); in the subsequent second step, for the different binding poses, the 
ligand binding energy is calculated by applying a scoring function so the predicted 
ligand-receptor complexes are therefore scored and ranked. The main differences among 
the different docking programs are the search algorithms that are used in the 
conformational search, and the scoring function employed to rank the different binding 
poses. The accuracy and the computational cost of this step depend also on the number 
of rotable bonds present in a ligand. Each program has a threshold of the maximum 
number of rotable bonds because numerous rotable bonds increase exponentially the 
computational cost. Three types of search algorithm can be applied: shape matching, 
systematic search and stochastic algorithms. The more time-efficient algorithms are the 
stochastic or non-deterministic ones.  
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In the stochastic algorithm random changes in the ligand are executed. This 
change will be accepted or rejected according to probabilistic criteria. Four types of 
stochastic algorithms are known: Monte Carlo (MC) methods, Evolutionary Algorithms 
(EA), Tabu search methods and Swarm Optimization (SO) methods.  
In MC methods Boltzmann probability function is applied (Equation 2). 
 𝑃 = 𝑒𝑥𝑝 [
−(𝐸1 − 𝐸0)
𝑘𝐵𝑇
] (Eq. 2) 
In (Equation 2) E0 and E1 represent the energy score before and after the change of the 
conformer respectively, kB the Boltzmann constant and T the absolute temperature of the 
system.  
Evolutionary algorithms search for the correct ligand binding mode using ideas 
based on genetics and evolutionary process in biological systems. A “natural protocol” is 
applied, which consists in the first generation of individuals and the evaluation of the 
fitness. According to the Darwin theory, the best-fit individuals for reproduction are 
selected, and after crossover and mutations new individuals are generated and again the 
fitness of them will be evaluated. Thus, the optimization is based on a selection process 
that mimics biological evolution. One of the most popular is the Genetic Algorithm 
(GA), in which an analogy with evolutionary selection is applied. Basically, the 
translation, orientation, and conformation of a small molecule describe the gene, each 
state (conformation) corresponds to the genotype, and the atomic coordinates correspond 
to the phenotype. The best solutions will survive and will reproduce (with crossover and 
mutation), whereas the worse ones will be discarded. Other genetic algorithms have 
been proposed in order to represent more complex situations.
207
 For example, an 
improvement of the genetic algorithm can be obtained by introducing a local search (LS) 
method.
208
 A LS method performs energy minimization, without requiring gradient 
information about the local energy landscape. Moreover it is possible to define the step 
size changing the number of consecutive failures, or increases in energy. The hybrid of 
the GA method with the adaptive LS method is named Lamarckian genetic algorithm.  
Another hybrid algorithm is the simulated annealing, in which a GA and LS 
methods are applied depending on the temperature.  
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The advantage of this method is the possibility to overcome energy barriers 
separating energetic valleys by means of high temperature.  
In order to evaluate the accuracy of an algorithm a scoring function plays a key 
role. The scoring function could be of three types:  
 Force Field (FF) based scoring functions (Equation 3),209 where a classic 
force field is employed to compute individual interaction terms such as van der 
Waals and electrostatic energies, stretching/bending/torsional energies. Several 
disadvantages are related to this scoring function. One of the disadvantages is the 
solvent effect, which is finally defined by a distance-dependent dielectric 
constant. Another problem related to the FF scoring function is how to treat the 
water. The Poisson-Boltzmann/Surface Area (PB/SA) model and the 
Generalized-Born/Surface Area (GB/SA) use implicit solvent models to 
overcome this problem. But the more severe challenge still remains the entropic 
effect.  
 𝐸 =  ∑ ∑ (
𝐴𝑖𝑗
𝑟𝑖𝑗
12 −
𝐵𝑖𝑗
𝑟𝑖𝑗
6 +
𝑞𝑖𝑞𝑗
𝜀(𝑟𝑖𝑗)𝑟𝑖𝑗
)
𝑗𝑖
 (Eq. 3) 
 
In (Equation 3) rij represents the distance between an atom i of the protein and an 
atom j of the ligand. Aij and Bij are the van der Walls parameters, and qi and qj 
are the atomic charges of the atom i and j respectively. ε(rij) reflects the 
screening effect of water on electrostatic interactions and it is usually set to is 
usually set to 4rij. 
 Empirical scoring function (Equation 4)210-211 calculates the overall binding free 
energy, by summing up a set of weighted empirical energy terms, including 
hydrogen bond (H-bond) and hydrophobic interactions. Compared to the FF 
scoring functions, it is more computationally efficient. Its applicability depends 
on the training set (known experimental data for a set of molecules) and the 
fitting to known binding affinities. Glide Score is one of the examples of 
empirical scoring function.  
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 ∆𝐺 =  ∑ 𝑊𝑖∆𝐺𝑖
𝑖
 (Eq. 4) 
ΔGi stands for the individual empirical energy terms and the corresponding 
coefficients Wi. 
 
 Knowledge-Based (KB) scoring functions (Equation 5)212-213 are based on 
the sum of distance-dependent statistical potentials between the ligand and the 
target. The structural information of the complex formed by the protein and the 
ligand is needed.  
 𝜔(𝑟) = −𝑘𝐵𝑇𝑙𝑛 [
𝜌(𝑟)
𝜌∗(𝑟)
] (Eq. 5) 
In (Equation 5) the scoring function is dependent on the density of the protein-
ligand atom pair at the distance r (ρ(r)) in the training set, and the pair density in a 
reference state (ρ*(r)) where there are no interatomic interactions at the absolute 
temperature T. kB is the Boltzmann constant.  
In this Thesis, three different docking protocols were used: AutoDock4,
214
 
Glide
204-205
 and VINA.
215
 Since docking programs are not specifically developed to treat 
with carbohydrates, further refinement of the proposed docked poses has been 
accomplished by means of MD simulations in water. If available, experimental 
information (i.e., NMR/X-ray data, binding/affinity data, etc.) has been taken into 
account in the calculations. 
1.3.2.1 AutoDock4 
AutoDock4
214
 is a freeware molecular docking program. The conformational 
search is performed with Lamarckian genetic method, but also a simulated annealing 
search method and a traditional genetic algorithm are available. A grid-based method is 
applied in order to quickly evaluate the binding energy of putative binding poses.  
The ranking of the docked binding poses are scored by a semi-empirical function. 
The binding free energy is calculated as the difference between the potential energy of 
ligand and the protein in the complex (bound state) and the potential energy of the ligand 
and protein in a “free” or unbound state (Equation 6).  
CHAPTER 1 
36 
 
 
∆𝐺 = (𝑉𝑏𝑜𝑢𝑛𝑑
𝐿−𝐿 − 𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑
𝐿−𝐿 ) + (𝑉𝑏𝑜𝑢𝑛𝑑
𝑃−𝑃 − 𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑
𝑃−𝑃 )
+ (𝑉𝑏𝑜𝑢𝑛𝑑
𝑃−𝐿 − 𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑
𝑃−𝐿 + ∆𝑆𝑐𝑜𝑛𝑓) 
(Eq. 6) 
Each potential energy contribution is given by the sum of van der Walls, 
hydrogen bonds, electrostatic and solvation term (Equation 7). 
 
 
𝑉 = 𝑊𝑣𝑑𝑊 ∑ (
𝐴𝑖𝑗
𝑟𝑖𝑗
12 −
𝐵𝑖𝑗
𝑟𝑖𝑗
6 )
𝑖 𝑗
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(Eq. 7) 
In van der Waals term (WvdW) A and B are parameters taken from the Amber 
force field,
216
 while in the hydrogen-bond term (Whbound) C and D are parameters 
depending on the distance (r) between the atom i and j. Both of the terms are potential 
based (6/12 in the van der Waals and 10/12 in the hydrogen bond).
217
 The electronic 
term (Welec) takes into account the partial charges of the atoms (qi and qj) in the solvent 
(ε(rij)). The desolvation potential is based on the volume (V) of the atoms around a given 
atom, weighted by a solvation parameter (S) and an exponential term based on the 
distance (rij) with a distance weighting factor σ of 3.5 Å.
218
 
In the final ranking and clustering-based scoring methods also the loss of entropy 
(ΔSconf) associated to the binding (Equation 8) is considered. This contribution is strictly 
related to the number of rotatable bonds (Ntors) in the ligand.  
Autodock4 is very versatile and has different utilities. It is possible to perform 
flexible docking, specifying which residues of the protein should be considered flexible 
during the docking. 
  
 ∆𝑆𝑐𝑜𝑛𝑓 = 𝑊𝑐𝑜𝑛𝑓𝑁𝑡𝑜𝑟𝑠 (Eq. 8) 
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1.3.2.2 Glide 
Glide is a commercial molecular docking program provided by Schrödinger.
204-
205, 219
 Possible binding sites of the receptor are hierarchical filtered, based on the shape 
and properties of the receptor that are represented on a grid by different sets of fields. A 
certain number of conformations is kept depending on the minima found in the torsion-
angle space of the ligand and these conformers are screened over the binding region or 
the whole space. This step is very crucial because strictly depends on initial geometry of 
the ligand. The “survived” conformations are then minimized using a standard molecular 
force field (OPLS-AA
220
) applying a distance-dependent dielectric model to threat the 
solvent effect. Eventually, the three to six lowest-energy poses are optimized by Monte 
Carlo algorithm. The predicting binding affinity and the ranking of the binding pose is 
performed using GlideScore function (Equation 9) based on ChemScore function.
211
  
 
 
∆𝐺𝑏𝑖𝑛𝑑
=  𝐶𝑙𝑖𝑝𝑜−𝑙𝑖𝑝𝑜 ∑ 𝑓(𝑟𝑙𝑟)
+  𝐶ℎ𝑏𝑜𝑛𝑑−𝑛𝑒𝑢𝑡−𝑛𝑒𝑢𝑡 ∑ 𝑔(∆𝑟)ℎ(∆𝛼)
+ 𝐶ℎ𝑏𝑜𝑛𝑑−𝑛𝑒𝑢𝑡−𝑐ℎ𝑎𝑟𝑔𝑒𝑑 ∑ 𝑔(∆𝑟)ℎ(∆𝛼)
+ 𝐶ℎ𝑏𝑜𝑛𝑑−𝑐ℎ𝑎𝑟𝑔𝑒𝑑−𝑐ℎ𝑎𝑟𝑔𝑒𝑑 ∑ 𝑔(∆𝑟)ℎ(∆𝛼)
+ 𝐶𝑚𝑎𝑥−𝑚𝑒𝑡𝑎𝑙−𝑖𝑜𝑛 ∑ 𝑓(𝑟𝑙𝑚) + 𝐶𝑟𝑜𝑡𝑏𝐻𝑟𝑜𝑡𝑏
+ 𝐶𝑝𝑜𝑙𝑎𝑟−𝑝ℎ𝑜𝑏𝑉𝑝𝑜𝑙𝑎𝑟−𝑝ℎ𝑜𝑏 + 𝐶𝑐𝑜𝑢𝑙𝐸𝑐𝑜𝑢𝑙 + 𝐶𝑣𝑑𝑊𝐸𝑣𝑑𝑊
+ 𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛 𝑡𝑒𝑟𝑚𝑠 
(Eq. 9) 
 
The lipophilic-lipophilic term (Clipo-lipo Σf(rlr)), hydrogen-bonding terms (Chbond-
neut-neutΣg(Δr)h(Δα), Chbond-neut-charged Σg(Δr)h(Δα)), charged-charged term (Chbond-charged-
charged Σg(Δr)h(Δα)) and metal-ligand interaction term (Cmax-matal-ion Σf(rlm)) are pretty 
similar defined as in ChemScore. Coulomb (CcoulEcoul), vdW (CvdWEvdW) and solvation 
terms are added.  
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The polar-hydrophobic term (𝐶𝑝𝑜𝑙𝑎𝑟−𝑝ℎ𝑜𝑏𝑉𝑝𝑜𝑙𝑎𝑟−𝑝ℎ𝑜𝑏) comes from Schrödinger’s 
active site mapping facility, and represents the contribution of a polar but non-hydrogen-
bonding atom is present in a hydrophobic region. Glide uses two forms of GlideScore, 
the standard precision (SP) and the extra precision (XP). The main differences between 
SP and XP docking are related to the chemical-physical properties. Actually XP docking 
applies large desolvation penalties to polar groups of both ligand and protein and takes 
in consideration specific motif which can enhance binding affinity.
204-205
 
 
1.3.2.3 VINA 
AutoDock VINA (acronym of Vina Is Not AutoDock) is one of the most popular 
molecular docking programs.
215
 A search space has to be defined by the user and 
maximum twenty binding poses per ligand are generated. The generated conformations 
are ranked by a hybrid scoring function in which empirical information from the 
conformational preferences of the complex (receptor-ligand) is extracted and used to 
compare with experimental afﬁnity measurements. The applied scoring function is based 
on the number of interactions that each conformation can form, following the formula 
(Equation 10):  
 𝑐 = ∑ 𝑓𝑡𝑖𝑡𝑖𝑗(𝑟𝑖𝑗)
𝑖<𝑗
 (Eq. 10) 
where i and j represent two atoms and ti and tj their types and rij the interatomic 
distance, excluding the 1-4 interaction. A symmetric set of interaction functions ftitj 
should be defined. Basically, this sum corresponds to the sum of intermolecular and 
intramolecular contributions. Finally, the optimization algorithm used is the Iterated 
Local Search global optimizer.
221-222
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1.3.3 Molecular Mechanics and Molecular Dynamics Simulations 
Molecular Mechanics (MM) or classical mechanics describes molecules as a set 
of bonded atoms whose interactions can be modelled using standard Newton mechanics 
instead of QM (see 1.3.1 section). The interactions between atoms are modelled with 
simple parameterized functions based on experimental values or ab initio calculations. 
These functions define the so-called force fields, which are used to easily calculate the 
energetic function of a system. The molecules are described as an ensemble of spheres 
representing the atoms and the nuclei positions have a fixed electron distribution, thus 
simplifying the complexity of the calculations. A force field consists of both the set of 
equations used to calculate the potential energy and forces from particle coordinates, as 
well as a collection of parameters used in the equations. The potential energy function 
(Equation 11) could be divided into two main terms: bonded potential energy (Equation 
12) and non-bonded (Equation13).  
 𝑉(𝑅)𝑡𝑜𝑡𝑎𝑙 = 𝑉(𝑅)𝑏𝑜𝑛𝑑𝑒𝑑 + 𝑉(𝑅)𝑛𝑜𝑛−𝑏𝑜𝑛𝑑𝑒𝑑 (Eq. 11) 
 
 
𝑉(𝑅)𝑏𝑜𝑛𝑑𝑒𝑑 = ∑ 𝐾𝑏
𝑏𝑜𝑛𝑑𝑠
(𝑏 − 𝑏𝑜)
2
+ ∑ 𝐾𝜃
𝑎𝑛𝑔𝑙𝑒𝑠
(𝜃 − 𝜃𝑜)
2
+ ∑ 𝐾
𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙𝑠
[1 + cos (𝑛 − )] 
(Eq. 12) 
 
 
𝑉(𝑅)𝑛𝑜𝑛−𝑏𝑜𝑛𝑑𝑒𝑑
= ∑ (𝜀𝑖𝑗 [(
𝑅min 𝑖𝑗
𝑟𝑖𝑗
)
12
− (
𝑅min 𝑖𝑗
𝑟𝑖𝑗
)
6
]
𝑛𝑜𝑛𝑏𝑜𝑛𝑑𝑒𝑑 
𝑎𝑡𝑜𝑚𝑝𝑎𝑟𝑖𝑠
+
𝑞𝑖𝑞𝑗
𝜀𝐷𝑟𝑖𝑗
) 
(Eq. 13) 
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The bonded potential energy (Equation 12) describes intramolecular or local 
contributions (bond stretching, angle bending, and dihedral and improper torsions) to the 
total energy, and the non-bonded one represents the repulsive and van der Waals 
interactions (12-6 Lennard-Jones potential) and the Coulombic interactions. The 
equilibrium values (b0, θ0, χ) are typically obtained either from ab initio or semi-
empirical QM calculations or by fitting to experimental data. In a classical force field, 
molecules are defined as group of atoms linked by elastic (harmonic) forces, according 
to the Hook’s law. Bond stretching and angle-bending are treated as harmonical function 
around the equilibrium value (b0, θ0) applying a force constant (Kb, Kθ). An oscillatory 
function is applied to the torsional term with a periodicity () between 0 and 2π and a 
phase () with a force constant (Kχ) (Figure 1.20). The force constant depends on the 
energy barrier to pass from two local minimum energies. In general, to keep the 
planarity of certain systems, improper general term is introduced. Improper terms have 
similar quadratic forms of angles, but with smaller spring constants.  
 
Figure 1.20. Representation of the bonded terms (bonds, angles and dihedrals 
term) of the force field equation. The atoms are represented as spheres and a bond as a 
spring. 
 
CHAPTER 1 
41 
 
The non-bonded interactions (Equation 13) consist of Lennard-Jones repulsion 
and dispersion 𝜀𝑖𝑗 [(
𝑅min 𝑖𝑗
𝑟𝑖𝑗
)
12
− (
𝑅min 𝑖𝑗
𝑟𝑖𝑗
)
6
] as well as Coulomb electrostatics 
𝑞𝑖𝑞𝑗
𝜀𝐷𝑟𝑖𝑗
 
(Figure 1.21). The 12-6 Lennard-Jones (LJ) potential is used to describe the repulsion 
between two atoms (i and j) in which the overlap of the electron clouds of both atoms 
induces dipoles generating an attractive component. The corresponding well depth (𝜀𝑖𝑗) 
(Equation 15) for the interaction between two atoms i and j is given by the geometric 
mean of each well depth for atom of the same type (Equation 14).  
 𝑅min 𝑖𝑗 =  
(𝑅min 𝑖 +  𝑅min 𝑖𝑗)
2
 (Eq.14) 
 𝜀𝑖𝑗 = √(𝜀𝑖𝜀𝑗) (Eq. 15) 
 
 
Figure 1.21. Left: Lennard-Jones potential for two atoms Right: Representation 
of Coulombic electrostatic term (extracted and modified from 
http://atomsinmotion.com/book/chapter5/md).  
The Coulombic term adds the electrostatic contribution due to the partial charges 
of each atom (qi and qj) in distance-dependent manner (𝑟𝑖𝑗), taking into account the 
permittivity of the solvent (𝜀𝐷). The current development of force fields for MD 
simulations are facing exciting challenges; for example, the development of polarizable 
force fields
223-224
, or the simulation of the behaviour of intrinsically disordered 
proteins.
225-230
  To study biological systems the most accurate approach would use QM 
calculations, but they are very time consuming.  
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In this context, MD simulations have become a very important tool to have 
insights into the conformational dynamics of the system, combined, if available, with 
NMR experimental information. In particular, MD simulations allow to study at 
different timescale and in solution, molecules and complexes. This technique has been 
used to study molecular properties, but also dynamic phenomena such as the interaction 
between ligand and protein. In MD simulations Newton’s second law of motion 
(Equation 16) is applied to monitor molecular systems over time using empirically 
derived functions. 
 
𝑑2𝑥𝑖
𝑑𝑡2
=
𝐹𝑥𝑖
𝑚𝑖
 (Eq. 16) 
xi is the Cartesian position of the atom I and Fxi represents the force acting on the atom 
with a mass mi and t the time. A classical MD simulation consists in different steps. The 
first step is an energy minimization, in which the search of a minimum in the energy 
landscaper of a system is performed, starting from higher initial energy state. Two 
different methods are applied in MD, the steepest gradient method and the conjugate 
method. In the steepest gradient method, an optimization of the geometry is performed 
until reaching the local minimum. Different parameters can be customized if the local 
minimum is not reached. This method depends on the starting geometry and is suitable 
for quicker optimization. The conjugate gradient method uses subsequent minimization 
steps by taking information by the previous step.
231
 In this phase the solvent 
environment is very important. Three different methods can be applied to treat the 
solvent context. In in vacuo simulation, a distance-dependent solvent is used. If the 
solvent is considered implicit, two different models can be applied, Generalized Born 
(GB) and Poisson-Boltzmann (PB) (see section 1.3.4). With explicit water, the 
simulation of complex takes place into a box with solvent molecules, under periodic 
boundary conditions (PBC) to avoid surface artefacts. Different water models have been 
proposed, but the most used is the TIP3P model in which the HOH angle is fixed to 
104.5 and fixed partial charges are assigned (-0.834 for the O and +0.147 for the H).
232
 
To calculate the infinite electrostatic interactions, particle mesh Ewald summation 
(PME) is used in which the summation into short- and long-range parts is split.  
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In the second step, bad contacts between solvent and solute are removed. In this phase, 
the velocity of the atoms is increased by heating and the velocities are calculated with 
standard temperature-dependent Maxwell-Boltzmann distribution. Successively there is 
the equilibrium step, in which the system is relaxed and energy, temperature, volume 
and pressure are controlled and monitored. Eventually, the production step will prompt 
the trajectories.  
Depending on the problem to solve, the choice of the correct force field is a 
crucial step. It is clear that the lack of unique force field for all the systems could be seen 
as a disadvantage but on the other side the variety of force fields for specific systems 
heads to a high accuracy. Amber package
233
 in fact contains several force field specific 
for lipids (to date Lipid14), for sugars (GLYCAM06), for proteins, nucleic acids and 
water molecules (ff14SB) and for general organic molecules (GAFF). Those force fields 
have been regularly used, in combination with structural experimental information, to 
gain insights into the dynamic and energetic behaviour of molecules and receptor-ligand 
complexes.  
1.3.3.1 AMBER ff14SB 
Among the biomolecule systems, proteins are one of the most studied. The 
computational studies of a protein are strictly related with the parameters set for the 
system. The most efficient parameters usually are from QM, but the computational cost 
will be very high. So different force fields for protein have been developed, and Amber 
ff14SB
234
 and its previous versions (ff99SB, ff99 and ff94) are widely used. Different 
problems are related with the development of a force field for proteins. Amber force 
field has fixed charges, that are usually less accurate than polarizable force field, but 
they are still quite reasonable. Another problem related to the simulation of a protein is 
the prediction and the reproducibility of the protein’s secondary structure. This 
limitation is strictly connected with the definition of the dihedral terms and the energy 
profile of the dihedrals terms. Parameters are usually calculated by ab initio methods 
and then fitted and validated with experimental results (especially NMR). In particular, 
the study of the backbone is dictated by two dihedral angles, φ (C−N−Cα−C) and ψ 
(N−Cα−C−N) (Figure 1.22).  
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Figure 1.22. Representation of the backbone. φ and ψ are the dihedral angles 
which are defined in a force field. 
 
1.3.3.2 GLYCAM06 
GLYCAM06
181
 is the most widely used force field designed for carbohydrates. 
QM data were employed to compute all torsion terms, derived in a hierarchical manner 
using fitting valence parameters. This is the only force field in which the same atom type 
(Cg) at the anomeric carbon (C1) is assigned in both anomers α and β. The anomeric 
carbon shows a different partial charge, calculated with ensemble-averaged partial 
charge sets, in α or β anomer. The feature to have just one C atom type facilitates the 
simulation of ring-flipping, having equilibrium between conformers with axial and 
equatorial substituents at the anomeric centre. GLYCAM06 is suitable for mono and 
oligosaccharides, for D and L enantiomers and for all glycosidic linkage possibilities and 
it is also the only force field to include parameter for N-glycosidic linkages. Great 
caution should be taken before attempt into mix the GLYCAM parameters for 
carbohydrates with non-AMBER parameter sets. GLYCAM turns the 1-4 non-bonded 
interactions off to correctly reproduce the rotation of the ω-angle (see 1.1.2 section). 
This choice aims to simulate the correct population present in each rotamer of this angle 
(gg, gt, tg), without being influenced by the possibility of O6 to interact with either O4 
or O5. GLYCAM is consistent in TIP3P water model. Parameter set was developed for 
the explicit solvent simulation of hexopyranose-based carbohydrates. This force field 
has been optimized to enhance the stability of the 
4
C1 chair conformation and to 
reproduce the gauche effect. In principle, GLYCAM was created to cover a large 
number of carbohydrates included furanoses
235
 and glycolipids in membranes.
236
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1.3.4 MM-PBSA/MM-GBSA 
Molecular Mechanics-Poisson-Boltzmann Surface Area (MM-PBSA) and the 
Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) are methods 
designed to quantitative estimate the binding free energy associated to a complex with 
implicit solvent. MM-PBSA uses the Poisson-Boltzmann equation to compute the 
electrostatic contribution to the free-energy; MM-GBSA uses the Generalized Born 
approximation, which is an approximate and faster treatment of the Poisson-Boltzmann 
equation.
237
 
These two methods combine MM calculations (for the conformational energy 
term) and continuum solvation model (for the solvation free-energy term) to calculate 
the binding energy (ΔG) associated to a system. To calculate ΔG, Gibbs free-energy 
formula is applied (Equation 17)  
 ∆𝐺 = ∆𝐻 − 𝑇∆𝑆 (Eq. 17) 
where ΔG is the variation of the free energy in a system, ΔH the variation of the 
enthalpy, ΔS the variation of the entropy in a system and T the temperature of the 
system. Initially the receptor and the ligand are solvated by water molecules. In the 
bound state, assuming that no covalent bonds are formed between the ligand and the 
receptor, non–bonded interactions are formed, and an entropic change is correlated with 
this process. The variation of the entropy is linked with the decrease of the 
conformational freedom of the ligand and the rearrangement of the water molecules that 
were surrounding the ligand and the receptor. The AMBER suit of programs allows to 
calculate the absolute free binding energies by both MM-PBSA and MM-GBSA 
approaches (Figure 1.23 represents the calculations are made). Basically, the ΔG of the 
binding is calculated as the difference between the ΔG of the solvated complex (∆𝐺 𝑠𝑜𝑙𝑣
𝐶 ) 
and the sum of the ΔG of the solvated ligand and receptor (∆𝐺 𝑠𝑜𝑙𝑣
𝑅 + ∆𝐺 𝑠𝑜𝑙𝑣
𝐿 ), taking 
also into account the ΔG associated to the complex in vacuum (∆𝐺𝑏𝑖𝑛𝑑,𝑣𝑎𝑐)(Equation 
18).  
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Figure 1.23. Representation of the cycle of the binding free energy calculations 
for a protein−ligand complex. 
 ∆𝐺𝑏𝑖𝑛𝑑,𝑠𝑜𝑙𝑣 = ∆𝐺𝑏𝑖𝑛𝑑,𝑣𝑎𝑐 +  ∆𝐺 𝑠𝑜𝑙𝑣
𝐶 − (∆𝐺 𝑠𝑜𝑙𝑣
𝑅 + ∆𝐺 𝑠𝑜𝑙𝑣
𝐿 ) (Eq. 18) 
∆𝐺𝑏𝑖𝑛𝑑,𝑣𝑎𝑐 takes into account the energy differences associated to bonds, angles 
and dihedrals upon binding and the electrostatic and van der Waals terms (∆𝐸 𝑀𝑀 ) but 
also the conformational entropy change (𝑇∆𝑆) that can be computed by normal mode 
analysis (Equation 19).  
 ∆𝐺 𝑏𝑖𝑛𝑑,𝑣𝑎𝑐 =  ∆𝐸 𝑀𝑀 −  𝑇∆𝑆 (Eq.19) 
The solvation free energy (∆𝐺 𝑠𝑜𝑙𝑣) can be split into two terms, the polar (or 
electrostatic), and the non-polar (or non-electrostatic) contributions (Equation 20). The 
polar contribution (∆𝐺 𝑃𝐵/𝐺𝐵 ) varies in function of the solute-solvent interaction and its 
contribution can be calculated either with the GB and PB model. The non-polar 
contribution (∆𝐺 𝑆𝐴) is assessed by solvent accessible surface area (SASA).  
 ∆𝐺 𝑠𝑜𝑙𝑣 =  ∆𝐺 𝑃𝐵/𝐺𝐵 +  ∆𝐺 𝑆𝐴 (Eq.20) 
A common strategy to reduce the computational cost and to reduce errors MM-
PBSA/MM-GBSA can be run using different snapshots of a MD simulation of the 
complex (receptor-ligand). In principle PB is more theoretically rigorous than GB, 
although GB is faster.
237
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1.3.5 Virtual Screening  
Virtual screening (VS) is a technique used in ligand-based and structure-based 
drug discovery field to search hits for a specific target or to find new lead compounds. In 
this Thesis, we have used a receptor-based virtual screening (RBVS) approach, where 
the availability of the 3D coordinates of the target is mandatory, either from X-ray 
crystallography, NMR or homology modelling. Prior knowledge about the ligand 
binding site may help in the identification of proper binders although, in some 
approaches, the search for novel binding pockets can be an additional interesting -and 
challenging-element in the drug discovery process.
238-239
 Virtual screening aims to 
reduce the number of compounds that are experimentally screened and to increase the 
probability to find new active hits. In a structure-based virtual screening there is a sensor 
which reflects the likelihood of a ligand to bind in the binding site. Than the chemical 
structures are compared to the sensor and a scoring function is applied to rank them. The 
comparison of the sensor and the structures can be based on chemical similarity, on 
pharmacophore and on shape. FLAP and Glide programs have been used to carry out the 
virtual screening of fragments data base (Chapter 2) and are briefly outlined below.  
1.3.5.1 FLAP 
FLAP (Fingerprints for Ligands And Proteins) is a VS program based on 
molecular fingerprints.
240
 In general, for virtual screening, two different approaches can 
be followed: ligand-based VS (LBVS) or structure-based VS (SBVS). The choice of the 
approach depends on the information available for the case of study. GRID Molecular 
Interaction Fields
217
 (MIFs) defines the molecular fingerprints, mapping the interaction 
between a molecule and a probe, a receptor in the SBVS or a ligand in LBSV. MIFs 
have been widely used in several computational techniques such as 3D-QSAR, ADME 
and pharmacokinetic modelling. Given that the 3D structure of the receptor is available, 
the putative binding site can be user-defined by a gridbox in which known aminoacids 
involved in the binding are included or, alternatively, a pocket-finding algorithm can be 
applied. The grid points are assigned depending on the chemical structure of the receptor 
(probe). The grid probes evaluate for example the possibility to have hydrogen bonds or 
lipophilic interactions between protein and ligand.  
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The initial number of grid points is reduced to representatives one based on a 
weighted energy function. Then, four points “hotspots” are generated and the distances 
between the points, named also Common Reference Framework, are calculated. The 
hotspots will define the pharmacophore fingerprint. After generating the MIFs of the 
receptor, during the screening, FLAP compares the MIFs of the binding site with the 
MIFs of the ligands. A data set of ligands will be screened, and molecules will be 
discarded or not depending on the overlapping with the hotspots. To quantify the 
similarity between the MIFs, a scoring function based on Tanimoto coefficient is 
applied. The output will give information about the scoring of each MIF, the sum of 
them (Glob-Sum) or the product (Glop-Prod) for each ligand. Once the initial searching 
and alignment is performed, only the best-scored conformer for each molecule is 
maintained.  
1.3.5.2 Glide 
Glide
204-205
 uses a hierarchical series of filters to search for possible locations of 
the ligand in the active-site region of the receptor. It has a systematic method to treat 
ligand flexibility, with an exhaustive search algorithm. The Glide protocol is intuitive 
and relies on four steps: the ligands and protein preparation, the receptor grid generation, 
and the docking process. Before launching the docking step, Glide has to generate a grid 
that represents the shape and the properties of the receptor, using several different sets of 
fields that provide progressively more accurate scoring of ligand poses. The grid permits 
to dock only the relevant region of the receptor, thus saving calculation time. Regarding 
the last point, the full docking VS workflow includes three docking stages: HTVS (High 
Throughput Virtual Screening), SP (Standard Precision) and XP (Extra Precision). The 
first stage performs HTVS docking. It is intended for rapid screening of a very large 
number of ligands and has much more restricted conformational sampling than SP 
docking. The second stage performs SP docking. It is appropriate for screening ligands 
of unknown quality in large numbers. The third stage is the XP docking and scoring. It is 
a more powerful and discriminating procedure using an implementation of a modified 
and expanded version of the ChemScore scoring function, called GlideScore and 
categorized as an empirical scoring function.  
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Glide can be used to perform virtual screening, accurate binding mode precision 
and, furthermore, Glide exhibits excellent docking accuracy and high enrichment across 
a diverse range of receptor types. 
1.3.6 Conformational analysis  
Molecular properties are deeply linked with the three-dimensional structure, or 
conformation. So the conformational analysis is very important to determine the 
characteristic related to a molecule. Especially in carbohydrate field this technique helps 
to understand sugar behaviour in water solution or in complex with a protein. This 
method could be used either alone or in combination with experimental techniques, 
usually solution state NMR spectroscopy methods. In fact, the combination of 
modelling/NMR protocols has been extremely useful to deduce the conformational and 
dynamic properties of free and bound carbohydrate molecules.
13, 179-180
 In this sense, 
very useful are carbohydrate databases (such as http://glycosciences.de) that collect 
available NMR data and X-ray experiment of particular dihedral angles, chair 
conformations and glycosidic linkages.  
The conformational search aims to find the minima local energy for a given 
molecule in order to correlate a molecule with its behaviour. The conformations are 
usually defined as a rearrangement of the atoms in space simply rotating single bonds. 
So the minimization of energy is a crucial step in this protocol. Different techniques can 
be used to achieve the lowest energy conformer from ab initio calculations, semi-
empirical methods or MD simulations. Moreover, this technique is also applied for 
docking studies, in fact it represents the first step of the docking protocol (see Section 
1.3.2). In this Thesis all the three methods were used. In particular, for ab initio 
calculation DFT methods were applied either in combination with semi-empirical 
method (in most of the cases MM3*) or/and MD simulation.  
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1.3.7 Homology modelling 
The availability of the 3D structure of a given protein is a limiting step in the 
drug design and development process. Usually, the 3D structures of the macromolecules 
are elucidated by NMR or X-ray crystallography techniques, and they are deposited in 
the public database Protein Data Bank (PDB).
111
 When the 3D structure for a protein of 
interest has not been resolved by experimental techniques, homology modelling is very 
powerful to predict the structure of a protein. In order to build a homology model, the 
availability of the experimental 3D structure (template) or multiple structures is 
required. Starting from the protein sequence (target) available on the Universal Protein 
Resource database (UNIPROT),
241
 a sequence alignment with the template is performed. 
This procedure is online accessible by means of Basic Local Alignment Search Tool 
(BLAST).
242
 The scoring of BLAST provides to estimate the quality of the sequence 
alignment using the BLOSUM62 (BLOck SUbstitution Matrix).
243
 In the score 
assignment, different parameters are taken into account such as the percentage of 
identity between the searched protein and the template (a good model has minimum 30% 
of the percentage identity)
244
 and the percentage of query cover. To build a homology 
model three different protocols can be applied: ab initio calculations (see Section 1.3.1), 
fold recognition and comparative modelling. With ab initio is possible to build small 
peptides. Fold recognition (or threading) protocol recognizes specific sequences whose 
folding motif is already know from experimentally elucidated 3D structures. With 
comparative modelling, the templates from the PDB are assumed to be homologous to 
the target and the templates guide the building of the three-dimensional model. In this 
Thesis, we uses the Phyre2 web server,
245
 which uses an ensemble fold recognition 
method with an in-house algorithm.
246
 Once the model is built, a subsequent refinement 
step, especially for the side chain, is necessary. This step can be carry out by MD 
simulation, restraining the Cα of the backbone.  
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Validation of the model can be performed by using different tools. In our studies, 
we have used the SAVES tool
247
 which validates the homology modelling prediction 
analysing different parameters. Overall structure geometry and the statistics of non-
bonded interactions is analysed and compared with highly refined structures. Moreover 
it inspects the compatibility between the predicted secondary structure for a protein with 
its own amino acid sequence. Also atomic volumes and the possibly similar structures 
are also checked and compared with existing crystal structures in PDB. SAVES is able 
to identify the presence of residue conformations that are not the expected ones. For 
example, the representation of the Ramachandran Plot is a useful tool to check backbone 
angles of the protein structure by comparing them with observed/experimental angles. A 
good homology model usually has a score of more than 90% meaning that at least 90% 
of the residues are in the most favourable energy region.   
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1.4 Objectives 
In this Thesis, the general objective is to elucidate the carbohydrate-protein 
interactions at the atomic level through computational techniques. In particular, the 
following systems will be studied: human galectins -1, -3, and -7, Pisum sativum lectin, 
Maackia amurensis seed lectin, and glycosyltransferase GalNAc-T2. The final aim is to 
provide new insights for the understanding of the molecular recognition events 
underlying the biological functions of these proteins. These studies will be carried out by 
addressing the following specific objectives: 
 
Chapter 2: Elucidation of the binding modes of fluorinated glycans with a model 
lectin from Pisum sativum. We seek the elucidation of the binding modes of a 
fluorinated trimannoside α1→3 and α1→6 linked and its fluorinated disaccharide 
derivatives. The molecular modelling studies will take advantage of 
19
F-NMR 
experimental data to unequivocally elucidate the binding mode of these ligands in 
particular for the non-fluorinated natural mannosides that has remained unresolved.  
 
Chapter 3: Computational study of the binding mode of several β-galactoside 
ligands towards human galectin-3. These ligands are Lac, LacdiNAc, and and three 
glycans containing the LacNAc motif: blood group A type II tetrasaccharide, and two 
compounds derived from the important xenoantigen α-Gal epitope. We seek the 
characterization of the key interactions required for the distinct recognition by galectin-
3, which has been related to immune responses. 
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Chapter 4: Computational design of novel selective galectin binders with 
improved affinity. By means of virtual screening protocols, the vicinal pocket close to 
the carbohydrate recognition domain will be explored to identify appropriate moieties 
able to be anchored to this pocket. We seek the design of modified OMe-Lac derivatives 
able to bind the galectins with improved affinity and with selectivity towards the 
different galectin subtypes. Selected candidates will be synthesized by collaborators and 
their affinity will be measured by biophysical techniques. 
 
Chapter 5: Computational study of the molecular recognition process of 
podoplanin by Maackia amurensis seed lectin (MASL). We explore the binding site of 
the two molecular species of the MASL, Maackia amurensis leukoagglutinin and 
Maackia amurensis hemagglutinin, and the possible recognition by the epitope of the 
glycoprotein podoplanin as a plausible mechanism for the protective activity of this 
lectin in osteoarthritis. 
 
Chapter 6: Computational study of the binding mode of a series of synthetic 
nucleoside mimetics as inhibitors of a model glycosyltransferase (GalNAc-T2). These 
less-polar nucleotide sugar analogues derived from uridine only containing the -
phosphate could be efficient ligands for the enzyme, as deduced from the experimental 
data. We seek the proposal of a computational 3D model for the binding mode of these 
ligands to provide further insights into the mechanism of the catalytic cycle of this 
family of enzyme, useful for the further design of more potent inhibitors. 
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CHAPTER 2 
 
MOLECULAR RECOGNITION STUDIES OF 
19
F GLYCOMIMETICS 
TARGETING PEA LECTIN. A COMBINED NMR & COMPUTATIONAL 
APPROXIMATION 
 
2.1. Introduction 
Molecular recognition processes are the pillars of biochemical 
communication. Subtle differences in chemical substitutions, geometry and 
structure in the molecular partners guarantee the effectiveness and specificity of 
the resulting response. Of all natural biomolecules, glycans are unequalled in 
their capacity for biological coding and signal translation into cellular 
messages.
1-3
 This power derives from the tremendous structural variability of 
glycans with respect to saccharide sequence, chemical modification, 
conformation and shape.
4
 For instance, branched and linear glycans present their 
saccharide moieties in different spatial orientations, translating into distinct 
biomolecular messages and effects even for identical saccharide composition.
5
 It 
is therefore critical to thoroughly analyse the structural details of glycan 
recognition, and NMR spectroscopy/molecular modelling are key techniques for 
this difficult task. 
Nevertheless, the distinction of homologous monosaccharidic units in 
complex oligo- and poly-saccharides remains a challenge by conventional NMR 
methods, given the low dispersion and high overlap of the 
1
H signals. 
Introduction of non-endogenous NMR active heteronuclei may greatly help to 
resolve such problems, and fluorine seems to be a good suited candidate.
6
 
Moreover, fluorine atom has been extensively used in medicinal chemistry for 
bioisosteric replacement of H and OH, so similar biological properties to the 
parent compound should be expected.  
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Thus, deoxy-fluoroglycans have widely been used to detect molecular 
interactions and deduce the enthalpic contribution of specific sugar hydroxyl 
groups to receptor binding.
7-8
 From the NMR point of view, the sensitivity of the 
19
F nucleus is almost comparable to that of 
1
H, while its chemical shift 
dispersion is significantly larger. Thus, 
19
F is extremely sensitive to variations in 
the chemical environment. 
19
F NMR spectrum therefore fairly generally allows 
for immediate distinction of the pertaining saccharide moiety, in stark contrast 
to the often highly degenerate 
1
H spectrum with extensive signal overlap and 
multiplet splitting. All 
19
F NMR parameters (e.g., chemical shift, linewidth, J-
couplings and relaxation times) are particularly useful in providing structural 
and dynamic information complementary to that provided by 
1
H and 
13
C NMR 
spectroscopy.
9
 For these reasons, fluorinated glycomimetics have received great 
interest,
10
 and have allowed to extend the use of 
19
F NMR methods also to the 
fields of medicinal chemistry and chemical biology.
11
  
This work aims to combine the use of fluorinated glycomimetics with 
novel 
19
F-based STD experiments (performed by Jiménez-Barbero’s group) and 
computational tools, to demonstrate the usefulness of such approach to assess 
the binding mode of complex glycans to lectins. As proof-of-principle, we have 
employed the trifluorinated glycomimetic of the ubiquitous trimannoside present 
in the inner core of N-glycans (Chart 2.1) and a model lectin. The plant lectin 
from pea, Pisum sativum (PSA), serves as a common model for studying glycan 
detection and epitope recognition in the quest for biomarkers. Reported X-ray 
and molecular modelling studies disagreed in providing a clear picture of the 
trimannoside epitope and the ligand binding mode into PSA.
12-13
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Substitution of the hydroxyl group on C2 in each of the three mannose 
(Man) moieties by fluorine has allowed us to characterise the otherwise rather 
elusive glycan binding epitope by robust 
19
F NMR experiments, assisted by 
molecular modelling methods. This trisaccharide has been chosen for its 
intrinsic complexity from the NMR perspective (three similar Man units). We 
have compared the molecular recognition features of the natural trimannoside 
(1) with those of its trifluorinated analogue (2) and its two fluorinated 
dimannoside fragments (3, 4).  
The experimental 
19
F and 
1
H NMR data have been complemented with 
computational methods to provide a 3D model for the interaction with the PSA, 
and to confirm, indeed, the coexistence of multiple binding modes.  
 
 
Chart 2.1. Structure of methyl 3,6-di-O-(α-D-mannopyranosyl)-α-D-
mannopyranoside (1), its disaccharide components, and its fluorine containing 
glycomimetics (2-4). The non-reducing terminal residues are labelled as arm A 
(1→3 linkage, ManI) and B (1→6 linkage, ManII). The reducing (branched) 
residues in the trisaccharides are dubbed ManIII. 
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2.2. Results 
Previously reported X-ray and molecular modelling studies on the PSA/1 
system could not provide definitive answers on the ligand binding mode and 
sugar epitope.
12
 In fact, possibly due to the high flexibility of the glycan, X-ray 
diffraction data (PDB ID 1RIN, Figure 2.1, left)
12
 could not identify the binding 
mode and showed only one mannose residue inside the lectin's recognition site, 
with no electron density observable for the other two sugar units. This result 
could be explained by the existence of an exchange process between alternative 
binding modes, differing in the particular Man unit bound at the recognition site. 
Another plausible explanation would be a single binding mode involving the 
1→6 linkage (arm B), where its intrinsic flexibility would lead to 
conformational averaging and a blurring of the electron density for the central 
and terminal 1→3 linked Man residues. In fact, early molecular modelling 
studies suggested this (1→6)-mode flexible interaction with the lectin,13 but 
more experimental data is needed to further clarify the binding mode.  
Previous studies have also shown that the dissociation constant of 
trimannoside 1 from PSA is moderate, with a KD = 0.19±0.07 mM, and three 
times stronger than for the monomer, -methyl-mannopyranoside.14 Thus, the 
two additional Man moieties contribute positively to the trimannoside binding, 
although their effect is small and the role of enthalpic/entropic compensation is 
not evident. PSA recognizes glucose (Glc) with virtually the same affinity as 
Man, which strongly suggests that the hydroxyl group at position C2 of the 
sugar moiety is not directly involved in key interactions. As mentioned above, 
the X-ray structure of the PSA/triMan complex (PDB ID 1RIN)
12
 showed only 
one Man residue at the PSA binding site, with all its hydroxyl groups except O2 
involved in intermolecular hydrogen bonds with different polar amino acid 
residues, mainly Asp111, Asn155, Gly159, Glu248, and Ala247. The very same 
binding site is occupied by Glc from sucrose in the X-ray complex with PSA 
(PDB ID 1OFS) (Figure 2.1 right). Therefore, 2-deoxy-fluoro substitution 
within all Man residues should not alter the binding features substantially 
(compound 2 in Chart 2.1).  
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Figure 2.1. Left: Pea lectin (cyan, PDB ID 1RIN) in complex with a 
mannoside moiety (magenta). Right: Pea lectin (green, PDB ID 1OFS) in 
complex with sucrose (yellow). The main residues involved in the binding are 
shown in sticks. 
In principle, the sugar moiety recognized by the lectin could correspond 
to any of the three Man residues and we therefore included both alternative 
fluorinated dimannosides into the NMR and computational studies, 
Man1→6Man and Man→3Man (compound 3 and 4, Chart 2.1). The 
binding epitopes were then analysed by using 1D STDreF experiments 
previously described by the Jiménez-Barbero’s group and novel 2D and pseudo 
3D extensions of the concept.
15
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2.2.1 The free state: conformational analysis by MM3* 
calculations and ab initio calculation, Molecular Dynamics 
simulations, and comparison to the NMR experimental data 
The conformation of the natural analogue 1 and related glycomimetics, 
including C-glycosyl compounds, have been extensively analysed.
16
 The NMR 
data obtained for the trifluorinated analogue 2 were complemented by molecular 
mechanics and quantum mechanics (DFT) calculations. The use of both, the 
standard molecular mechanics (MM) protocol with the MM3* force field
17
 
included in  Macromodel,
18
 and the DFT calculations at the B3LYP level, 
allowed to predict a conformational distribution for 2 fairly similar to that found 
for 1.
16
 Six conformers that especially differ around the ψ and ω angles of the 
Manα1→6Man linkage and the ψ angle of the Manα1→3Man linkage have been 
identified. Then, the angles and distances deduced from the NMR experiments 
(analysis of the 
3
JHH coupling constants, 
1
H,
1
H-NOESY and 
1
H,
19
F-HOESY, for 
more information see Figure 2.A1-2.A4 and Table 2.A1-2.A2 in Annex II) were 
compared to the corresponding geometry parameters deduced from the 
theoretical calculations. Previous studies on the trimannoside 1 led to the 
conclusion that the conformational behaviour of this flexible saccharide is well 
described by a model in which six major conformations contribute.
19
 The two 
highly populated structures are those in which the Man1→6Man linkage is 
defined as exo-syn/anti in back-folded gg conformer. Similarly for compound 
2, the NMR experiments show that the  and  angles of the Man1→3Man 
linkage correspond to a concerted population of two states resulting in two 
major conformations: (, ) = (-60, -60) and (-40, 20), 2a and 2b respectively 
(Figure 2.2). MM and DFT calculations suggest the predominance of the 
conformer 2b (Figure 2.3). 
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Figure 2.2. Structural model for the trimannoside analogue 2 in solution. 
The various transitions correspond to those described for natural compound 1 
and analogues.
16
 The suffixes a-f design the six discussed conformers. 
Conformers 2a and 2b are the major ones in solution, followed by 2c and 2d. 
The contribution of 2e and 2f is minor, although still significant. 
 
 
Figure 2.3. Top: adiabatic curve obtained by molecular mechanics 
calculation (MM3*). Legend of relative energy scale is shown in kcal/mol. The 
blue areas are the most favourable regions for  and ψ and in red the less one. 
Bottom: energy profile torsion of   and ψ obtained by DFT calculations 
(B3LYP/3-21G). Only values of  and ψ between -90 and 90 degrees are shown.  
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The two conformers with  torsion angle at the Man1→6Man linkage 
in the extended gt conformation, resulting in roughly linear molecules (2c, 2d), 
are less populated. Finally, the two minor conformers 2e and 2f differ from the 
major conformers 2a and 2b in the dihedral angles  about the Man1→6Man 
linkage. Thus, the Man1→6Man linkage is defined as exo-syn/syn+ and 
results in a slightly bent structure. Our study is based on the comparison 
between the structural analysis reported for the natural analogue 1
19
 and those 
obtained for the mimic 2. Then, the comparison of the angles and distances 
deduced from the NMR analysis with the corresponding geometry parameters 
deduced from computational calculations permitted to have an estimation of the 
actual population distribution of the different conformers.  
The contribution of the two major geometries was also estimated through 
the analysis of interatomic distances using the calculated structures (Figure 2.2) 
compared to the experimental ones. A good agreement between the 
experimentally derived interatomic distances and those calculated for an average 
population distribution was reached. Molecular dynamics simulations (20 ns) 
were also performed to assess the conformational stability of the different 
conformers.  
For the bonds, angles and torsions involving F atom, parameters were 
taken from gaff force field.
20
 Charges were calculated with DFT and adapted for 
GLYCAM force field
21
 (Table 2.1).  
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Table 2.1. Partial charges assigned to each atom of compound 2. SA1 
residue is the α-2-F-mannose substituted in position 1 (ManI and ManII). SA2 
(ManIII) residue is the α-2F-mannose substituted in positions 1, 3 and 6. The 
parameters for the OMe group present in position 1 of the central Man were 
taken from GLYCAM force field.
21
 
 Atom Type SA1 SA2 
 
C1 0,400000 0,400000 
H1 0,000000 0,000000 
C2 0,287172 0,199808 
H2 0,000000 0,000000 
C3 0,212473 0,203358 
H3 0,000000 0,000000 
C4 0,277689 0,256190 
H4 0,000000 0,000000 
C5 0,175601 0,248887 
H5 0,000000 0,000000 
C6 0,249863 0,227038 
H61 0,000000 0,000000 
H62 0,000000 0,000000 
O6 -0,738010 -0,395602 
H6O 0,473381 
 
O5 -0,354505 -0,427901 
O4 -0,776756 -0,693712 
H4O 0,481578 0,425474 
O3 -0,706108 -0,381428 
H3O 0,466263 
 
F2 -0,254641 -0,256112 
 
Angles (, ψ and  of the Manα1→6Man and the Manα1→3Man 
linkages) were monitored, leading to the identification of different conformers. 
Agreement with the previous conformational analysis was detected, thus 
validating the parameters and charges employed, also useful for the MD 
simulations of the complexes. According to the MM calculations, all glycosidic 
torsion angles  are governed by the exo-anomeric effect that leads to exclusive 
population of the exo-syn conformer for glycosidic linkages. Different values of 
the ψ dihedral and  torsion angles of the Man1→6Man linkage in extended gt 
and back-folded gg conformers were found (Figure 2.4). 
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Figure 2.4. Top: plot obtained from 20 ns of MD simulation of 
compound 2 in the free state, starting from the gg (ω=~1800) rotamer. The exo-
anomeric conformer is unique at the glycosidic linkage, together with certain 
flexibility at ψ torsion. The gg rotamer is strongly predominant.  
Bottom: plot obtained from 20 ns of MD simulation of compound 2 in the free 
state, starting from the gt (ω=~-60) rotamer. Trajectories of the , ψ and  
torsion angles at the Mana1→6Man linkage are shown. After a few ns, the gg 
rotamer becomes strongly predominant. 
Therefore, we can conclude that the substitution of the hydroxyl groups 
at position 2 with fluorine atoms not only does not influence the ring 
conformation but also has no consequences on the conformational behaviour 
around the glycosidic linkages. Fittingly, these conformational analysis and MD 
simulations permitted to conclude that the ensemble average of conformers in 
the free state for the trifluorinated trimannoside mimic 2 is basically the same 
than that for the natural trimannoside 1. 
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2.2.2 The bound state: integrating NMR results, docking 
calculations and MD simulations 
Interestingly, in the X-ray structure of concanavalin A, another model 
lectin for the study of glycan binding, in complex with the trimannoside 1 (PDB 
ID 1CVN), the αMan 1→6 linked provides the major contacts with the lectin 
recognition site.
22
 Analogously, in order to assess the actual Man unit that is 
effectively bound to the PSA, we then conducted docking calculations of ligands 
1-4 into the PSA structure followed by MD simulations of the resulting 
complexes. The X-ray structure of PSA in complex with trimannoside 1 (PDB 
ID 1RIN), with only one terminal Man elucidated, was used as 3D geometry of 
the lectin for the docking calculations. Additional docking calculations were 
performed with trimannoside 2 with PSA geometry from 1OFS (PSA in 
complex with sucrose). Fittingly, all the docking models of the 
PSA/trimannoside complexes discarded the possibility of the reducing central 
residue Man to be accommodated into the lectin binding site. In fact, there 
would be important steric clashes between the protein backbone and the 1→3 
and 1→6 branches. Our calculations suggested that both A and B arms could 
be readily accommodated into the binding site (Figure 2.5).  
  
Figure 2.5. Docked binding poses of compound 2 into the X-ray 
crystallographic structure of PSA (yellow) from PDB ID 1RIN. Left: binding 
pose “I”: compound 2 (purple) is bound to the PSA through the arm A. Right: 
binding pose “II”: compound 2 (green) is bound to the PSA through the arm B. 
Only in the case of binding pose I, the fluorine atom on ManIII  is close to the 
PSA. 
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Particularly for compound 2, the docking calculations, with both 
AutoDock4 and VINA, led to two main predicted binding poses dubbed I and II 
(Figure 2.5), with only 1 kcal mol
-1
 of difference in the predicted binding 
energies in favour of the binding pose I. For both cases, we performed the MD 
simulations of the best docked complexes and analysed the ligand-protein 
interactions. In particular, we selected the docked poses from AutoDock4. In 
binding pose I, the arm A (1→3 linkage) is accommodated in the binding site; in 
the alternative pose II, the arm B (1→6 linkage) provides the major interactions 
with the lectin binding site. In fact, in both cases, equivalent interactions to 
those described in the X-ray PSA/Man complex (PDB ID 1RIN) are found for 
the interacting Man moiety: OH-3 interacts simultaneously with the NH group 
from Gly159 and the Asp111 carboxylate group, OH-6 interacts with the NH 
group from Glu248, and O5 establishes a hydrogen bond with the NH group 
from Ala247. Only in pose I, OH-4 interacts with the NH group from Gly129. 
No direct interactions are found for OH-2 from the interacting Man. This 
binding mode is also equivalent to that for Glc in the PSA/sucrose complex 
(PDB ID 1OFS). For the best predicted binding poses, additional interactions 
were found between the other terminal Man and the lectin, mainly with the 
Tyr154 CO group (Figure 2.6). Nevertheless these interactions were lost along 
the MD simulation, resulting in this terminal Man residue dangling into the 
solvent.  
 
Figure 2.6. MD simulation (50 ns) for the PSA/2 complexes starting from 
the two alternative docked binding poses I (arm A, grey) and II (arm B, black). 
In both MD simulations, the interaction with Tyr154 is lost almost at the 
beginning.  
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Other docked binding poses did not show this remote interaction and the 
alternative terminal mannoside (ManII for pose-I-like binding modes and ManI 
for pose-II-like binding modes) was always exposed towards the solvent with no 
interactions with the lectin. As for the branched ManIII, this sugar was placed 
close to the PSA only in the case of binding pose I (Figure 2.4).  
Regarding the 1→3 and 1→6 difluorinated dimannosides 4 and 3, the 
docking calculations predicted binding poses inside the Man recognition site 
with basically the same interactions involving the residues participating in the 
binding of the trimannoside: Gly129, Asn155, Asp111, Glu248, and Ala247. 
Interestingly, for the 1→6 derivative (compound 3 in Chart 2.1), only the 
binding pose with the ManII inside the binding site was obtained, while for the 
1→3 derivative (compound 4 in Chart 2.1), both binding poses through ManI 
and through ManIII were predicted (Figure 2.7). 
  
 
Figure 2.7. Top: docked binding poses of the α1→3 difluorinated 
dimannoside (4) with PSA (yellow). Two main binding poses were observed: one 
with the ManIII in the binding site (blue-left) and one with the ManI (cyan-right) 
in the binding site. Bottom: superimposition of several binding poses (grey) for 
the α 1→6 derivative (3). Docking calculations exclude the possibility to have 
ManIII inside the binding site. The same ligand/lectin interactions present in the 
X-ray crystallographic structure of the PSA/Man complex (with residues 
Gly129, Asn155, Asp111, Glu248, and Ala247, PDB ID 1RIN) were observed in 
all the docked poses. 
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In order to validate experimentally these models, 1D 
1
H,
19
F-STDreF 
NMR experiments using the complexes of PSA with the 1→3 and 1→6 
difluorinated disaccharide mimics 4 and 3 were first acquired. Fittingly, the 
analysis of the results demonstrated the participation of the reducing sugar unit, 
ManIII, of the glycan only when the terminal ManI, 1→3 linked is recognized 
(compound 4). In contrast, for the alternative analogue 3, the reducing end does 
not show any STD and thus, remains solvent exposed (Figure 2.8), in full 
agreement with the docking predictions. 
 
Figure 2.8. 1D 
1
H,
19
F-STDreF spectra. Top: STDreF spectrum of 3. 
Only the 1→6 Man residue shows STD signal, being the reducing moiety 
solvent exposed. Bottom: STDreF of 4. Both Man residues take part in the 
binding event. 
The stability of the two possible PSA/2 docked complexes (through arm 
A, pose I, and arm B, pose II) was assessed by MD simulations (Figure 2.9, 
left), which also provided a detailed picture of the lectin-ligand interactions. 
Both complexes were maintained stable along the 50 ns of MD simulations, 
mainly through the interactions with either the 1→3 arm (starting from docked 
pose I, Figure 2.4, top) or the 1→6 arm (starting from docked pose II, Figure 
2.4, bottom).  
Thus, from a qualitative perspective, neither of these simulations would 
point to a preferred binding pose. This suggests difficulties to clearly resolve the 
conformation of the complete trimannoside by X-ray crystallography, reason 
why only clear electron density maps for the terminal Man was provided.
12
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In fact, the RMSD of the heavy atoms of the ligand in both complexes 
(binding pose I and binding pose II) shows a high instability during the MD 
simulation (Figure 2.9, right and Figure 2.10). 
 
  
  
Figure 2.9. Representative plots from MD simulation of the two 
complexes PSA (PDB ID 1RIN)/2 from pose I (top) and pose II (bottom).  
Left: variation of the RMSD of the protein backbone and side chains found for 
the 50 ns MD simulation starting from pose I (top) and pose II (bottom) of the 
PSA/2 complex. Right: variation of the RMSD of the ligand (heavy atoms) for 
the 50 ns MD simulation starting from pose I (top) and pose II (bottom) of the 
PSA/2 complex. 
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Figure 2.10. RMSD fluctuation of single monomers in both binding poses.  
The interactions of the ManIII with the PSA were minor throughout both 
simulations, although in the docked binding pose I this ManIII was predicted to 
be closer to PSA. As outlined above in the docking calculations, in the complex 
through the arm A (pose I), the hydrogens H1, H2, and H4 of the reducing 
ManIII were close to Phe153 and Ala247 side chains (Figure 2.11).  
 
Figure 2.11. Superimposition of two PSA/2 complexes from the MD 
simulations. Top (green): compound 2 is bound through the 1→3 linked ManI 
(arm A), and hydrogens H1, H2, and H4 of the reducing ManIII are close to 
Phe153 and Ala247. Bottom (purple): compound 2 is bound through the 1→6 
linked ManIII (arm B) and ManIII is more apart from Phe153 and Ala247. 
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Interestingly, the analysis of the contributions to the protein/ligand 
binding energy by means of the MM-PBSA method suggests a slight preference 
binding pose (Figure 2.12 and Table 2.2). Indeed looking in details the van der 
Waals, the electrostatic and the polar solvation contribution of the key residues 
in Figure 2.12 and the energy contribution of each mannose to binding (Table 
2.2), a minor preference for the binding pose II is observed. In particular, this 
preference is dictated by electrostatic interaction between Glu248 and ManII in 
the binding pose II (Figure 2.13). Since the energy differences are not 
significant, there results are not conclusive towards a preferred binding pose. 
 
 
Figure 2.12. MD simulation (50 ns) for the PSA/2 complexes starting 
from the two alternative docked binding poses I (arm A) and II (arm B). The 
MM-PBSA suggests basically the same aminoacids are involved for the two 
alternative complexes. 
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Figure 2.13. Plot showing the variation of the RMSD, during 50 ns of 
MD simulation, of the distance between the H of the NH group of the Glu248 
from PSA and the O6 from ManI in the binding pose I (grey) and the O6 
fromManII in binding pose II (black) 
Table 2.2. Energetic contribution of each mannose to the binding in the 
both docked poses 
 
Contribution of 
each mannose to 
the binding  
energy in the  
pose I  
(kcal/mol) 
Standard 
Deviation 
Contribution of 
each mannose to 
the binding 
energy in the  
pose II 
(kcal/mol) 
Standard 
Deviation 
ManI -10,316 0,0661 -2,947 0.0614 
ManII -0,100 0,0216 -11,932 0.0635 
ManIII -1,163 0,0056 -1,626 0.0094 
Total -11,579  -16,505  
     
In a second step, regular 
1
H-STD-based competition binding experiments 
were also employed to determine that the fluorinated glycomimetics indeed 
compete with the natural mannosides for the same binding site
23
 and to estimate 
their relative affinities. The addition of the fluorinated mimics to one sample 
containing -methyl-Man in the presence of PSA led in all cases to the decrease 
in the STD signals of the reference ligand, and to the appearance of STD signals 
from the glycomimetics (Figure 2.14), thus confirming that a competitive 
binding process is taking place. 
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Figure 2.14 a) 
1
H-STD competition experiments: PSA (30 μM) in 
presence of a 0.7 mM concentration of α-methyl-Man and upon the gradual 
addition of a 0.1 mM (2), 0.4 mM (3) and 1.6mM (4) concentration of compound 
2, as a competitor. b) Expanded regions region are shown: the α-methyl-Man 
methyl group (3.49 ppm) STD signal intensity is progressively reduced, while 
the STD signal for the methyl group of compound 2 at 3.52 ppm was observed. 
 
The obtained binding affinities for the 
19
F-containing saccharides 2-4 
from the STD competition experiments are very similar and only slightly weaker 
than those reported for trisaccharide 1 (Table 2.3). The binding affinity for 4 is 
in between those obtained for the trisaccharides 1 and 2 and that reported for the 
single monosaccharide. However, the estimated KD for 3 is basically identical to 
that of the monosaccharide, as also suggested from the STDreF experiment. 
Only the non-reducing Man moiety contributes to the binding event. Therefore, 
the binding data are in agreement with the X-ray structure (PDB ID 1RIN) and 
the MD simulations, and point out that there is one residue providing the major 
ligand/lectin contacts (KD for α-methyl-Man is 0.65±0.16 mM), while the 
additional Man moieties only provide an additional minor stabilization of the 
complexes (KD for the disaccharides are ca. 0.41-0.65 mM, while KD for the 
trisaccharides are ca. 0.19-0.23 mM). 
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Table 2.3. Affinity constants determined through 
1
H-STD NMR 
experiments 
Compounds Estimated KD (mM) 
Methyl -D-mannopyranoside 0.65 ±0.16
11
 
1 0.19 ±0.07
11
 
2 0.23 ±0.03 
3 0.63 ±0.17 
4 0.41 ±0.03 
 
The overlapping of key 
1
H NMR resonances at the sugar region 
precluded further analysis of the binding epitope at the residue level by using 
standard STD analysis. In order to address this problem, Prof. Jiménez-
Barbero’s group employed novel 2D 1H, 19F STD-TOCSYreF NMR 
experiments (data not shown). These experiments take advantage from the 
presence of the 
19
F nuclei, thus additionally allowing for further specific 
resolution enhancement comparison with classical experiments such as STD-
TOCSY. This information may also be deduced from the already described 
TOCSYreF experiment,
19, 24-25 although the version by Prof. Jiménez-Barbero’s 
group is improved with some technical modifications regarding the TOCSY 
mixing sequence. Thus, the experiment allows for the integration of the STD 
signals at every particular residue and for every proton at one particular sugar 
ring. Interestingly, the results underline the major participation of the 1→3 
linked ManI (arm A) in PSA binding, being the signals from this residue the 
most intense ones (globally stated as 100%, Table 2.4) in the STD-TOCSYreF 
spectrum. Nevertheless, the protons belonging to the 1→6 linked ManII (arm 
B) also show significant STD signals (60% of relative intensity, Table 2.4) 
demonstrating, beyond all doubts, the simultaneous existence of a second 
binding mode,
13
 for which the mannose moiety 1→6 linked is at the 
recognition site of Pea lectin.  
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According to the STD data, the contribution of this binding mode II is 
smaller than that of the alternative pose I, although still significant. The O-
methylated ManIII at the reducing end of the glycan also shows STD signals, 
although at lower extent (20% of relative intensity, Table 2.4).  
Table 2.4. Quantitative and relative estimation of the STD signals for 
every fluoromannose unit. The individual (per proton) and global (per residue) 
STD intensities are given. 
Relative STD Intensity 
 ManI ManII ManIII 
H1 37 % 17 % n.d* 
H2 100 % 60 % n.d* 
H3 37 % 31 % 25 % 
H4 35 % 48 % 20 % 
H5 43 % - - 
 H6R - - - 
H6S - - - 
Residue 100 % 62 % 20 % 
*Due to the overlapping between H1 and H2 signal it is not possible to 
estimate quantitatively the individual STD contribution arising from those 
protons. 
This observation also agrees with that described above for the 
disaccharide 4. The docking and MD simulations analysis from the 
PSA/trifluoromannoside 2 discarded the possibility of direct interaction of the 
reducing Man moiety at the binding site, but pointed at the proximity of the 
ManIII hydrogens H1, H2, and H4 with Phe153 and Ala247 side chains. 
Therefore, in this particular case, it is highly plausible that the interaction of 
ManI at the major binding site also allows for minor contacts of the reducing 
ManIII with the lectin, as pointed out in the MD simulations. Therefore, the 
combination of the modelling and NMR experimental data indicates the co-
existence of two different binding modes for the trifluorinated trimannoside 
when interacting with the plant lectin from Pisum sativum. This example 
accounts for the complementarity between these techniques for the elucidation 
of complex molecular recognition problems where experimental techniques 
cannot provide a full response. Moreover, we have provided a novel example of 
the usefulness of the 
19
F NMR applied to the recognition of fluorinated-glycans, 
technique with a many potential applications in the near future. 
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2.3. Material and Methods  
The ring numbering system used in this work is standard for sugar 
systems, from C1 to C6. The arm A corresponds to the 1→3 linked Man also 
dubbed ManI. The arm B corresponds to the 1→6 linked Man also dubbed 
ManII. The reducing (branched) Man is dubbed ManIII. Glycosidic torsion 
angles are defined as:  = H1(i)-C1(i)-O1(i)-Cn,  = C1(i)-O1(i)-Cn-Hn,  = O5(i)-
C5(i)-C6(i)-O6(i), where i indicates a given residue and n a ring position. 
 Ligand preparation. Ligands 1-4 were generated starting from no-
fluorinated analogues obtained by the carbohydrate builder from GLYCAM.
21
 
For the compound 2-4, the OH-2 groups of each Man residue were replaced by 
fluorine atoms. Optimized geometries and charge calculations of the ligands 1-4 
were obtained by using the MM3* force field within Macromodel.
18
 Also 
sucrose (αGlc1-2βFru) and α-mannose, used for the validation of the docking 
protocol (see below).  
Conformational analysis, DFT calculations and MD simulations of the 
ligand at the free state. For the glycosidic linkages 1→3 and 1→6 a coordinate 
scan was performed with MM3* and adiabatic curves were obtained (e.g. Figure 
2.3, top). The energy profile torsion (e.g. Figure 2.3, bottom) for the glycosidic 
linkages were obtain by coordinate scan with DFT calculation with 
Gaussian03.
26
 B3LYP/3-21G was used as basis set. MD simulations were 
performed using AMBER12 suite of programs.
27
 Charges for the fluorinated 
moieties were calculated using Gaussian03
26
 at the B3LYP level of theory and 
the 6-31G++ basis set. RESP charges were derived with Antechamber, using the 
RESP fitting method. GLYCAM06 was used as force field. Each ligand was 
solvated within a cubic periodic water box of TIP3P waters at a minimum 
distance of 10 Å and a MD simulation of 20 ns was run. The behaviour of the 
ligand was analysed with the cpptraj module, included in the AmberTools13 
package.
27
 The torsion angles were monitored along the MD trajectory. 
Protein preparation. The X-ray structures of PSA in complex with 
trimannoside (PDB ID 1RIN, resolution of 2.6 Å) and sucrose (PDB ID 1OFS, 
resolution of 1.80 Ǻ) were used. Water molecules were removed. Hydrogens 
were added with Epik
28
 at physiological pH.  
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The manganese and calcium ions were kept. Histidine protonation was 
established as HIE with the exception of His166 which was assigned as HIP 
because of the proximity to Glu150 carboxylate side chain and Asp165 CO 
group. The protein structure was minimized with OPLS 2005 with implicit 
solvent (water). For the docking calculations, Gasteiger charges were assigned 
by AutoDockTools.
29
 Missing residues Leu213-Glu214-Glu215-Glu216-
Asn217, far away from the binding site, were added with PyMOL.
30
 Finally, 
MD simulations were performed during 20 ns using the AMBER12 package and 
the Amberff10 force field, and the stability of the protein was corroborated by 
RMSD monitorization. 
Validation of the docking methodology. The docking protocols with 
AutoDock4 and VINA were followed for the prediction of the binding of 
sucrose and mannose towards the Pea lectin (from PDB IDs 1OFS and 1RIN, 
respectively). The X-ray crystallographic pose was predicted in both cases with 
both programs AutoDock4 and VINA.  
Docking calculations. Docking calculations were performed with 
AutoDock4 and VINA.
31
 With AutoDock4, the Lamarckian genetic algorithm 
was used to sample different conformations of the ligands, by randomly 
changing all the torsion angles and overall orientation of the molecule. A three-
dimensional grid was defined centred on an equidistant point to the side chains 
of key binding residues: Phe153, Tyr154 and Gly216. The grid spacing was 
0.375 Ǻ (50 x 48 x 68 Ǻ), and a distance-dependent dielectric constant was 
used. The original Lennard-Jonnes and hydrogen-bonding potentials provided 
by AutoDock were also used. After docking, the 200 solutions were clustered in 
groups with root-mean-square deviation less than 1.0 Ǻ. The clusters were 
ranked by the lowest energy representative of each cluster.  
MD simulations of the complexes. The two best docked solutions for 
ligand 2 (binding pose I and binding pose II) were considered as starting 
geometries to perform the MD simulations. Five Na
+ 
counterions were added to 
neutralize the system. Each system was then solvated by using TIP3P waters in 
a cubic box with at least 10 Ǻ of distance around the complex. GLYCAM06, 
gaff, and Amberff10 were used as force fields.  
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The MD simulations were carried out by using the sander module in the 
GPU accelerated version of AMBER12, using CUDA programming language 
and NVIDIA graphics cards. The shake algorithm was applied to all hydrogen 
containing bonds, and 1 fs integration step was used. Periodic boundary 
conditions were applied, as well as the smooth particle mesh Ewald method to 
represent the electrostatic interactions, with a grid space of 1 Ǻ. Each system 
was gently annealed from 100 to 300 K over a period of 25 ps. The system were 
then maintained at temperature of 300 K during 50 ps with a solute restraint and 
progressive energy minimizations, gradually releasing the restraints of the solute 
followed by a 20 ps heating phase from 100 to 300 K, where restraints were 
removed. Production simulation for each system lasted 50 ns. Coordinate 
trajectories were recorded each 2 ps throughout production runs, yielding an 
ensemble of 5000 structures for each complex, which were finally analysed. The 
residue contribution to the free binding energy along the simulations was 
calculated by means of the MM-PBSA method. 
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Annex II 
 
Figure 2.A1. Strips of 2D 
1
H,
19
F-COLOC NMR spectrum of 2 at the 
corresponding frequency of the 
19
F atom at every mannose unit. This experiment 
allows the analysis for the 
x
JFH coupling constants of the protons directly 
coupled to the 
19
F atom at two or three bonds. In this way, the ring 
conformation could be easily assessed. 
 
 
Figure 2.A2. Strips of 2D 
1
H,
19
F TOCSYreF experiment (80 ms mixing 
time) of 2 at the corresponding frequency of the 
19
F atom at every mannose unit. 
The spin systems for each one of the monosaccharidic units are now determined 
in a non-ambiguous manner. 
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Figure 2.A3. Strips of 2D 
1
H,
19
F HOESY (400 ms mixing time) of 
molecule 2 for each fluorine atom at the proper mannose unit (orange). Intra-
residue 
1
H-
19
F nOe cross peaks are highlighted with a red line; while inter-
residue nOe cross peak is labeled with a green line. No other inter-residue 
heteronuclear nOe are observed above the noise level. In blue, 
1
H, 
19
F-TOCSY 
spectrum (80 ms mixing time) as chemical shift reference. 
 
 
 
Figure 2.A4. Strip of 2D NOESY spectra (600 ms mixing time) for 2 
taken at H1 frequencies (axis y) of the three Man moieties. Key inter-residual 
NOEs are highlighted. 
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Table 2.A1. Relevant inter-atomic distances (Å) for the key conformers of 
mimic 2 from molecular mechanics calculations. Relative energies are reported. 
The descriptors in Arabic numeral refer to the particular mannose sugar ring. 
The comparison with the essential experimental NOE contacts with 
conformational information is also provided. The relevant intra and inter 
residue and ensemble average <r
-6
>
-1/6
 proton-proton and proton-fluorine 
distances (Å) were estimated from the integration of the observed NOEs cross 
peaks using the ISPA approximation. 
Compound 2 
Atom Pair 
Calculated distance for each conformer (Å) and steric 
energy values [kcal∙mol-1] 
Observed 
NOE 
Intensity 
Experimental 
distance (Å) 
(±5%) 
Average 
derived 
conformer* 
2a 
[+5.7] 
2b 
[+0.2] 
2c 
[+5.5] 
2d 
[0.0] 
2e 
[+18.8] 
2f 
[+13.2] 
H1 
III 
OCH3 2.4 2.4 2.4 2.4 2.4 2.4 Very 
strong 
2.4 2.4 
H3 
III 
H1 I 3.1 2.1 3.1 2.1 3.1 2.1 strong 2.6 2.6 
H4 
III 
H1 I 2.7 4.3 2.7 4.3 2.7 4.3 medium 3.0 3.5 
H6R 
III 
H1 II 3.0 3.0 3.0 3.0 3.6 3.6 medium 3.0 3.1 
H6S 
III 
H1 II 2.4 2.4 2.4 2.4 3.0 3.0 strong 2.6 2.5 
H2 
II 
H3 II 2.5 2.5 2.5 2.5 2.5 2.5 Very 
strong 
2.5 2.5 
H2 
III 
H5 I 3.3 2.6 3.3 2.6 3.3 2.6 Medium 
strong 
2.8 2.9 
F III H4 III 2.7 2.7 2.7 2.7 2.7 2.7 strong 2.6 2.7 
F III H5 I 4.6 2.7 4.6 2.7 4.6 2.7 Medium 
weak 
3.4 3.6 
 
Table 2.A2. Chemical shift assignments (ppm) and 
3
JHH values (Hz) of 
the trimannoside analogue 2. 
 1→3 arm (ManI)  1→6 arm (ManII)  Reducing residue (ManIII) 
Position 1H 19F  1H 19F  1H 19F 
1 5.27 (2.0)  (7.6)  5.06 (2.0)  (7.3)  4.89 (2.0)  (7.4) 
2 4.81 (2.5) -204.2 (49.0)  4.74 (2.3) -206.0 (49.0)  4.88 (2.3) -204.2 (49.0) 
3 3.87 (9.3)  (32.0)  3.82 (9.0)  (32.0)  3.91 (9.3)  (30.3) 
4 3.66 (10.0)   3.65 (‡)   3.86 (9.6)  
5 3.75 (‡;‡)   3.67 (3.5;‡)   3.81 (3.6; 2.0)  
6R 3.81 (11.3)   3.80 (12.7)   4.02 (11.4)  
6S 3.72   3.73   3.70  
OCH3       3.36  
Bracketed values in the 
1
H and 
19
F columns are 
3
JHH and 
x
JFH values, 
respectively. ‡ J coupling could not be quantified due to spectral overlap. 
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CHAPTER 3 
 
STRUCTURAL INSIGHTS ON THE RECOGNITION OF THE ΑLPHA-TYPE 
HISTO-BLOOD ALPHA-GAL EPITOPE BY GALECTIN-3 
 
3.1. Introduction 
Molecular recognition events are essential for life processes. Glycan-
protein interactions are the key for many diverse beneficial and pathological 
events.
1
 Among glycan receptors, galectins are specific galactose binding lectins 
that have been reported to participate in a myriad of biological events of 
different nature, mainly through the specific recognition of galactose contained 
in glycans on cell surfaces, in a crosstalk process between glycan and lectin 
containing cells. Therefore, in the last years the interest in these proteins as 
therapeutic targets has increased since the development of selective galectins 
inhibitors could improve the prognosis of many diseases.  
Recently, their role in innate immunity, through the recognition of 
glycans on pathogens, has been proposed.
2-4
 The recent demonstration that 
galectins 4 and 8 are able to kill E. coli bacteria expressing blood group B 
antigen
5
 has reinforced this idea, and raised the question whether immuno 
lectins would have a role in protection against pathogens expressing self-like 
antigens. The presence of blood group epitopes on erythrocytes is intriguing and 
it has been related with evolutionary processes arising from the pressure to react 
against pathogen producing blood group type molecules for attachments to cells 
and subsequent invasion.
6
 Other glycans very similar to self antigens, have been 
proposed as molecular patterns for the recognition of parasites by the immune 
system, a process in which galectins would be involved.  
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In particular LacdiNAc (compound 1 in Scheme 3.1, βGalNAc1-
4GlcNAc), very similar to lactose (Lac, βGal1-4Glc), is present in vertebrates as 
constituents of N-glycans, is highly abundant in helminth parasites, and it has 
been proposed as a parasite pattern for galectin-3 (gal-3) mediated immune 
response.
7
 
Even though gal-3 has been reported before to indeed recognize A-type 
histo-blood group type II tetrasaccharide
8
 and LacdiNAc.
7
 LacdiNAc-glycans 
constitute a parasite pattern for galectin-3-mediated immune recognition.
7
 With 
higher affinity than that for lactose,
9
 the structural basis of such interactions is 
not available yet. Herein we describe the atomic details of the interaction of gal-
3 with a variety of glycans of different size, from the simple LacdiNAc 
disaccharide (1) to the blood group A type II tetrasaccharide (compound 4 in 
Scheme 3.1, GalNAc1-3(Fuc1-2)Gal1-4GlcNAc), passing by the α-Gal 
trisaccharide (compound 2 in Scheme 3.1, Galα1-3Galβ1-4GlcNAc) and α-Gal 
tetrasaccharide (compound 3 in Scheme 3.1, Galα1-3Galβ1-4GlcNAcβ1-3Gal). 
Compounds 2 and 3 contain the α-Gal epitope (Galα1-3Galβ1-4GlcNAc), which 
is a major xenoantigen expressed on glycoconjugates of non-primate mammals. 
In turn, apes and humans produce a natural antibody (anti-Gal), which 
specifically binds α-Gal epitope. Anti-Gal is produced as the most abundant 
antibody (1% of immunoglobulins) in all individuals, and represents an 
important barrier for xenotransplantation.
10
 However, this antibody is not the 
only responsible for the rejection of pig xenograft organs in humans, since 
lectins have also been shown to be involved in that process. Specifically, gal-3 
has been identified as the receptor for monocyte-dependent recognition of 
porcine endothelium via binding to α-Gal epitope, playing an important role in 
delayed xenograft rejection.
11
 The work has been performed through a 
combination of experimental NMR methods, both from the ligand and the 
galectin’s perspective, and molecular modelling protocols.  
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Using this combined approach, we here report the ligand-receptor 
interactions accounting for the gal-3 recognition of the important xenoantigen α-
Gal epitope, showing the important role of gal-3 in the initial recognition and 
adhesion of human monocytes to porcine aortic endothelial cells which may 
contribute to delayed xenograft rejection.
10
 
 
 
1. LacdiNAc 
(GalNAcβ1-4GlcNAc) 
 
2. α-Gal trisaccharide 
(Galα1-3Galβ1-4GlcNAc) 
 
 
 
3. α-Gal tetrasaccharide 
(Galα1-3Galβ1-4GlcNAcβ1-3Gal) 
 
 
Lactose, Lac 
(Galβ1-4Glc) 
 
 
 
4. blood group A type II tetrasaccharide 
(GalNAc1-3(Fuc1-2)Gal1-4GlcNAc) 
Scheme 3.1. Chemical structure of the studied ligands. 
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3.2. Results 
3.2.1.  The recognition of LacdiNAc by gal-3 
Docking calculations were undertaken to predict the binding pose of 
compounds 1-4 in galectin-3. Three different docking protocols (AutoDock4, 
VINA, and Glide) were used in order to check whether the results were in 
agreement, and avoid any bias due to the scoring function. Overall, the docking 
results from the three programs were in very close agreement, predicting low 
energy poses similar to that for lactose in the X-ray structure (PDB ID 3ZSJ). 
For MD simulations, we took into consideration the best docked solution energy 
from AutoDock4. 
Docking calculations showed the best pose of compound 1 (LacdiNAc) 
bound to gal-3 to be very similar to that of lactose (Figure 3.1). Indeed, all the 
sugar-lectin intermolecular interactions are analogous to those described for 
lactose binding.
12
 In particular, the CH-π interaction between the GalNAcβ and 
Trp181 is present, as well as the Gal-specific hydrogen bond between the OH4 
of the GalNAcβ with His158. Other intermolecular hydrogen bonds are also 
present involving Arg162, Asn174, Glu184, and Arg186 of the lectin and 
several polar groups of the disaccharide. This docking-based structure was then 
submitted to 50 ns MD simulation to assess the stability of the complex.  
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Figure 3.1. Left: Docked binding pose of LacdiNAc (compound 1, 
represented in pink sticks) in complex with gal-3 (X-ray crystal structure PDB 
ID 3ZSJ, grey surface) superimposed with crystallographic lactose binding pose 
(cyan sticks). Right: atomic details of the interactions established by LacdiNAc 
(in pink sticks) and the carbohydrate recognition domain (CRD). A net of 
hydrogen bonds is formed by the hydroxyl groups of the LacdiNAc and the side 
chains of Arg186, Arg162, His158, Arg144 and Asn160. Moreover the GalNAc 
moiety establishes a stack interaction with Trp181.  
The RMSD values for the heavy atoms of the ligand and the protein 
backbone and side chain were monitored along the 50 ns of MD simulation. 
Variations smaller than 2 Å were registered, showing that the complex was 
stable along the MD simulation time (Figure 3.2). 
  
Figure 3.2. Left: Computed RMSD for heavy atoms of the ligand 1 in the 
MD simulation of the complexes of gal-3 (PDB ID 3ZSJ) with LacdiNAc.  
Right: Computed RMSD for the lectin backbone (black) and the side chain 
(grey) in the MD simulation of the complexes of gal-3 with LacdiNAc (1). 
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The predicted 3D structure was in complete agreement with the NMR 
experimental data. From the ligand point of view, the bound conformation is 
analogous to that in the free state, with protons H1GalNAc-H4GlcNAc at a 
distance of 2.5 Å, in agreement with the trNOESY experiment (Figure 3.A1 in 
Annex III). The STD data (Figure 3.3) show in fact that the GalNAc residue of 1 
is in close contact with the protein, in agreement with the docked structure, with 
both acetyl groups exposed to the solvent. In particular H4 and H6 of GalNAc 
are involved in CH-π interaction with Trp181. Clear chemical shift perturbations 
are observed for the interacting residues in the HSQC (Figure 3.4) recorded for 
the gal-3/1 complex, including the lateral side chain signals for Arg186 and 
Arg162, which are directly involved in intermolecular hydrogen bonds.  
 
Figure 3.3. STD for gal-3/1 at a 1/90 molar ratio. Both acetyl groups 
received similar saturation transfer from the protein that is below 20% 
(STD relative). The protons of the linker showed no significant STD 
effect. 
Moreover a correlation between HSQC data and energetic analysis 
contribution was performed. In particular, the region of the arginine showed a 
clear perturbation of their signal (Figure 3.4) in agreement with the energy 
contribution of these residues in the MM-PBSA analysis (Figure 3.5, top). As in 
HSQC analysis, a comparison between energetic values of the lactose/gal-3 
complex and LacdiNAc/gal-3 complex was analysed. Globally, slight 
differences in terms of energy were detected. In particular, LacdiNAc/gal-3 
complex shows a higher electrostatic contribution of the Arg162 and Arg186 
than in the lactose-gal-3 complex, in agreement with HSQC data (Figure 3.4-
right). From the MM-PBSA analysis is possible to note as the switch from Gal 
moiety in the lactose to the GalNAc moieties in LacdiNAc seems to be more 
favourable for the stacking interaction with Trp181. 
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Figure 3.4. The interaction of 1 with gal-3. Left: A. Overlaid 
1
H-
15
N 
HSQC spectra of gal-3 CRD (black) and in the presence of 20 equivalents of 1 
(red). B. Comparison between chemical shift differences for 1 (red) and lactose 
(black), highlighting a group of residues differentially perturbed by 1 (Arg162-
Phe163-Asn164). Right: Plot of the arginine region in the 
1
H-
15
N HSQC spectra 
of gal-3 (in black) upon addition of 1 (red). Arg186 and Arg162 show 
significant chemical shift variations. Arg144 shifts very little. In contrast, 
Arg151, Arg129, Arg168, Arg169, and Arg183 do not show any perturbation 
upon ligand binding. 
 
 
 
Figure 3.5. Pair wise energy decomposition analysis by MM-PBSA.  
Top: Energy contribution of the CRD aminoacids with relative standard 
deviations in gal-3-LacdiNAc complex. Bottom: Comparison of the energy 
contribution of the CRD aminoacids in the gal-3-lactose and gal-3-LacdiNAc 
complexes. 
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3.2.2.  The recognition of the α-Gal epitope by gal-3 
Complexes for gal-3 with the two α-Gal epitope glycans (2 and 3) were 
generated and submitted to docking calculations. The 3D perspective showed by 
the docked structures suggested that the presence of additional sugars in 
compounds 2 and 3 does not interfere with the recognition of the central lacNAc 
(Galβ1-4GlcNAcβ) moiety. The predicted binding mode of compound 2 (Figure 
3.6) indicated that the interactions with the lacNAc moiety are kept as in the 
corresponding crystal structure, i.e. hydrogen bonds involving side chains of 
aminoacids His158, Arg162, Arg186 and Glu184, and the typical CH-π 
interaction between the Trp181 indole ring and the α-face of the β-linked 
GalNAc. Besides, the docking calculations predicted the positioning of the 
additional Galα1-3 onto the vicinal strand, providing extra hydrogen-bonds with 
the Arg144 and Asp148 side-chains. The docked binding pose was then 
submitted to 50 ns of MD simulation. The complex gal-3/compound 2 has been 
observed to be stable along all the simulation (Figure 3.7), as it possible to see 
from the RMSD of the backbone and sidechain of the protein. Nevertheless 
during the MD simulation, compound 2 establishes new interactions with the 
vicinal pocket through a slight relocation into the binding site (Figure 3.6-
bottom). 
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Figure 3.6. Top: Structural docking model of the complex of the X-ray 
crystallographic structure of gal-3(grey surface, PDB ID 3ZSJ) with compound 
2 (Galα1-3Galβ1-4GlcNAc orange). Bottom: Comparison between the docked 
binding pose of compound 2 (orange) and the average structure of MD 
simulation (cyan) at 23 ns are superimposed. New hydrogen bond interactions 
are predicted between the additional α(1-3)-linked galactose moiety and the 
Arg144 and Asp148 side-chains (shown in sticks).  
  
Figure 3.7. Left: RMSD of the backbone and sidechain of gal-3 in 
complex with compound 2. Right: RMSD of the heavy atoms in compound 2 
along the 50 ns of MD simulation. 
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For tetrasaccharide 3 two different binding modes were proposed. 
Additionally to the crystallographic-like pose (Figure 3.8, left), another binding 
pose was identified for which the reducing end Galβ unit makes contacts with 
the carbohydrate binding site and Galα 1-3-linked OH-4 establishes a hydrogen 
bond with Asp239 (Figure 3.8, right). These docking-based complexes are in 
good agreement with the selective chemical shift perturbations, occurring only 
in the presence of 2 and 3, but not with lactose. 
 
  
Figure 3.8. Left: View of the major docked pose for compound 3 (deep 
teal sticks) bound to the X-ray crystallographic structure of gal-3 (PDB ID 
3ZSJ, grey cartoons). The predicted binding pose for the LacdiNAc moiety 
closely resembles that of the lactose-like crystallographic structure. Main 
residues involved in the binding are depicted with grey sticks.  
Right: Docked structure from the alternative cluster of the complex of the α-Gal 
tetrasaccharide 3 (blue sticks) with X-ray crystallographic structure of gal-3 
(PDB ID 3ZSJ). The reducing Gal moiety makes contacts with the lectin, while 
the non-reducing residues are exposed to the solvent. This minor pose may 
explain the STD-data regarding the observations of certain degree of saturation 
at the reducing end gal unit. 
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The stability of the different complexes was evaluated by MD 
simulations. The glycans-gal-3 complexes formed with both predicted poses for 
ligand 3 were highly stable, with very minor RMSD deviations in the Cα and 
sugar heavy atoms (below 2 Å, Figure 3.9).  
  
  
Figure 3.9. Top: RMSD of the backbone and sidechain of gal-3 in 
complex with the major binding pose (left) and the minor one (right) of 
compound 3. Bottom: RMSD of the heavy atoms the major binding pose (left) 
and the minor one (right) of compound 3 along the 50 ns of MD simulation. 
In any case, the HSQC data unequivocally indicate that the major 
complex corresponds to the most populated docked pose (structure shown in 
Figure 3.8-left), while the STD data suggest that a minor contribution of the 
alternative docked pose shown in Figure 3.8-right may also co-exist. The 
analysis of the data provided insights on the energy values of the new 
interactions for 2 and 3 relative to the disaccharides, as well as the associated 
movements.  
From a MM-PBSA analysis, it was possible to assess subtle differences 
between the complexes. In particular, compound 2 establishes better interactions 
with Arg144 and Trp181 (Figure 3.10). This behaviour is also observed in the 
binding energy predicted from the docking studies. 
0
1
2
3
0 10 20 30 40 50
R
M
SD
 (
Å
) 
Time (ns) 
Sidechain Backbone
0
1
2
3
0 10 20 30 40 50
R
M
S
D
 (
Å
) 
Time (ns) 
Cα Sidechain
0
2
4
0 10 20 30 40 50
R
M
S
D
 (
Å
) 
Time (ns) 
0
2
4
0 10 20 30 40 50
R
M
S
D
 (
Å
) 
Time (ns) 
CHAPTER 3 
112 
 
 
Figure 3.10. Pair wise energy decomposition analysis by MM-PBSA.  
a) Energy contribution of the CRD aminoacids with their relative standard 
deviations in gal-3-compound 2 complex.  
 
 
 
Figure 3.11. Top: Energy contribution of the CRD aminoacids with their 
relative standard deviations of gal-3 in complex with the major binding pose of 
compound 3.Bottom: Energy contribution of the CRD aminoacids with their 
relative standard deviations of gal-3 in complex with the minor binding pose of 
compound 3. 
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The energy contribution in the binding with ligand 2 (Figure 3.10) results 
to be very similar to the energy contribution of compound 3 (Figure 3.11). 
Appreciable difference is seen in the electrostatic contribution of Trp181 that in 
the case of the binding with compound 3 is higher due to the interaction between 
the NH of the indole ring and the O6 of the αGal moiety. As a general 
conclusion, the recognition of the LacdiNAc (compound 1) and the α-Gal 
epitope-derived oligosaccharides 2 and 3, all of which can be essentially 
understood as substituted lacNAc molecules, show analogous recognition 
features to those observed for that disaccharide and for lactose. In addition, 
selective local perturbations detected by NMR (Figure 3.12 and Figure 3.13), 
and interpreted by molecular modelling, permit to map the location of the 
additional Gal- decorating moieties at the adjacent pocket close to the Gal-
binding site in gal-3. 
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Figure 3.12. Left: A: Comparison between the chemical shift 
perturbations observed for 2 (orange) and lactose (black). B: Overlaid 
1
H-
15
N 
HSQC spectra of gal-3 (black) and with 10 eq. of 2 (orange). C: Comparison 
between the chemical shift perturbations for 3 (purple) and lactose (black). Key 
differences are highlighted. D: Overlaid 
1
H-
15
N HSQC spectra of gal-3 CRD 
(black) and with 10 eq. of 3 (purple). Right: Top: Plot of the arginine region in 
the 
1
H-
15
N HSQC spectra of gal-3 (in black) upon addition of 2 (red). Arg186, 
Arg144, and Arg162 show clear chemical shift variations, especially Arg186 
and Arg144. In contrast, Arg151, Arg129, Arg168, Arg169, and Arg183 do not 
show any perturbation upon ligand binding. Bottom: Plot of the arginine region 
in the 
1
H-
15
N HSQC spectra of gal-3 (in black) upon addition of 3 (red). 
Arg186, Arg144, and Arg162 show chemical shift variations, especially Arg186 
and Arg144. In contrast, Arg151, Arg129, Arg168, Arg169, and Arg183 do not 
show any perturbation upon ligand binding. The changes for Arg144 and 
Arg162 are similar for both molecules. A different perturbation is observed for 
Arg186 in either complex. The variation of Arg144 is evident, while this was not 
the case for the complex with 1. 
 
 
Figure 3.13. Left: Epitope mapping deduced from STD data, with 
colours showing relative STD intensities to the most saturated signal.  
Right: Epitope mapping deduced from STD data, with colours showing relative 
STD intensities to the most saturated signal. 
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3.2.3.  The recognition of blood group A type II tetrasaccharide  
A molecular model for the complex between gal-3 and 4 was then 
generated (Figure 3.14). From the STD (Figure 3.15) and the chemical shift 
perturbation analysis, it can be assumed that the lactose moiety of the 
tetrasaccharide is located at the lactose binding site and establishing the typical 
interactions: the α face of Gal establishes CH-π contacts with Trp181, and there 
are hydrogen bonds involving His158, Arg162, Asn174, Glu158 and Asn160 of 
the protein and OH4, OH6 and O5 of Gal and OH3 of GlcNAc, respectively. On 
the other side, the trNOESY analysis indicates that there is no conformational 
deviation from the free state upon binding. Thus, by using these two premises a 
starting complex was built, which was submitted to one initial 50 ns MD 
simulation. Different parameters were monitored in order to check the stability 
of the complex. The RMSD of the backbone of the protein was kept below 1.25 
Å (Figure 3.14).  
  
Figure 3.14. Left: Structural docking model of the complex of X-ray 
crystallographic structure gal-3(PDB ID 3ZSJ) with compound 4 (green sticks). 
Aminoacids involved in the binding are shown in grey sticks.  
Right: RMSD in the Cα of gal-3 in complex with compound 4. 
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As mentioned above, the typical interactions for the recognition of 
lactose are kept. The only H-bond in which GlcNAc participates is that between 
OH6 and the indole NH of Trp181. Besides, a hydrophobic interaction between 
the methyl of the acetyl group with Ala146 could take place, although from the 
MM-PBSA analysis (Figure 3.16) the van der Waals contribution was small (-
0.4 kcal mol
-1
). The fitting of GlcNAc residues requires rearrangement of the 
side chain of Arg144 that folds back towards the protein backbone adopting a 
particular orientation. This fact is in agreement with the observation of a strong 
chemical shift perturbation of its backbone NH and side chain resonances upon 
ligand binding, effect not observed with other ligands. The fucose residue is far 
from the protein surface, and establishes no contact with the lectin.  
   
Figure 3.15. A: On top STD and below corresponding reference spectra 
for a 43 uM/2mM gal-3/4 sample. Signals with an asterisk indicate protons with 
no or very weak STD effect. The methyl groups of the Ac are assigned to their 
corresponding residues. Proton signals with strongest STD effect clearly 
identified are annotated with the corresponding STD percentage relative to the 
largest value (H1GalNAc). 
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Figure 3.16. Pair wise energy decomposition analysis by MM-PBSA.  
Energy contribution of the CRD aminoacids with their relative standard 
deviations in gal-3-4 complex. 
 
Previous studies have shown that gal-3 recognizes the blood group 
antigens with higher affinities with respect to lactose.
9
 In particular, 4 has been 
reported to bind gal-3 more than one order of magnitude better than lactose at 
298K. Thermodynamic studies showed a difference of ca. 1.9 kcal mol
-1
, with a 
strong enthalpy-entropy compensation phenomenon. The authors claimed that 
there is a positive enthalpic contribution, related to a water-mediated hydrogen 
bond between OH4 of the fucose and Glu165. However, our data suggest that 
the fucose moiety is not involved in any contact with the lectin and that, 
therefore, the reported increase of enthalpy could be related to a hydrogen bond 
between OH6 of GalNAc and NH of the Trp181 indol, as also suggested from 
MM-PBSA results. 
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3.3. Material and Methods  
Protein Preparation: Around 42 crystallographic structures of galectin-3 
are available at the Protein Data Bank,
13
 40 of those are from Homosapiens. For 
our studies we used PDB 3ZSJ
12
 with a resolution of 0.86 Ǻ, in complex with 
the natural ligand lactose. The protein were prepared using the Protein 
Preparation Wizard tool included in Maestro.
14
 Water molecules, co-factors of 
crystallization and ligands were removed, missing atoms were added, side 
chains and loops were filled by Prime, and hydrogens were added with Epik at 
physiological pH. For the preparation of the protein, the protonation of His158 
was considered as HID.
12
 This final structure of the protein was minimized with 
OPLS 2005 force field as implemented in Maestro with implicit solvent (water). 
The final minimized structure was used for docking purposes. 
Ligand Preparation The ligands (Scheme 3.1) used in this study were 
lactose (compound 1, βGalNAc1-4GlcNAc), α-Gal trisaccharide (compound 2, 
αGal1-3βGal1-4GlcNAc), α-Gal tetrasaccharide (compound 3, αGal1-3βGal1-
4βGlcNAc1-3Gal) and the blood group A type II tetrasaccharide (compound 4, 
GalNAc1-3(Fuc1-2)Gal-4GlcNAc). β configuration was used for all the 
terminal sugar. The ligands were generated using the carbohydrate builder from 
GLYCAM,
15
 and minimized with semi-empirical method AM1. In order to get 
an optimal starting geometry for the docking calculations, a conformation 
analysis was performed with Macromodel
14
 using MM3* force field. Most 
stable conformations for glycosidic linkages and O5C5C6O6 dihedral angle 
were chosen for each monosaccharide. 
Validation of the docking methodology. The docking protocols with 
AutoDock4, VINA and Glide were followed for the prediction of the binding of 
lactose in the galectin-3 (from PDB ID 3ZSJ). The X-ray crystallographic pose 
was predicted in the three cases with the three programs AutoDock4, VINA and 
Glide. 
  
CHAPTER 3 
119 
 
Docking Calculations Docking calculations we performed by means of 
three different programs: AutoDock4,
16
 Vina,
17
 and Glide
18
. In order to validate 
the docking protocol, we docked lactose in gal-3, obtaining results in full 
agreement with the crystallographic binding pose with the three docking 
programs AutoDock4 (RMSD = 0.727 Å), Vina (RMSD = 0.906 Å) and Glide 
(RMSD = 0.686 Å). Lamarckian genetic algorithm in AutoDock was used to 
sample different conformations of the ligands, by randomly changing the torsion 
angles and overall orientation of the molecule. A three-dimensional grid was 
defined (68 x 60 x 40 Ǻ) centered on an equidistant point to His158 and Try181. 
The grid spacing was 0.375 Ǻ, and a distance-dependent dielectric constant was 
used. The original Lennard-Jonnes and hydrogen-bonding potentials provided 
by AutoDock were also used. After docking, the 200 solutions were clustered in 
groups with root-mean-square deviation less than 1.0 Ǻ. The clusters were 
ranked by the lowest energy representative of each cluster. Calculations with 
Glide were only able to reproduce the crystallographic pose for lactose when 
two crystallographic water molecules were kept: the one close to Glu184 and 
Arg186, and the one close to Arg144 and Arg162. Van der Waals scaling factor 
and partial charge cutoff were kept as default, which are 1.0 and 0.25, 
respectively. The other parameters were kept as default as well. The key 
residues from the CRD (Trp181, His158 and Arg162) were used to generate the 
box center position, and box size was 20x26x20 grid point, being the spacing 
between points of 1 Å. The output file was generated writing 5 poses per ligand 
conformation and the RMSD for the clustering was set in less than 2 Å. 
Molecular dynamics (MD) simulations of the ligands in the free state. 
All the studied ligands were submitted to 10 ns MD simulations with explicit 
water to monitor the preferred conformations in the free state. Every dihedral 
angle was monitored observing that O5C5C6O6 dihedral angle was maintained 
around -60 in the expected gauche-gauche conformation for glucose residues, 
and around +60 in the expected gauche-trans conformation for galactose 
residues according to the conformational analysis and the literature.
19
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Molecular dynamics (MD) simulations of the gal-3 complexes. The best 
docked solutions for each ligand were considered as starting geometries to 
perform the MD simulations. GLYCAM06, Gaff, and ff99EP were used as force 
fields. All MD simulations were carried out by using the sander module in 
AMBER12 (www.ambermd.org). Four Cl- counterions were added to neutralize 
the system. Each system was then solvated by using TIP3P waters in a cubic box 
with at least 10 Ǻ of distance around the complex. The shake algorithm was 
applied to all hydrogen containing bonds, and 1 fs integration step was used. 
Periodic boundary conditions were applied, as well as the smooth particle mesh 
Ewald method to represent the electrostatic interactions, with a grid space of 1 
Ǻ. Each system was gently annealed from 100 to 300 K over a period of 25 ps. 
The system were then maintained at temperature of 300 K during 50 ps with a 
solute restraint and progressive energy minimizations, gradually releasing the 
restraints of the solute followed by a 20 ps heating phase from 100 to 300 K, 
where restraints were removed. Production simulation for each system lasted 50 
ns. Coordinate trajectories were recorded each 2 ps throughout production runs, 
yielding an ensemble of 5000 structures for each complex, which were finally 
analysed. 
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Annex III 
 
Figure 3.A1. On top 
1
H-
13
C HSQC spectrum of 1, and below NOESY 
spectrum. The dashed lines indicate the assignment along F2 of the GlcNAc 
protons showing interresidual NOE (positive) with H1GalNAc. 
 
 
Figure 3.A2. Superimposition of the ROESY (grey and red contours) and 
NOESY (black and blue contours) of 4 in different regions. While the crosspeaks 
of H5GlcNAc are of similar intensity in the ROESY and the NOESY, those 
corresponding to MeFuc are lost in the NOESY spectrum. 
 
  
CHAPTER 3 
124 
 
Table 3.A1. Interproton ROE intensities and derived distances for 4. In 
bold interresidue ROEs. 
proton proton ROE crosspeak 
intensity 
ROE derived 
distance (Å) 
Average distance (Å) 
from MD (10n) 
GalNAc     
H1 H2 strong   
 H4 Gal strong 2.2 2.2 
 H3 Gal weak 3.3 2.9 
Fuc     
H1 H2 strong  2.4 
 H3 
H3 GalNAc 
weak 
strong * 
 
2.3 
 
2.8 
 H2 Gal * strong * 2.4 2.6 
 H3 Gal very weak   
 H5 GalNAc weak (noise) 2.9 (noise) 2.8 
H5 H4 strong   
 H3 medium  2.5 
 H5 GlcNAc medium 2.4 2.7 
H6 (Me) H5 strong   
 H4 strong   
 H3 GlcNAc med/weak 2.8  
 H5 GlcNAc weak 3.0  
 H2 Gal very weak   
Gal     
H1 H5 
H3 § 
strong 
med (?) 
  
2.7 
 H4GlcNAc 
H6 GlcNAc § 
strong 
med (?) 
2.2 2.4 
 and § overlap 
 
 
Figure 3.A3. Comparison between the NOESY spectrum of 4 free in 
solution (A, C, E) and in the presence of gal-3 (B, D, F) in different regions. 
Inter-residue NOEs are annotated and marked with pink squares, intra-residue 
with grey squares.  
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Figure 3.A4. A: Average chemical shift differences for backbone amides 
{[(1H)]2 + [((15N))/2)]2}0.5 of gal-3 upon addition of 20 equivalents of 
lactose. B: Superimposition of the 
1
H-
15
N HSQC spectra of apo gal-3 (black) 
and in the presence of 20 equivalents of lactose (pink). 
 
 
Figure 3.A5. A: Average chemical shift differences for backbone amides 
{[(1H)]2 + [((15N))/2)]2}0.5 of gal-3 upon addition of 20 equivalents of 
lactose. B: Superimposition of the 
1
H-
15
N HSQC spectra of apo gal-3 (black) 
and in the presence of 20 equivalents of lactose (pink). C: Left: Region of the 
backbone 
1
H-
15
N HSQC spectra of gal-3 (in black) upon addition of 4 (left, in 
blue) and lactose (right, in pink). Right panel. Plot of the arginine region in 
the 
1
H-
15
N HSQC spectra of gal-3 (in black) upon addition of 4 (red). 
Arg186, Arg144, and Arg162 show chemical shift variations variations, 
especially Arg186 and Arg144. In contrast, Arg151, Arg129, Arg168, Arg169, 
and Arg183 do not show any perturbation upon ligand binding. 
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CHAPTER 4 
 
COMPUTATIONALLY-DESIGNED GALECTIN BINDERS WITH  
HIGH-AFFINITY PROFILE 
 
 
Synthesis of the compounds was performed at the laboratories of Prof. Stefan 
Oscarson (University College Dublin, Ireland) and Prof. José Carlos Menéndez 
(University Complutense of Madrid, Spain). NMR studies are being performed 
at the laboratory of Prof. Jesús Jiménez-Barbero (CIC bioGUNE, Derio, Spain). 
ITC studies are being performed at CIB-CSIC and IQFR-CSIC with the 
collaboration of Prof. Margarita Menéndez. 
 
4.1  Introduction 
Galectins are β-galactosides binding proteins involved in many 
physiological and pathological processes. In mammals, they exert a wide range 
of biological functions and play an important role in immune and inflammatory 
responses, and regulation of the cell cycle, among other processes. Also 
galectins have been identified as key players in cancer and immune pathologies 
pointing towards these proteins as important targets for development of drugs 
for cancer therapy and immunotherapy.
1-5
 Current research confirms the 
involvement of galectins in tumour progression and indicates that galectins 
could serve as therapeutic targets, and have prognostic value.
1
 In particular, 
galectins -1, -3, and -7 are adhesion/growth-regulatory galectins whose 
functions have been shown to be correlated among them in several tumoral 
processes.
6-7
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Galectin-3 participates in the regulation of inflammation,
8
 and mediates 
important tumor-related functions (tumorigenesis, cell adhesion, proliferation, 
differentiation, angiogenesis, metastasis), being involved in the development 
and malignancy of several types of tumor.
9
 Therefore, synthetic galectin-3 
binders have been pursued for the understanding of the molecular regulation of 
gal-3 expression and for the development of new antitumoral therapeutic 
strategies.
10-12
 Galectin-1 also acts in cellular adhesion, mobility and invasion, 
tumor-induced angiogenesis, and apoptosis, although the mechanisms of action 
in these processes are still not well understood. However, the overexpression of 
galectin-1 in cancer progression indicates that the role of galectin-1 is 
significant.
13-14
 In fact, both galectins, -1 and -3, seem to be the major players in 
cancer biology and, therefore, have stimulated significant research interest. 
However, less is known about galectin-1 pathways compared to galectin-3.
1, 15
 
Galectin-7 is one of the less well studied galectins. Information 
regarding altered galectin-7 expression between normal and tumor types is also 
mostly limited to single reports. In addition, some findings resemble the 
differences in galectin-3 expression with respect to cancer subtype and cellular 
localization. These observations further exemplify that galectin localization 
might be used to distinguish between histological subtypes.
1
 
The possibility of targeting galectins differently has been pursued as an 
interesting aim in the glycomimetics field. Selective galectin binders could help 
in cellular essays to unravel the mechanisms regulated by galectins and their 
different (and sometimes opposite roles). Moreover, selective galectin ligands 
with improved affinity would also be interesting molecules with therapeutic 
applications. Although it is known that galectins bind carbohydrates through a 
carbohydrate recognition domain (CRD), a deeper knowledge of the interactions 
that take place and the search of new binding pockets to anchorage putative 
modulators, are key factors for the development of galectin modulators.
10
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Different strategies have been followed to obtain glycomimetics 
targeting galectins with improved affinity and selectivity. Given galectins 
specifically recognize β–galactosides, an evident starting point is the 
modification of the galactose moiety to produce different monosaccharides.  
In particular, changes on the anomeric position and position 3 of the 
galactose ring have been performed. Nevertheless, the most used strategy has 
pursued the modification of disaccharide scaffolds, mainly the lactose. Chemical 
modifications include: the substitution of the glycosidic linkage in order to 
improve the glycolytic stability; the insertion of relatively long linkers on 
position 1 in order to have multivalent systems; the introduction of substituents 
in position 3 of the galactose moiety and/or positions 2 and 3 of the glucose 
moiety; and the use of other disaccharide scaffolds, such as the digalactose.
16-18
 
To date, a large number of galectin-1 and galectin-3 inhibitors have been 
synthesized, although it is scarce the information about selective galectin-7 
inhibitors.  
In rational drug design it is evident that structural information is of 
paramount importance.
19
 For example, the knowledge of the conformational 
change of Arg144 in galectin-3, in presence of aromatic ring establishing a 
cation-π interaction, has permitted the synthesis of several galectin-3 
inhibitors.
20
 However, to the best of our knowledge, there are no computer-aided 
studies for the design of galectin ligands with improved selectivity and affinity. 
In particular we are interested in the identifications of novel scaffolds 
able to lead to second generation of lactose derivatives with different selective 
binding properties towards human galectins 1, 3, and 7 that be helpful for the 
study of galectin mechanisms and putative activity as galectin modulators. We 
have undertaken fragment-based virtual screening studies to identify moieties 
which can be accommodated in the secondary pocket close to the carbohydrate 
recognition domain of the galectin. Our studies have led to the design of novel 
ligands with improved predicted binding affinity, and, putative selectivity 
towards gal-1, -3 and -7. These studies can assist in the further development of 
synthetic glycans with potential therapeutic applications.  
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4.2  Results 
4.2.1 Design of selective galectin ligands.  
From the study of galectins is very easy to underlines how CRD could be 
very similar among protein of the same family. They shared some common 
futures such as the presence of an arginine, a histidine and a tryptophan. So we 
start to explore the adjacent binding site of the CRD which is already known to 
have some conformational changes depending on the ligand interacting with 
them, such as the conformational change of the Arg144 in the galectin 3 in the 
presence of a ligand with an aromatic portion.
21
 So, we focus the attention in 
particular on galectin-1, -3 and -7 which seem to be very interesting as 
therapeutical targets. The necessity to aim to a specific galectin is mandatory. 
Given that -galactose is the molecular pattern characteristic of the 
specific recognition of all galectins, this moiety is usually maintained in the 
reported synthetic glycomimetics aiming to target galectins. Moreover the 
natural ligand for galectins is a lactose or lactosamine. Therefore, we focused 
our attention in the adjacent pocket of the CRD in order to explore the 
possibility to identify possible specific moieties with good binding properties 
(Figure 4.1). We explore this region through binding site pocket finder software 
(SiteMap).  
 
   
Figure 4.1. Surface representation of gal-1 (PDB ID 1GWZ, green), gal-3 (PDB 
ID 3ZKJ, cyan) and gal-7 (PDB ID 4GAL, magenta). 
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4.2.2 Virtual screening of a fragment library. 
Keeping the lactose as in the crystal binding pose, we performed a 
fragment-based virtual screening in the adjacent region using two different 
protocols. In particular, we used the area delimited by Ser29-Lys63-Tyr119 for 
galectin-1, Arg144-Lys176-Lys233 in galectin -3 and Lys6-Arg31-Lys64 for 
galectin-7. The surface area of these pockets was approximately 1200 Å
3
. The 
fragment library used in this work was the Maybridge data base, which contains 
more than one thousands drug-like fragments. FLAP and Glide were used as VS 
tools. The choice of the fragments was dictate from the best scoring marks.  
From FLAP virtual screening, two amino acids per galectin were chosen 
to determine the centre of two different pockets that were merged together, in 
order to study the complete adjacent pocket. Pocket extension and thickness 
were 8 and 26 for all the cases, respectively, and high accuracy performance 
option was chosen. Best fragments, i.e. fragments with a GlobScore of more 
than 0,9 (26 for gal-1, 32 for gal-3, and 30 for gal-7), were considered to build 
the methyl-lactose (OMe-Lac) based ligands. In the case of Glide, VS protocol 
comprises 3 levels of performance: High-Throughput Virtual Screening 
(HTVS), Standard Precision (SP) docking and Extra Precision (XP) docking. In 
every step, only 30% of the fragments were kept. By applying this protocol, 26 
fragments were asked to Glide to be selected for each galectin 1, 3 and 7, 
starting from the Maybridge database. An average of 25% of the fragments was 
repeated in more than one galectin by both FLAP and Glide VS protocols. 
In total, taking into account both results from FLAP and Glide, and 
alternative binding poses and possible linkage connections with the lactose 
moiety, more than 300 possible fragment poses were analyzed in order to build 
the full OMe-Lac ligands based on these fragments. Only fragments with the 
appropriate orientation and position were considered, i.e. binding pose of the 
fragment should be near lactose binding site and the linkage position should be 
oriented towards position 3 of galactose residue. Finally, 106 fragments were 
selected to build OMe-Lac based ligands (Figure 4.2).  
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Figure 4.2. Left: Scheme of the protocol applied for the virtual screening on 
each galectin. Right: Cartoon representation of galectin 3, bound to lactose. 
Yellow sphere represents the merge of two pockets used to perform virtual 
screening with the Maybridge database. 
 
4.2.3 Docking of the designed methyl-lactose derivatives. 
For synthetic reason, we designed the ligands based on the OMe-Lac 
scaffold and more than one hundred (106) structures were built using the best 
binding fragments. The three-dimensional structures were then prepared 
(minimized and charged) to docking purpose. To validate the protocol and to 
estimate an improvement of affinity we firstly perform docking studies by 
means of AutoDock4 with OMe-Lac. Then the new 106 ligands were docked at 
first in galectin-1 (PDB ID 1GZW), galectin-3 (PDB ID 3ZSJ and 1KJR) and 
galectin-7 (PDB ID 4GAL). Moreover we apply the same protocol with the 
other human galectins (galectin-2 PDB ID 5DG2, galectin-4 PDB ID 4XZP, 
galectin-8 PDB ID 4BMB, galectin-9 PDB ID 3NV4 and galectin-10 PDB ID 
1G86). 
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Focusing on galectin-1, -3 and -7 we compared the predicted docked 
poses for each designed compound with each galectin. For each compound the 
lowest energy lactose-like binding pose was taken into consideration. The 
choice of best candidates for synthesis was dictated by different criteria. Among 
lowest-energy binding poses we chose those with an improvement of energy in 
comparison with the predicted binding energy of the OMe-Lac for the same 
galectin and with a worsening of the binding energy for the other galectins, 
comparing with the OMe-Lac predicted binding energy. Among the best 
candidates, we chose compounds J013, J228 and J683 given the commercial 
availability or the synthetic accessibility of the corresponding moiety to be 
condensed to the amino-lactose (Figure 4.3).  
 
Figure 4.3. 2D representation of the best candidate compounds obtained by 
crossing the two VS protocols (FLAP and Glide). 
Preliminary results from NMR and ITC studies confirm the high affinity 
gained by the designed compounds. At the present moment of writing this 
Doctoral Thesis, the NMR and ITC experiments are not completed and we do 
not have available accurate data to be included here. Deeper analysis is in 
progress, together with MD simulations of the corresponding galectin 
complexes in order to elucidate the atomic details of the recognition processes. 
 
 
  
CHAPTER 4 
134 
 
4.3  Material and methods  
Protein Preparation: More than 150 X-ray crystallographic structures of 
human galectins are available at the Protein Data Bank
22
: 27 structures for gal-1, 
4 for gal-2, 40 for gal-3, 12 for gal-4, 15 for gal-7, 28 for gal-8, 15 for gal-9, and 
4 for gal-10. For our studies we used the X-ray structures with the following 
PDB IDs: 1GZW for gal-1, 5DG2 for gal-2, 3ZSJ and 1KJR for gal-3, 4XZP for 
gal-4, 4GAL for gal-7, 4BMB for gal-8, 3NV4 for gal-9, and 1G86 for gal-10. 
In the case of gal-3, two different structures were used in order to take into 
consideration the conformational change of the Arg144 (Figure 2.3.1). As 
shown in Figure 2.4, the presence of a ligand with an aryl group in position 3 of 
the galactose moiety induces a change in the conformation of the Arg144 side 
chain and the establishment of CH-π interaction, increasing the affinity of the 
ligand towards the protein.
28
 
  
Figure 2.4. Crystal structures of gal-3 (in green) with different ligands. Left gal-
3 complexed with lactose (represented in purple sticks, PDB ID 3ZSJ). Right: 
gal-3 complexed with L3 (represented in yellow sticks, PDB ID 1KJR). Arg144 
in both crystal structures is shown.  
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The proteins were prepared using the Protein Preparation Wizard tool 
included in Maestro.
23
 Water molecules, co-factors of crystallization and ligands 
were removed, missing atoms and cap termini were added, side chains and loops 
were filled by Prime, and hydrogens were added with Epik
24
 at physiological 
pH. For the preparation of the protein, the protonation of the main histidine in 
the CRD (His158 in gal-3) considered as HID.
25
 This final structure of the 
protein was minimized with OPLS 2005 force field as implemented in Maestro 
with implicit solvent (water). The final minimized structure was used for 
docking purposes.  
Virtual Screening of Maybridge database. To perform the virtual 
screening in galectins -1, -3 and -7 Maybridge database was imported.
26
 
Maybrige database consists of 1002 different drug-like fragments of different 
chemical composition and properties. Additional entries were added for the L2 
benzene fragment, L3 tetrafluorated benzene fragment and a naphthalene 
fragment as reference fragments with reported experimental data.
21
 The 
protonation state of every fragment at physiological pH was calculated by 
Epik.
24
 Two different virtual screening protocols were applied by means of two 
VS programs: FLAP
27
 and Glide.
28
 
VS Protocol with FLAP program. The pocket point radius was 2.0 Å and 
high accuracy performance was chosen. To explore only the adjacent accessory 
pocket of each galectin, we took in consideration the “lactose space” setting as 
macromolecule the complex of each galectin with lactose (¡Error! No se 
encuentra el origen de la referencia.). Table 4.1 shows the two aminoacids 
chosen as the centre of the pocket of each galectin. The pocket extension and 
thickness were 8 and 26 for all the cases, respectively. 
Table 4.1. Chosen aminoacids for the pocket centre to perform virtual screening 
on galectin-3, -1 and -7. 
Protein Galectin-3 Galectin-1 Galectin-7 
Centric 
aminoacids 
Arg144/Asp148 Val31/Asn33 His34/Arg32 
CHAPTER 4 
136 
 
The VS protocol was validated using Chembl database.
29
 For the 
validation protocol we use the galectin-3. In Chembl database we found 62 
known as active galectin-3 binders and 48 as inactives. So, we performed a VS 
in the pocket centred in the Trp181 with extension and thickness of 15 and 5, 
respectively.  
Building of the designed compounds. To build the designed compounds, 
OMe-Lac (βGal1-4βGlc-OMe) scaffold was used. The OMe-Lac moiety was 
obtained by means of GLYCAM
30
 carbohydrate builder tool. The selected 
fragments from VS studies (32, Glob-Prob score up to 0.9 for FLAP + Glide) 
were attached through an amidic bond to the position 3 of the galactose. These 
106 new ligands were then minimized with MMFFs force field with 
Macromodel
31
 and Gasteiger charges were added with AutoDockTools.
27
  
 
Figure 2.3.5. General structure of the novel compounds 
Validation of the docking protocols. Different docking protocols were 
applied (described below): AutoDock4,
32
 VINA
33
 and Glide.
34
 In order to 
validate the docking protocol, we docked lactose in hgal-3, obtaining results in 
full agreement with the X-ray crystallographic binding pose with the three 
docking programs AutoDock4 (RMSD = 0.727 Å), Vina (RMSD = 0.906 Å) 
and Glide (RMSD = 0.686 Å). 
Docking with AutoDock4. The same grid box coordinates and size for all 
the ligands were used in the same protein. The box size chosen was big enough 
to ensure that all ligands could be docked. A three-dimensional grid was defined 
(68 x 60 x 40 Ǻ) centered on an equidistant point to His158 and Try181. The 
centre of the box for each galectin was fixed as the centroid of the key residues 
from the CRD (Trp, His and Arg). In particular, Trp181, His158 and Arg162 
were chosen for gal-3, Trp68, His44 and Arg48 for gal-1, and Trp69, His49 and 
Arg53 for gal-7.  
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The grid spacing was 0.375 Ǻ, and a distance-dependent dielectric 
constant was used. The original Lennard-Jonnes and hydrogen-bonding 
potentials provided by AutoDock were also used. After docking, the 200 
solutions were clustered in groups with root-mean-square deviation less than 1.0 
Ǻ. The clusters were ranked by the lowest energy representative of each cluster.  
Docking with VINA. The same gridboxes used with Autodock4 were 
employed also for VINA protocol. Twenty conformers for each ligand with each 
protein were generated.  
Docking with Glide. The ligands were prepared by means of LigPrep tool 
in Maestro. Ligand minimization was performed with OPLS_2005 force field. 
The specified chiralities were retained as well as the ionization state. The same 
grid boxes in terms of size and centre were generated. Van der Waals scaling 
factor and partial charge cutoff were kept as default, which is 1.0 and 0.25, 
respectively. Unlike AutoDock4 and VINA, first a number of conformers were 
generated; the best poses were kept and posteriorly docked into the proteins. 
Standard precision Glide Docking was performed, maintaining all the default 
parameters except the partial charge cutoff of Van der Waals radii, which was 
set in 0.5, to enhance the contribution of the Trp interaction to the global 
binding energy. The output file was generated writing 5 poses per ligand 
conformation and the RMSD for the clustering was set in less than 2 Å. 
Calculations with Glide were only able to reproduce the crystallographic pose 
for lactose when two crystallographic water molecules were kept: the one close 
to Glu184 and Arg186, and the one close to Arg144 and Arg162. van der Waals 
scaling factor and partial charge cutoff were kept as default, which are 1.0 and 
0.25, respectively. The other parameters were kept as default as well. The key 
residues from the CRD (Trp181, His158 and Arg162) were used to generate the 
box center position, and box size was 20x26x20 grid point, being the spacing 
between points of 1 Å. The output file was generated writing 5 poses per ligand 
conformation and the RMSD for the clustering was set in less than 2 Å. 
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MD simulation. The best docked solutions for each ligand were 
considered as starting geometries to perform the MD simulations. GLYCAM06, 
gaff, and ff14SB were used as force fields. All MD simulations were carried out 
by using the sander module in AMBER14 (www.ambermd.org). Counterions 
(Na+ and Cl-) were added to neutralize the system. Each system was then 
solvated by using TIP3P waters in a cubic box with at least 10 Ǻ of distance 
around the complex. The shake algorithm was applied to all hydrogen 
containing bonds, and 1 fs integration step was used. Periodic boundary 
conditions were applied, as well as the smooth particle mesh Ewald method to 
represent the electrostatic interactions, with a grid space of 1 Ǻ. Each system 
was gently annealed from 100 to 300 K over a period of 25 ps. The system were 
then maintained at temperature of 300 K during 50 ps with a solute restraint and 
progressive energy minimizations, gradually releasing the restraints of the solute 
followed by a 20 ps heating phase from 100 to 300 K, where restraints were 
removed. Production simulation for each system lasted 50 ns. Coordinate 
trajectories were recorded each 2 ps throughout production runs, yielding an 
ensemble of 5000 structures for each complex, which were finally analysed. 
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CHAPTER 5 
 
TARGETING SIALIC ACID-MODIFIED RECEPTORS AS A POTENTIAL 
THERAPY FOR OSTEOARTHRITIS 
 
The results here presented constitute a collaborative work with the group 
of Dr. María D. Mayán (CellCOM-SB Research Group) from the Instituto de 
Investigación Biomédica de La Coruña (INIBIC) in Spain. Dr. Mayán conceived 
the study and members of her group conducted the experiments and analyses 
(Paula Carpintero-Fernandez, Raquel Gago-Fuentes, Marta Varela-Eirin, 
Benigno Acea, and Eduardo Fonseca). Dr. Martín-Santamaría and Alessandra 
Lacetera designed, performed and analysed the computational studies. All the 
authors discussed the results. Dr. Goldberg, shareholder of Sentrimed Inc., acted 
as scientific advisor. Sentrimed Inc. supplied reagents including the lectin 
MASL. There is a patent to declare (International Application No.: 
PCT/US2014/045229). This does not interfere with the author’s adherence to the 
journal policies on sharing data and materials.  
 
5.1. Introduction  
Osteoarthritis (OA) is the most prevalent form of arthritis and one of the 
most common diseases worldwide.
1-2
 Nearly 10% of the adult population is 
affected by OA causing considerable socioeconomic cost. OA patients suffer 
from the degradation of articular cartilage at the synovial joints. Its prevalence 
and severity increase with age, but treatments only provide symptomatic relief. 
The only option to restore joint functionality is a total joint replacement with an 
artificial device. Articular cartilage functions as a cushion to cover and protect 
the joints between bones. The cartilage is formed by an extracellular matrix 
(ECM) of collagen 2 consisting of fibrils that are integrated within an abundant 
anionic network of proteoglycan aggregates.  
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These proteoglycans and collagen fibres, along with glycoproteins and 
water, form a macromolecular network to produce a protective matrix that 
facilitates articular movement and they are synthesized by chondrocytes. OA is 
characterized by the triggering of events that lead to the degradation of the 
cartilage ECM and loss of joint function.
3
 The susceptibility of cartilage to 
arthritic degradation depends on specific posttranslational modifications of 
ECM proteins. Glycosylation is the most common posttranslational modification 
of cell surfaces and ECM proteins.
4
 As a result, chondrocytes carry a dense coat 
of carbohydrates on their surfaces. These carbohydrate moieties mediate a wide 
variety of cell-cell and cell-matrix interactions that are critical for cartilage and 
bone development and function. Carbohydrate chains vary according to cell and 
tissue type and undergo modifications during a variety of processes including 
cellular differentiation, phenotypic changes, and oncogenesis.
5-8
 The ability to 
regulate the events of signalling cascades to protect cartilage from the catabolic 
effects that induce ECM degradation will undoubtedly help to avoid or delay 
invasive therapeutic methods such as total joint replacement and to ameliorate 
the negative effects of arthritis, one the most common causes of disability that 
impacts over 350 million people worldwide. 
In particular, sialic acids are 9-carbon carboxylated sugars that are 
usually found as terminal monosaccharides.
9
 Sialyltransferases (SiaTs) transfer 
sialic acids in α-2,3-, α-2,6- or α-2,8- moieties to the N- or O-linked 
oligosaccharides of glycoproteins. The α-2,3- and the α-2,6-SiaTs show a 
mutually exclusive expression pattern and a remarkable tissue specificity. 
Specific sialylation motifs lead to differential effects of glycoproteins on 
fundamental aspects of cell behaviour including growth, migration, intercellular 
communication, inflammation, ECM production,
10-11
 and chondrocyte 
function.
6, 12-13
 Advances in clarifying the molecular mechanisms governing 
pathogenesis of OA have raised an emerging significance of glycan-protein 
(lectin) recognition in different aspects of pathophysiology. 
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 Among the glycan-binding proteins, the Maackia amurensis seed lectin 
(MASL) can bind to sialylated glycoproteins,
14-16
 in particular, to terminal -
2,3-sialylated oligosaccharides. MASL has been reported to be composed of two 
molecular species, leukoagglutinin (MAL) and hemagglutinin (MAH), although 
it is important to mention that a recent study has pointed to the presence of only 
one single species.
17
 
Specific changes in lectin and glycan presentation underlie the 
involvement of molecular recognition aspects in the pathogenesis of several 
disorders. Mayán’s group has undertaken an extensive analysis of the effects of 
the lectin MASL on primary human chondrocytes and cartilage integrity using 
samples from healthy donors and OA patients as well as animal models of 
arthritis. The results indicate that MASL preserves the structure and function of 
cartilage under diverse arthritic insults by interfering with the function of -2,3-
sialylated transmembrane receptors, such as the mucin-type transmembrane 
glycoprotein podoplanin (PDPN).
18
 These findings suggest that MASL inhibits 
the activation of signal transduction pathways that lead to progressive cartilage 
destruction during the pathogenesis of arthritis by increasing reactive oxygen 
species (ROS), inflammatory cytokines, and metalloproteinases. We propose the 
direct interaction of MASL with PDPN as a plausible mechanism for this 
protective activity of the lectin, and our computational studies have provided a 
3D molecular model for such interaction. 
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5.2. Results 
5.2.1. Molecular binding characteristics of the interaction of PDPN 
with MASL 
Dysregulation within the glycome of chondrocytes has been suggested as 
master regulators of clinically relevant inflammatory-response genes and 
cartilage degeneration.
6, 12, 19-21
 Remarkably, previous reports indicate that 
osteoarthritic cartilage degeneration is promoted by factors that shift the 
expression of -2,6-sialylated glycoproteins to -2,3-sialylated glycoproteins in 
chondrocytes.
6, 12, 21
 The results presented here indicate that MASL can target 
these -2,3-sialylated glycoproteins in cartilage and protect articular 
chondrocytes from the detrimental effects of inflammatory and catabolic events. 
In particular, our data suggest that PDPN is a functionally relevant -2,3-
sialylated glycoprotein expressed by osteoarthritic chondrocytes.  
PDPN is induced during oncogenesis and inflammatory processes.
18, 22-30
 
The PDPN receptor consists of an intracellular tail, a transmembrane domain, 
and an extracellular domain. While the intracellular tail can be modified by 
protein kinases,
24, 31
 the majority of the protein consists of a highly glycosylated 
extracellular domain that impacts PDPN signalling and can be effectively 
targeted by antibodies and lectins.
32-34
 In particular, the lectin MASL shows 
dynamic abilities to target PDPN and normalize the morphology and phenotype 
of tumour cells.
32-33
 In addition, PDPN increases matrix metalloproteinases 
(MMP) activity in tumour cells,
35-37
 and MASL, by targeting PDPN, blocks 
ECM degradation which is required for malignant cell invasion.
32-33
 Results by 
Mayán’s group indicate that MASL can protect and maintain the normal 
chondrocyte phenotype in the presence of damaging insults that would 
otherwise lead to cartilage degradation by shifting the sialylation patterns in 
chondrocyte glycoproteins and increasing the levels of ROS, MMPs and 
inflammatory cytokines (data not shown). Changes in the expression of 
sialyltransferases can reshape the arthritic cartilage glycophenotype reactivity 
contributing to activation of inflammatory pathways.  
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Additionally, previous studies have reported that TNF blockers inhibit 
PDPN expression
38
 which is upregulated in synovial cells from RA patients.
25-28, 
38-39
 Results by Mayán’s group for OA (data not shown) are consistent with 
these previous observations for tumour cells (regarding PDPN and MMP 
activity) and for RA (regarding PDPN and inflammation). Interestingly, MASL 
has been used in traditional medicine to treat inflammatory ailments including 
arthritis.
40
 However, the active ingredients that underlie this purported activity 
have not yet been identified. In this study, an affinity chromatography-purified 
and commercially available lectin was used as a pure substance
32
 to investigate 
the chondrocyte glycophenotype using various models and inflammatory 
conditions in vitro and in vivo (data not shown). 
Moreover, we have provided a computational model describing the 
molecular recognition between MASL and the sialylated glycoprotein PDPN, 
identifying the relevant interactions at atomic detail. Terminal sialic acids are 
involved in many cellular functions, and changes in their biosynthesis or 
degradation are involved in degenerative disorders such as diabetes, 
inflammatory disorders or Alzheimer's disease by affecting ligands, masking 
antigenic sites, controlling signalling pathways or regulating immunological and 
inflammatory functions.
41-43
 There is a growing interest in the targeting of 
catabolic and inflammatory signalling pathways for the prevention of cartilage 
and joint degeneration in OA and RA. Here, we focus on the lectin MASL that 
holds promise for drug discovery research for the treatment of arthritis. The 
increased levels of the α-2,3-SiaT isoforms and the corresponding increase in 
the levels of -2,3-sialylated glycoproteins in osteoarthritic chondrocytes may 
shed mechanistic light on the pathophysiology of OA. The ability of MASL to 
target sialylated glycoproteins such as PDPN, which is also induced during OA 
and RA, and to protect chondrocytes from insults leading to cartilage 
degradation might offer further possibilities for therapeutic interventions and 
novel arthritis treatments that may include the regulation of sialylation during 
acute disease stages.
25-28
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5.2.2. α-2,3-sialylated glycoproteins are induced in arthritic 
chondrocytes 
MASL was used to investigate the presence of sialic acid modifications 
in chondrocytes from normal and osteoarthritic articular cartilage. In situ 
analysis of surgical joint replacement samples (cartilage) from OA patients 
indicated that chondrocyte glycoproteins in osteoarthritic cartilage are highly -
2,3-sialylated compared with those in normal articular cartilage. Chondrocytes 
from healthy cartilage showed significantly reduced MASL binding, which was 
restricted primarily to the superficial zone. In contrast, the cartilage explants 
from OA patients showed strong MASL binding in the superficial and 
intermediate tissue zones. Expression of the α-2,3-sialylated glycoprotein PDPN 
receptor is induced during degenerative joint diseases including rheumatoid 
arthritis (RA).
25-28
 In addition, PDPN plays important roles in tissue 
development, repair, and inflammation.
18, 23-24
 For example, the binding of the 
C-type lectin-like receptor 2 (CLEC-2) to the sialylated extracellular domain of 
PDPN has been implicated in inflammatory reactions,
44-47
 and the molecular 
binding characteristics for this interaction have been recently reported.
48
 
Because MASL has a strong affinity for these types of proteins based on their 
sialic acid motifs, we sought to determine if MASL recognized PDPN in 
arthritic chondrocytes. Higher levels of PDPN were detected in the superficial 
and deeper zones of osteoarthritic cartilage in comparison with cartilage from 
healthy donors. In addition, PDPN and MASL colocalized in human 
chondrocytes. Taken together, these results indicate that PDPN expression is 
induced in osteoarthritic chondrocytes and that MASL can target PDPN on 
chondrocytes.  
  
CHAPTER 5 
149 
 
5.2.3. PDPN and MASL: structural background for the study of 
sialyllactose interaction 
We next sought to characterize the MASL/PDPN recognition at the 
atomic level using molecular modelling techniques. As previously mentioned, 
MASL is composed of two isolectins: MAL and MAH.
49
 MAL has been 
reported to preferentially bind to sialyllactose or sialyllactosamine (Figure 5.1-
top, Neu5Acα2-3Galβ1-4GlcNAc), typical structure of N-glycans, and to show a 
decreased affinity when the Galβ-1-4GlcNAc linkage is replaced by Galβ-1-
3GlcNAc.
50-51
 Conversely, MAH exhibits a higher affinity for a disialylated 
tetrasaccharide containing both -2,3- and -2,6-sialyl motifs (Figure 5.1-
bottom, Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα), present in O-glycans. A 
model of the tetrasaccharide binding MAH has already been reported.
52
  
 
Neu5Acα2-3Galβ1-4GlcNAc 
 
 
Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα 
Figure 5.1. 2D structure of the preferred Maackia amuresis ligands.  
Top: sialyllactosamine, preferred by MAL. Bottom: tetrasaccharide, preferred 
by MAH. Both sugars contain -2,3 or/and -2,6 sialyl  linkages (in grey, 
Neu5Ac). 
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The 3D structure of MAL has been resolved by X-ray crystallography 
(PDB ID 1DBN) in complex with sialyllactose (Neu5Acα2-3Galβ1-4Glc) 
(Figure 5.2). MAL has 12-stranded β-sheets and contain two metal binding sites, 
one for the manganese and one for the calcium. The sialyllactose is located in a 
cavity which can accommodate the three sugar moieties. The sialic acid 
carboxylate establishes an ionic interaction with the ammonium group of 
Lys136. The glucose is perfectly accommodated between two tyrosine aromatic 
rings (Tyr165 and Tyr250).  
 
 
 
Figure 5.2. Representation of the X-ray crystallographic structure of MAL in 
complex with sialyllactose (PDB ID 1DBN). Sialyllactose is shown in green 
sticks. Left: a general view of the complex MAL-sialyllactose. MAL is 
represented in grey cartoon-surface and manganese and calcium are shown as 
violet and green spheres respectively. Right: atomic detail of the sialyllactose-
MAL interaction. Two main interactions are established in this complex: a 
stacking interaction between the glucose of the sialyllactose and the Tyr165 and 
Tyr250. The carboxylate from the sialic acid establishes an ionic interaction 
with the Lys136 ammonium group. 
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Regarding the mucin-type sialoglycoprotein PDPN, it contains a highly 
conserved motif known as the platelet aggregation-stimulating (PLAG) 
domain,
53
 in which a disialyl core is located at the Thr52 residue (Figure 5.3), 
attached by an O-glycosilation. Under normal conditions, this disialyl core 
consists of the tetrasaccharide Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα that 
contains both the -2,3- and -2,6-sialyl motifs (Figure 5.4). PDPN is a type-I 
transmembrane glycoprotein, with an extracellular domain rich in serines and 
threonines and a short intracellular domain, putative sites for cAMP 
phosporylation and protein C kinase. The 3D structure of this disialyl core in 
complex with the C-type lectin-like receptor 2 (CLEC-2) has been elucidated by 
X-ray crystallography (PDB ID 3WSR).
48
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Figure 5.3. Sequence of three domains of the podoplanin (PDPN).In the third 
domain (PLAG 3) it is present the Thr52 (in green) which is usually 
glycosilated.  
 
Figure 5.4. 3D structure of the extracellular glycosylated moiety of podoplanin 
(PDPN) adapted from PDB-ID 3WSR. The peptidic portion is shown in green. 
Thr52 is O-glycosylated with Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα 
(shown in beige).  
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5.2.4. Computational studies of the PDPN/MASL recognition 
We were prompted to perform molecular docking of the PDPN 
tetrasaccharide core with the MASL structure to provide 3D clues regarding the 
MASL/PDPN recognition. For MAL, the X-ray crystal structure from PDB ID 
1DBN was used. In the case of MAH, a homology model was obtained by using 
the Phyre2 web portal server
54
 and MAL structure as template (see 1.3.7. 
section). MAH-sidechain was refined by performing MD simulations. The 
prediction of the binding poses of the PDPN tetrasaccharide in both MAL and 
MAH lectins was carried out by means of Glide
55
 docking program. 
All the docked poses in both proteins predicted the Neu5Acα2-3Galβ1-
3GalNAcα portion to be placed in the site defined by two serines (Ser133 and 
Ser135 in MAL and Ser102 and Ser104 in MAH), three tyrosines (Tyr165, 
Tyr160 and Tyr250 in MAL and Tyr134, Tyr129 and Tyr45 in MAH), a lysine 
(Lys136 in MAL and Lys105 in MAH) and an aspartic acid (Asp166 in MAL 
and Asp135 in MAH) (Figure 5.5). Docking binding poses place the glycolic 
chain of the Neu5Ac2-6 moiety either exposed to the solvent or interacting with 
the close Tyr (Tyr165 in MAL and Tyr134 in MAH) through hydrogen bonds. 
In both docking studies, the carboxylic group of the Neu5Acα2-3 is involved in 
an hydrogen bond with the NH group of a Ser (Ser135 in MAL and Ser104 in 
MAH) and in a ionic interaction with the ammonium group of a Lys (Lys136 in 
MAL and Lys105 in MAH). The amide NH group of the Neu5Acα2-3 
establishes a hydrogen bond with the OH group of Ser133 in MAL and Ser102 
in MAH. Also the hydroxyl groups of the galactose moiety form several 
hydrogen bonds. In particular the OH groups in position 2 and 6 interact with 
the side chains of Tyr74 and Asp166 in MAL and Tyr45 and Asp135 in MAH 
respectively. In MAL, the GalNAc unit is not perfectly fitted between the 
Tyr250 and Tyr165, due to the steric hindrance of the Tyr250 that in MAH is an 
alanine (Ala219). As consequence, the binding with MAH results to be 
favourable. Nevertheless in MAL several hydrogen bonds can take place.  
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The anomeric hydroxyl group and the NH of GalNAc moiety establishes 
hydrogen bonds with the side chain of Tyr165 and the glycolic chain of the 
Neu5Acα2-6  with the side chain of Glu253. The Neu5Acα2-6 unit, instead, 
could point to different part of the protein in consequence to the flexibility of the 
2-6 linkage. Although the predictions indicate that the binding to both lectins is 
possible, the theoretical binding energy was more favourable towards the MAH 
protein (docking score for MAL -8.431 kcal/mol anf for MAH -8.640 kcal/mol), 
in agreement with previously reported data.
50
 Analysis of the ligand-receptor 
interactions showed that the recognition of the tetrasaccharide for the sialic acid 
α-2,3- moiety shares common characteristics for both isolectins, in particular, 
polar interactions involving Ser102, Ser104, and Lys105 of MAH and Ser133, 
Ser135, and Lys136 of MAL. These results are in agreement with mutagenesis 
studies with MAH in which a loss of ligand binding is shown when the Lys105 
is mutated to Gly, or Asp135 to Asp.
56
 Differences between MAH and MAL 
became apparent when analysing the anchorage of other ligand moieties aside 
from the sialic acid α-2,3- moiety. The Galβ-1-3 moiety is well accommodated 
into the MAH binding site, while the presence of Tyr250 in the MAL lectin 
makes this anchorage difficult. Conversely, the X-ray complex of sialyllactose 
and MAL (PDB ID 1DBN) shows that the alternative glycosidic linkage (the 
Galβ-1-4 moiety instead of the Galβ-1-3 moiety) permits binding without 
hindrance from the Tyr250 side chain, thus establishing CH-π interactions and a 
polar interaction with the Glu253 carboxylate.  
 
 
 
Figure 5.5. Docked tetrasaccharide (Neu5Acα2-3Galβ1-3(Neu5Acα2-
6)GalNAcα, shown in beige) in complex with X-ray crystallographic structure of 
MAL (cyan,left) from PDB ID 1DBN and the homology model of MAH 
(magenta,right). Labels of selected residues are depicted.  
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Of note, Tyr250 and Glu253 are not present in MAH, which instead 
holds Ala219 and Ala222. Moreover, the selectivity of the tetrasaccharide for 
MAH could also be explained by the presence of positively charged residues 
(Arg81 and Lys221) in the region harbouring the -2,6 sialic acid interaction 
(Figure 5.6).  
  
Figure 5.6. Docked tetrasaccharide (Neu5Acα2-3Galβ1-3(Neu5Acα2-
6)GalNAcα, shown in beige) in complex with MAL (left) and MAH (right). 
Proteins are represented with the electrostatic potential surface. Yellow boxes 
mark the most important differences in the binding site. 
The side chains of these Arg81 and Lys221 in MAH residues establish 
hydrogen bonds interactions with the glycerol hydroxyl groups. However in 
MAL instead of the lysine and the arginine there are an asparagine (Asn110) and 
a threonine (Thr252). These two residues have side chains shorter than the 
residues of MAH, reason why Neu5Ac2-6 is not able to bind this region. The 
stability of both complexes was corroborated by 40 ns of MD simulation. Along 
all the simulation the complexes were stable according to the RMSD values 
(Figure 5.7).  
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Figure 5.7. Left: RMSD of Cα along 40 ns of MD simulation. The RMSD of 
both, the tetrasaccharide in complex with MAL (black) and MAH (in grey) are 
stable along all the simulation. Right: RMSD of the heavy atom of the 
tetrasaccharide along the MD simulation. Also in this case the RMSD shows the 
stability of the ligand in complex with MAL (black) and MAH (grey). It has to be 
mentioned that the variation of the RMSD is due to the sugar moieties 
(Neu5Acα2-6) exposed to the solvent. 
These results allow us to propose a molecular model for the interaction 
of the PDPN tetrasaccharide with the MASL isolectins MAH and MAL, in 
which the binding to both lectins is possible. Also, our models point towards a 
preferred binding towards MAH due to the establishment of stronger 
interactions than in the case of MAL. It is plausible that this molecular 
recognition mechanism involving MASL lectins could be shared by other 
sialylated glycoproteins such as the membrane-type metalloproteinases, 
integrins or CD44, providing an interesting example for the study of 
glycopeptide-lectin binding in cartilage. 
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5.3. Material and Methods  
Computational modelling of the MASL proteins. MASL is a tetramer 
formed by a MAH protein
49
 of 32 kD and a MAL protein of 37 kD. A crystal 
structure of MAL is available at the Protein Data Bank
57
 (PDB ID 1DBN) at a 
resolution of 2.75 Å. Chain A was used, the co-factors of crystallization, the N-
acetyl-D-glucosamine and the sialyllactose ligands were removed, and cap 
termini were inserted with the Protein Preparation Wizard within the Maestro 
suite 8.
58
 Manganese and calcium ions were kept. All of the water molecules 
were removed, except those involved in the coordination of manganese and 
calcium. Protonation state was established by Epik, and the calculated one was 
maintained. The protein was minimized and charges were calculated with 
OPLS2005 using water as implicit solvent.
59
  
The MAH homology model (Ref. Q7M1M0, UniProt) was generated 
with the Phyre2 web portal server
54
 using MAL (Ref. P0DKL3, UniProt) as a 
template, with a query cover of 95% and a percentage of identity of more than 
80% (Figure 5.8). The protein was prepared with the Protein Preparation 
Wizard, polar hydrogen ions were added, residues were maintained at a state of 
protonation calculated by Epik, and cap termini were added. To verify the 
stability of the model, we performed a molecular dynamics simulation of 5 ns 
using Amber12.
60
 Molecular dynamics (MD) simulation of MAH was run using 
Amber 12. The protein was hydrated with a cubic box containing explicit TIP3P 
water molecules extending 10 Å away from any protein atom to simulate an 
aqueous environment with the help of AmberTools and counter ions were added 
to neutralize the system. Before the MD simulations, the system was 
equilibrated with the following protocol: an initial 8000 steps of steepest descent 
minimization, followed by heating of the system with position restraint (constant 
force of 20 kcal mol-1 Å-2) for all protein atoms during 10 ps of MD simulation 
to increase the temperature from 100 K to 300 K, plus an additional 15 ps at a 
constant temperature of 300 K. The position restraint was gradually decreased 
during 100 ps at a constant temperature of 300 K, until the entire system was 
under no restraints with a constant temperature (300 K) and pressure (1 atm).  
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After equilibration, MD simulation was run for 20ns at a constant 
temperature (300 K) and pressure (1 atm). Short and long-range forces were 
calculated every one and two time-steps, respectively (each time-step = 2.0 fs), 
constraining the covalent bonds involving hydrogen atoms to their equilibrium 
values. Long-range electrostatic interactions were accounted for by means of the 
particle mesh Ewald approach for applying periodic boundary conditions. The 
root mean square deviation (RMSD) as a function of time with respect to the 
starting structure for the α-C atoms was computed using cpptraj. For docking 
purposes, the final snapshot (after 20 ns) was taken in consideration. 
tr|P0DKL3 MATSNSKPTQVLLATFLTFFFLLLNNVNSSDELSFTINNF 40 
tr|Q7M1M0 SDELSFTINNF 11 
   
tr|P0DKL3 VPNEADLLFQGEASVSSTGVLQLTRVENGQPQKYSVGRAL 80 
tr|Q7M1M0 MPNQGDLLFQGVATVSPTGVLQLTSEENGQPLEYSVGRVL        51 
   
tr|P0DKL3 YAAPVRIWDNTTGSVASFSTSFTFVVKAPNPDITSDGLAF 120 
tr|Q7M1M0 YTAPVRIWDSTTGAVASFSTSFTFVVKAARG--ASDGLAF 89 
   
tr|P0DKL3 YLAPPDSQIPSGSVSKYLGLFNNSNSDSSNQIVAVELDTY 160 
tr|Q7M1M0 FLAPPDSQIPSGSVSKYLGLFNNSNSDSSNQIVAVEFDTY  129 
   
tr|P0DKL3 FAHSYDPWDPNYRHIGIDVNGIESIKTVQWDWINGGVAFA 200 
tr|Q7M1M0|Q7M1M FGHSYDPWDPNYRHIGIDVNGIESIKTVQWDWINGGVAFA  169 
   
tr|P0DKL3 TITYLAPNKTLIASLVYPSNQTTFSVAASVDLKEILPEWV 240 
tr|Q7M1M0 TITYLAPNKTLIASLVYPSNQTSFIVAASVDLKEILPEWV 209 
   
tr|P0DKL3 RVGFSAATGYPTEVETHDVLSWSFTSTLEANCDAATENNV 280 
tr|Q7M1M0 RVGFSAATGAPKAVETHDVRSWSFTSTLEANSPADVDN 247 
   
tr|P0DKL3 HIARYTA 287 
            
tr|P0DKL3 =   UniProt sequence for MAL 
tr|Q7M1M0 = UniProt sequence for MAH 
 
Figure 5.8. MAL and MAH sequences alignment. The alignment between the 
MAL and MAH sequences has been performed with the T-Coffee web server.
61
 
The residue differences between the two sequences have been underlined in 
orange, indicating a high sequence similarity. Some key amino acids mentioned 
in the text are highlighted in blue (MAL: Asn110, Pro111, Tyr250, Thr252, 
Glu253; MAH: Arg81, Gly82, Ala219, Lys221, Ala222). Importantly, both 
isolectins have very similar carbohydrate binding sites. Cys272 in MAL has a 
critical role for homodimerization.
32, 62
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Computational modelling of the ligand Neu5Acα2-3Galβ1-3(Neu5Acα2-
6)GalNAcα. The tetrasaccharide Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα 
(Figure 5.1) was generated by the carbohydrate builder from GLYCAM.
63
 In the 
X-ray crystallographic structure containing CLEC-2 (PDB ID 3WSR), this 
tetrasaccharide is present attached to the PDPN and the Neu5Acα2-3 unit is 
exposed to the solvent; for this reason, the corresponding electron densities were 
missing.
48
 Eight conformations of the tetrasaccharide were generated by the 
carbohydrate builder, but only two structures fit with the X-ray crystallographic 
pose (PDB ID 3WSR).
48
 The final structures were minimized with 
MacroModel
64
 using the MM3* force field. 
Docking calculations. A set of 122 possible conformations of the 
tetrasaccharide Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα was generated 
with MacroModel
64
 by performing a conformational search with OPLS 2005 in 
the implicit solvent,
59
 and the conformations were charged with the same force 
field. The docking was performed by means of the Glide program.
55
 The 
prepared structures for MAL and MAH were employed as macromolecules. A 
cubic grid box of 25
3
 Å
3
 was generated defining the centre as the centre of mass 
between Tyr250, Tyr165, Tyr74, and Ser135 for MAL and between Ala219, 
Tyr134, Tyr45 and Ser104. A standard precision docking was applied. 
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MD simulation: The best docked solutions for MAH and MAL ligand 
were considered as starting geometries to perform the MD simulations. 
GLYCAM06, gaff, and ff14SB were used as force fields. All MD simulations 
were carried out by using the sander module in AMBER14 
(www.ambermd.org). Na
+
 counterions were added to neutralize the system. 
Each system was then solvated by using TIP3P waters in a cubic box with at 
least 10 Ǻ of distance around the complex. The shake algorithm was applied to 
all hydrogen containing bonds, and 1 fs integration step was used. Periodic 
boundary conditions were applied, as well as the smooth particle mesh Ewald 
method to represent the electrostatic interactions, with a grid space of 1 Ǻ. Each 
system was gently annealed from 100 to 300 K over a period of 25 ps. The 
system were then maintained at temperature of 300 K during 50 ps with a solute 
restraint and progressive energy minimizations, gradually releasing the restraints 
of the solute followed by a 20 ps heating phase from 100 to 300 K, where 
restraints were removed. Production simulation for each system lasted 40 ns. 
Coordinate trajectories were recorded each 2 ps throughout production runs, 
yielding an ensemble of 5000 structures for each complex, which were finally 
analysed. 
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CHAPTER 6 
 
GLYCOMIMETICS TARGETING GLYCOSYLTRANSFERASES: SYNTHETIC, 
COMPUTATIONAL AND STRUCTURAL STUDIES OF LESS-POLAR CONJUGATES 
 
The results here presented constitute a collaborative work with the group of Prof. 
Pedro Merino (Universidad de Zaragoza) and Dr. Ramón Hurtado-Guerrero (BIFI, 
Universidad de Zaragoza) in Spain. The synthesis of the molecules was carried out at 
Merino´s laboratory and X-ray crystallographic studies were performed at Hurtado-
Guerrero´s laboratory. Dr. Martín-Santamaría, Alessandra Lacetera and Mattia 
Ghirardello performed and analysed the computational studies at the CIB-CSIC. 
 
6.1. Introduction  
 Glycosyltransferases (GTs) are key enzymes responsible of the 
incorporation of carbohydrates into a variety of acceptor biomolecules, including 
proteins, lipids, oligosaccharides and different metabolites.
1-3
 The resulting 
glycoconjugates mediate a wide range of functions from structure and storage to 
signalling and, in consequence, they are related with important diseases. Therefore, 
chemical manipulation of GTs activity could lead to the development of useful 
therapeutic drugs.
4
 Because of it, considerable synthetic efforts have been directed 
toward the preparation of efficient GT inhibitors.
5-11
 Transfer of the sugar residue 
occurs from an anionic nucleotide sugar donor to the acceptor substrate; it can take 
place with retention or inversion of configuration at the anomeric centre of the sugar 
residue.
12
 In this context, the elucidation of the mechanisms used by GTs has been 
pursued with much attention.
13-18
 Of note, only nine sugar donors are known to be 
involved in protein glycosylation in mammal organisms,
19
 which is the most 
abundant post-translational modification in nature. Six of these sugar donors contain 
the uridine moiety (Figure 6.1) that is in line with the existence of GTs employing 
UDP sugars as the most predominant in nature.
20
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Figure 6.1. Uridine-based sugar donors. 
 
Most of designed inhibitors mimic nucleotide phosphate sugars by 
incorporating anionic groups to emulate binding of the diphosphate bridge.
21-24
 
However, such compounds are not capable of permeating into cells due to their high 
polarity.
25
 In order to overcome this problem, neutral inhibitors have also been 
prepared,
26-31
 and derivatives in which the phosphate group was replaced by a 
different apolar group showed enhanced cell internalization
30-31
 even though some 
reduction in binding affinity might be found. Vocadlo and co-workers demonstrated 
that UDP-5SGlcNAc acts as an inhibitor of OGT
32
 but it should be generated inside 
the cell from precursor 5SGlcNAc by using the salvage pathway. Yet, most of the 
designed compounds resulted in poor biological activity because they do not 
incorporate the nucleoside moiety loosing recognition and selectivity by the target 
enzymes.  
 Design, preparation and binding studies of less polar uridyl-sugar 
analogues 6 have been performed as suitable GT binders in which the β-phosphate 
unit has been replaced by an alkyl chain (Figure 6.2).  
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Figure 6.2. C-analogues of uridine dinucleotide sugars. 
 
Insertion of methylene (2)
33
 and replacement of the anomeric oxygen by a 
methylene (3)
34-38
 or propylene (4)
39
 groups has already been reported, but 
compounds 2-4 are still too polar due to the presence of two phosphate units (Figure 
6.2). Compound 3a has been evaluated against three bacterial UDP-galactopyranose 
mutases and showed only moderate inhibition although crystallographic studies 
showed that it is bound to the active site of the enzyme in a novel conformation not 
observed previously.
37
 As model enzyme, we have selected GalNAc-T2, a member 
of important N-acetylgalactosaminyl transferases (GalNAcTs E.C. 2.4.1.41) involved 
in mucin biosynthesis.
40-41
 In particular, a previous computational study with 
GalNAc-T2 reported by Masgrau and co-workers anticipated that UDP-2'-deoxyGal 
should not be a good donor substrate whereas UDP-Gal could be a valid sugar donor 
in some cases.
42
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Based on these precedents, analogues 6 have been designed, where one 
phosphate group has been replaced by an ethylene group, as suitable GT binders, 
exemplified on GalNAc-T2 as model enzyme. The synthetic strategy is based on 
coupling between uridine and phosphoalkyl sugars, which are prepared through 
radical hydrophosphonylation
43
 of allyl sugars.  
Through tryptophan fluorescence spectroscopy and X-ray studies have been 
demonstrated that two of these compounds bind moderately to the enzyme. In 
particular, trapping of a galactose moiety-containing compound bound to an inactive 
form of GalNAc-T2 provides hints for improving their affinity by the incorporation 
of the β-phosphate or alike negative groups. Furthermore, in silico studies support 
the aforementioned findings and as well as that the presence of only one phosphate 
group close to the sugar moiety could be enough for the uridyl-sugar analogue to 
interact with the protein. These combined studies also provide new evidences of the 
GalNAc-T2 catalytic mechanism cycle. 
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6.2. Results  
6.2.1. Crystallographic and binding studies 
In order to validate whether our compounds might have a biological effect, 
we selected the glycosyltransferase GalNAc-T2 as an exemplar. This enzyme is part 
of a large family of 20 members that transfers a GalNAc moiety from UDP-GalNAc 
onto Ser or Thr residues of proteins in the presence of manganese.
44
 This enzyme 
predominantly uses UDP-GalNAc as the sugar donor though in some cases it might 
also use UDP-galactose.
42,44
  
 
Figure 6.3. Scheme of the synthesis of partially free phosphonates. 
Prompted by this, we determined whether the compounds 14d and 14e 
(Figure 6.3), that contains a Gal and GalNAc moiety, respectively, might bind to this 
enzyme. Tryptophan fluorescence spectroscopy studies for compound 14d rendered 
Kd's of 269 ± 40 and 254 ± 20 µM, and for compound 14e rendered Kd's of 800 ± 10 
and 915 ± 180 µM, in the absence and presence of 2 mM Mn
+2
, respectively, 
suggesting that the interaction with Mn
+2
 for these ligands might not be crucial for 
their binding (Figure 6.4). Contrary to GalNAc-T2 preferences for UDP-GalNAc as 
the favourite donor substrate for catalysis, the results also suggest that the compound 
with the galactose moiety (14d) was ca. 3.5-fold better binder than the one with the 
GalNAc moiety (14e). 
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Compound 14d traps the enzyme in an inactive state. To understand the 
binding mode of these compounds to GalNAc-T2, we solved the crystal structure of 
GalNAc-T2 in complex with compound 14d. Despite numerous attempts were 
carried out with both compounds (14d and 14e) by co-crystallisation and soaking 
experiments, we only managed to get the complex with 14d by soaking experiments 
in orthorhombic crystals previously grown with UDP/Mn
+2
. The structure was solved 
at 2.07 Å, allowing us to solve and interpret the density maps (see Table 6.A1 in 
Annex VI).  
 
Figure 6.4.Quenching of intrinsic GalNAc-T2 tryptophan fluorescence 
measured at increasing concentrations of the compound 14d in the absence and in 
the presence of Mn
+2
. All data points represent the means ± S.D. for three 
measurements. The Kd for compound 14d was determined by fitting fluorescence 
intensity data against compound 14d concentration. 
 
The asymmetric unit as was reported earlier displays 6 molecules of GalNAc-
T2.
44
 Three out of six GalNAc-T2 molecules present in the asymmetric unit showed 
clearly density maps for the presence of both UDP/Mn
+2
 and compound 14d in each 
active site, while the other three remaining GalNAc-T2 molecules contained UDP 
(Figure 6.5). The crystal structure shows that the typical GT-A fold (catalytic 
domain) is located in the N-terminal region and the lectin domain is located in the C-
terminal region (Figure 6.6). 
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Figure 6.5. Compound 14d electron density map. Electron density maps are 
FO–FC syntheses (blue) contoured at 2.2  for UDP/14d, and 2FO–FC syntheses 
(blue) contoured at 1.0  for the residues Asp224, His226 and His359. The 
manganese atom is shown as a pink sphere. 
 
 
Figure 6.6. Surface representation of GalNAc-T2 in complex with compound 
14d/UDP, UDP and UDP-5S-GalNAc. Protein, flexible loop, nucleotides/compound 
14d are coloured in grey, yellow and green, respectively. The active and inactive 
states correspond to closed (4D0Z) and open (5FV9 and 2FFV) conformations, 
respectively. 
 
Strikingly, GalNAc-T2 in complex with compound 14d adopts an inactive 
state conformation, which has been reported previously for other binary complexes 
containing either glycopeptides or UDP (Figure 6.6).
40, 44-45
 Both, active and inactive 
states have been found to be determinant during the catalytic cycle of this enzyme 
and are associated to the motion of a flexible loop that can oscillate between closed 
and open conformations, respectively.  
14d
UDP (2FFV) UDP-5S-GalNAc (4D0Z)
Lectin
domain
Catalytic
domain
UDP/14d (5FV9)
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In particular, UDP and compound 14d are exposed to the solvent due to the 
open conformation of the flexible loop, whereas UDP-5S-GalNAc is covered by the 
flexible loop, which adopts a closed conformation, rendering the enzyme in an active 
state (Figure 6.6, PDB ID 4D0Z). Compound 14d induces an inverted-uridine 
conformation and an unusual 4-coordinate Mn
+2
 complex. A closer inspection of the 
active site reveals that the uridine moiety of both compound 14d and UDP adopts an 
unusual inverted conformation, which was also found earlier in a structure of this 
enzyme in complex with UDP (Figure 6.7 and PDB ID 2FFV).
45
 This atypical 
conformation was proposed to represent a final step during the catalytic cycle of 
GalNAc-T2 in which UDP was ready to exit the enzyme.
44-45
 One major difference 
stands out between both complexes: the metal is unusually 4-coordinate in our 
crystal structure, and 5-coordinate in the GalNAc-T2-UDP complex (PDB ID 2FFV; 
Figure 6.7). The metal in the former structure is coordinated by the α-phosphate, 
Asp224, His226 and His359 (Figure 6.7, A3), whereas in the latter complex, the 
metal is additionally coordinated by the UDP β-phosphate (Figure 6.7, B1 and B2). 
However, 6-coordinate Mn
+2
, which requires the previous residues, pyrophosphate 
and an extra water molecule to form an octahedral complex, is not only the most 
common coordination in crystal structures of this enzyme but also the most abundant 
in proteins in general.
40, 44-46
 These results suggest that these UDP-phosphonate 
scaffolds, with only the alpha-phosphate, are weaker ligands in terms of binding to 
GalNAc-T2 but they are still suitable binders for this enzyme.  Previously, different 
crystal structures obtained from the same type of orthorhombic crystals suggested 
that UDP might be present in both active and inactive states of the enzyme. On the 
contrary to our structure, UDP in these crystals always adopted the typical 
conformation found for UDP-GalNAc, which was required for an efficient 
turnover.
44
 Thus, it is tempting to speculate that compound 14d has allowed us to 
trap a conformation at a very final step of the catalytic cycle of this enzyme in which 
UDP would be ready for an immediate departure from the enzyme.  
The crystal structure also supports the aforementioned Kd's, confirming that 
compound 14d does not rely on Mn
+2
 for binding to GalNAc-T2. Regarding direct 
interactions between the enzyme and the nucleotides/compound 14d in the different 
complexes, it is important to mention that compound 14d shows less-interactions 
than UDP (PDB ID 2FFV) and UDP-5S-GalNAc (PDB ID 4D0Z) (Figure 6.7).  
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It is important to note that Trp331, a critical residue in the catalytic cycle of 
these enzymes,
45
 is adopting an “out” (out of the active site) conformation in the 
complex with 14d/UDP (Figure 6.7, A1) which correlates well with the inactive state 
of GalNAc-T2. On the contrary, Trp331 adopts an “in” (inside the active site) 
conformation in the complex with UDP-GalNAc that sets up the enzyme in an active 
state (Figure 6.7, C1). 
Most of the direct interactions between the uridine moiety of compound 14d 
and the enzyme are kept as the UDP from the reported PDB ID 2FFV, whereas a 
larger number of direct interactions are established between UDP-GalNAc and the 
enzyme, presumably because the active site is covered by the flexible loop (Figure 
6.6-6). Finally, the phosphonate of compound 14d does not interact directly with any 
residue and the galactose moiety is recognised exclusively by Glu334 (Figure 6.7, 
A2), likely explaining the poor binding of this compound to the enzyme. In fact, in 
the docking studies, we found that the Gal moiety adopts several alternative binding 
poses within the sugar site. 
6.2.2. Docking Studies 
In order to have a 3D picture of the putative binding ability of this family of 
compounds, docking calculations were performed for analogues 14 in both 
conformations of GalNAc-T2: closed (active, PDB ID 4D0Z) and open (inactive, 
PDB ID 2FFV). The calculations were able to predict reasonable docked binding 
poses for all the ligands, although with some slight differences. UDP, UDP-GalNAc, 
and UDP-5S-GalNAc were also docked for comparison purposes in order to validate 
the computational protocol. Interestingly, all the compounds were predicted to bind 
in both conformations (open and closed) inside the active site of the enzyme with 
binding poses similar to those found in the crystallographic structures. For the 
subsequent studies, the best predicted binding poses in terms of binding energies 
from Glide were taken into consideration.  
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Figure 6.7. Structural features of the sugar nucleotide binding site for the 
GalNAc-T2 in complex with UDP/14d. Panel A1 shows a close-up view of the active 
site in complex with UDP-Mn
+2
/14d. Panel A2 shows a detail on metal interactions. 
Panels A3 and A4 depict a 2D scheme of the interactions between 14d and UDP, 
respectively, and the residues of GalNAc-T2. Panels B1 and C1 show a close-up view 
of the active site in complex with UDP/Mn
+2
 and UDP-5S-GalNAc-Mn
+2
, 
respectively. Panels B2 and C2 depict a 2D scheme of the interactions between the 
ligands and the residues of GalNAc-T2. The nucleotides are depicted as green 
carbon atoms with the exception of UDP in the crystal structure with compound 14d, 
which is depicted with orange carbon atoms. Protein residues of the active site and 
the flexible loop are illustrated as grey and yellow carbon atoms, respectively. The 
manganese atom and a water molecule are shown as lilac and red spheres, 
respectively. Hydrogen bonds and protein/UDP-Mn
+2
 coordination are depicted as 
black dashed lines. 
Predicted binding energies were higher in comparison to the reference 
diphosphate compounds, due to the consequently decreased ionic phosphate-
manganese interaction caused by the lack of the -phosphate group (Table 6.1).  
Table 6.1. Values of predicted binding energy from Glide docking 
Predicted binding energy with 2FFV  
(in kcal/mol) 
Predicted binding energy with 4D0Z  
(in kcal/mol) 
UDP UDP-
GalNAc 
14d 14e UDP UDP-
GalNAc 
14d 14e 
-6,642 -6,217 -6,57 -4,075 -8,651 -9,41 -6,73 -8,511 
 
Even though, docked binding energies were favourable, thus validating the 
phosphonate scaffold of analogues 14 as a possible platform for the optimization of 
GTs binders.  
E334
H226H359
D224
UDP-5S-GalNAc (4D0Z)
Polar/Hidrophobic interactions Metal/Metal coordination
UDP (2FFV)
UDP/14d (5FV9)
A1 A2 A4
B1 B2 C1 C2
H359
R201
D176
Mn2+
D224
L204H226
E334
S207
H359
R201
D176
Mn2+
D224 L204
H226
S207
R362
A3
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The best binding energies were always predicted for the active (closed) 
conformation, in agreement with a binding pose with more GalNAc-T2/ligand 
interactions, although the docking results pointed to the ability to bind also to the 
open conformation, which in fact, is preferred in the crystal structure. Probably, both 
possibilities might co-exist in the equilibrium of the conformational ensembles. 
Docking calculations are able to estimate both binding poses while the limitations of 
X-ray, in this case, have not allowed us to obtain the closed 3D structure. No main 
differences in the predicted binding energy were found among the phosphonate 
analogues 14, pointing to a lack of preferred binding. For compounds 14, the main 
contributions to the binding are provided by the uridine-enzyme H-bonds as in the 
4D0Z complex, and, to a lesser extent, from the ionic phosphonate-Mn
+2 
interaction 
through one or two of the phosphonate oxygens. 
In the case of the active conformation of the GT, an interesting difference was 
found regarding the binding of the sugar moiety of analogues 14, which also showed 
alternative binding poses where the sugar moiety reaches Ala307 CO group and 
Asn146 side chain, according to the highly flexible aliphatic chain. For the inactive 
conformation of GalNAc-T2, the docking calculations placed the synthetic analogues 
in the equivalent region than in the case of the active conformation (Figure 6.8).  
The uridine moiety is observed to rotate in a similar way to the 
crystallographic pose, and the overall conformation of the ligand was found to adopt 
a more bended conformation, with the sugar moiety placed in front of the uridine 
plane. For comparison purposes we performed docking calculations for 14d to our 
crystallographic structure (PDB 5FV9, chain "B") finding similar results between the 
crystallographic pose for 14d and the docked pose for UDP-GalNAc. 
We conclude, from the overall docking study, that compounds 14 are putative 
GalNAc-T2 binders where the uridine moiety plays the major role in the binding in 
agreement with the crystallographic binding poses, while the phosphonate group and 
the sugar moiety provide additional interactions, not finding differences among the 
type of sugar.  
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Figure 6.8. Left panel: Superimposition of docked poses in GalNAc-T2 (PDB-
ID 2FFV) of compound 14d (cyan) and UDP-GalNAc (purple). Open loop is shown 
in yellow. Right panel: Superimposition of docked poses in GalNAc-T2 (PDB-ID 
4D0Z) of compound 14d (cyan) and UDP-GalNAc (purple). Closed loop is shown in 
magenta. 
6.2.3. tMD simulation 
In order to shed light into the conformational changes that the protein needs 
to suffer from the inactive to the active conformation (opening/closing process), and 
to analyze the required interactions to host the substrate, targeted molecular 
dynamics (tMD) simulation was undertaken for the GalNAc-T2/UDP-GalNAc 
complex. The simulation was started from the complex in the inactive open 
conformation (from the docked binding pose) towards the complex in the active 
closed conformation (from the docked binding pose of UDP-GalNAc, very similar to 
the crystallographic complex with UDP-5S-GalNAc) (Figure 6.7). The analysis of 
the root mean square fluctuation (RMSF) (Figure 6.9) during the tMD simulation 
time identified a main fluctuation corresponding to the flexible loop Arg362-Ser373 
with a maximum value for Pro370. This main change corresponds to the folding of 
the loop over the substrate, sealing it in the active site, and leading to the closed 
conformation. Additionally to Asp224, His226 and His359 side chains, Mn
+2
 ion was 
found to coordinate with two phosphate oxygens (Figure 6.10). During the 
progression of the tMD simulation, one water molecule entered into the coordination 
sphere, according to a 6-coordinate Mn
+2
 model (Figure 6.10). 
Asp176
Arg201
Tyr367
Arg362
His365
His145
Asn146
Asp176
Arg201
Tyr367
Arg362
His365
His145
Asn146
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Figure 6.9. Root mean square fluctuation (RMSF) for the C atoms for 
GalNAc-T2 in complex with UDP-GalNAc during the tMD simulation. Values 
corresponding to the flexible loop Arg362-Ser373 are marked in yellow. 
 
 
Figure 6.10. Left: Distances between the Mn
+2
 ion and the phosphate oxygens 
(alpha -a- and beta -b-) along the tMD simulation time. Right: Distances between the 
Mn
+2
 ion and one water molecule along the tMD simulation time entering into the 
coordination sphere. 
 
Several functional groups from the GalNAc-T2 are establishing interactions, 
especially those involving the uridine moiety. In particular, the NH in position 3 of 
the uracyl ring establishes a stable hydrogen bond along the simulation with the 
Asp176 side chain (Figure 6.11-right and Figure 6.12). The CO groups at positions 2 
and 4 of the uracyl ring are establishing alternating hydrogen bonds with Arg201 and 
Thr143 side chains (Figure 6.11-right and Figure 6.13-13) during the rotation of the 
uridine. This rotation is allowed for the torsional change undergone by the 
diphosphate linker. Also stacking interactions between the His145 side chain and the 
uracyl moiety are identified. Most of these interactions are always found in the 
crystallographic structures in agreement with a specific anchorage for the uracil 
moiety. On the contrary, the flexibility of the diphosphate linker allows the GalNAc 
to rotate and move in the closing process, changing the interactions along the 
simulation, adapting to the new surrounding environment. 
0
4
8
12
70 170 270 370 470 570
R
M
S
F
 (
Å
)
Residue number
CHAPTER 6 
178 
For example, in the inactive conformation, the GalNAc is involved in two 
hydrogen bonds: one between the endocyclic GalNAc oxygen and the Arg362 
backbone NH, and another one between the N-acetylamido CO group and the 
Arg362 guanidium group. After the closing, these interactions with the Arg362 are 
lost, and new hydrogen bonds are established: one between the GalNAc OH-3 and 
the backbone NH of Gly309; and another one between the OH-4 from the GalNAc 
moiety and the Ala307 CO group. Moreover new CH-π interactions are formed 
between the ribose and the Tyr367 indole ring. 
 
Figure 6.11. Superimposition of five structures of the GalNAc-T2/UDP-
GalNAc complex along the tMD simulation of the transition from the open (black, 
loop in yellow) to the closed (white, loop in magenta) conformation. Intermediate 
protein structures are shown grading from yellow (starting geometry), orange 
(intermediate geometries) to magenta (final target geometry).  Ligand UDP-GalNAc 
is shown in yellow for the open complex, and in magenta for the closed complex. 
Left: Full perspective. Right:  Detail showing some representative residues. 
 
 
Figure 6.12. Distance between the two carboxylate oxygens (each distance is 
represented in orange and blue colours) from Asp176 side chain and the NH in 
position 3 from the uracyl along the tMD simulation time. 
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Figure 6.13. Superimposition of five structures of the GalNAc-T2/UDP-
GalNAc complex along the tMD simulation of the transition from the open (black, 
loop in yellow) to the closed (white, loop in magenta) conformation. Intermediate 
structures are shown grading from yellow (starting geometry), orange (intermediate 
geometries) to magenta (final target geometry). Ligand UDP-GalNAc and Mn
+2
 ion 
are shown in magenta for the closed complex. 
 
 
Figure 6.14. Superimposition of docked pose in GalNAc-T2 (PDB-ID 5FV9) 
of UDP-GalNAc (magenta). Crystallographic pose of UDP is shown in green as 
reference. 
Summarizing, the tMD may give us an approximation to the binding pose 
changes that the UDP-GalNAc suffers in the closing/opening process when bound to 
the GT. The specific interactions for the GalNAc in the closing/opening process may 
be useful to understand the catalytic mechanism cycle of this enzyme, and to help for 
the designing of selective GT binders. In fact, we provide a plausible explanation for 
the role of the N-acetylamido group in the binding, which supports its higher affinity 
to the enzyme in comparison to UDP-Gal. 
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6.3. Material and Methods  
Macromolecule preparation. Two X-ray crystal structure of GalNAc-T2 were 
selected: one in the closed active conformation (PDB ID 4D0Z, in complex with 
UDP-5S-GalNAc, EA2 peptide and Mn
+2
), and the second one in the open inactive 
conformation (PDB ID 2FFV, in complex with UDP and Mn
+2). Chain “A” was 
selected in both PDB structures. All water molecules, ethylene glycol and ligands 
were removed, while Mn
+2
 ions were kept. By using the Maestro package,
47
 missing 
residues were added and modeled, and neutral terminal N and C groups and 
hydrogen atoms were added. Charges were assigned to all atoms with OPLS_2005 
force field, and the final protein structure was finally minimized with the same force 
field. 
Ligand preparation. 3D structure for UDP was extracted from PDB 2FFV. 
3D structure for UDP-GalNAc was built from the 3D structure of UDP-5S-GalNAc 
from PDB 4D0Z. UDP-5S-GalNAc was also prepared for docking as a reference 
compound. The 3D structure of compounds 16 were built from their SMILES codes. 
All ligands were subjected to geometry optimization by using the MMFFs force filed 
implemented in Maestro. This method was chosen comparing the docking results for 
reference compounds by applying different force fields. 
Docking calculations. Docking was performed by means of Glide program
[41]
 
and AutoDock4 program.
48
 In Glide, a cubic grid box of 25
3
 Å
3
 was generated for 
each protein, defining as centre the centre of mass among Asp176, His145, Arg362, 
and His226 residues. For all the ligands, the torsional angles were allowed to rotate 
with no restrictions. A standard precision docking was performed for both structures. 
In the case of AutoDock, different conformers of the starting geometries of the 
ligands were docked by using the Lamarckian genetic algorithm, by randomly 
changing the torsion angles and overall orientation of the molecule. A volume for 
exploration was defined with a grid spacing of 0.375 Å, centered on the centre of 
mass among Asp176, His145, Arg362, and His226 residues, and a 3D grid of 21 × 
18 × 19 Å
3
 for 4D0Z, and 21 × 21 × 18 Å
3
 for 2FFV. After docking, the 200 
solutions were clustered in groups with root mean-square deviations less than 2.0 Å. 
The clusters were ranked by the lowest energy representative of each cluster.  
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Docking results from both Glide and AutoDock methods were analysed and 
taken together for the discussion. 
Targeted molecular dynamics (tMD) simulation. The tMD simulation was 
performed with the AMBER12 software
49
 by using the ff10, gaff and Glycam force 
fields.  The Cα atoms of the starting structure (GalNAc-T2 in complex with UDP-
GalNAc in the open conformation) were restrained to the corresponding positions of 
the target structure (GalNAc-T2 in complex with UDP-GalNAc in the closed 
conformation). Explicit water solvent (TIP3BOX model) was considered by adding 
the same number of water molecules to both complexes. Also, the same number of 
counterions (4 chlorine ions) was added. Energy minimization of all the initial 
structures (closed and open states) was carried out using the steepest descent method 
in AMBER12 for 500 steps and the non-bonded cut off was 9 Å. For the tMD 
simulation, the SHAKE algorithm was used, the time step was 0.002 ps, and the non-
bonded cut off was 15 Å. The temperature coupling method was used to keep the 
temperature constant at 300 K and Berendsen temperature coupling scheme was 
used. No positional restrains were applied. The total simulation time was 5 ns. 
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Annex VI 
Table 6.A1. Data collection and refinement statistics. Values in parentheses 
refer to the highest resolution shell. Ramachandran plot statistics were determined 
with PROCHECK. 
 GalNAc-T2-14d 
Space group P212121 
Wavelength (Å) 0.97 
Resolution (Å) 
20-2.07 
(2.124-2.07) 
Cell dimensions (Å) 
a =116.49 
b = 121.75 
c = 250.15 
Unique reflections 215817 
Completeness 99.8 (99.84) 
Rsym 0.061 (0.632) 
I/(I) 15.6 (2.6) 
Redundancy 5.7 (5.7) 
Rwork / Rfree 0.189/0.246 
RMSD from ideal geometry, bonds (Å) 0.017 
RMSD from ideal geometry, angles (º) 1.996 
<B> protein (Å2) 48.81 
X1<B> Ethlenglycol (Å2) 64.24 
<B> Glycerol (Å2) 71.18 
<B>  DRG(Å2) 64.33 
<B>  UDP (Å2) 47.52 
<B> Mn+2 (Å2) 32.78 
<B> solvent (Å2) 49.87 
Ramachandran plot: 
Most favoured (%) 
Additionally allowed (%) 
Disallowed (%) 
 
93.37 
5.09 
1.53 
PDB ID 5FV9 
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CONCLUSIONS 
 
Molecular modelling techniques have been extensively applied to the elucidation 
of glycan-protein interactions at the atomic level of several systems with biological 
interest, and have provided new insights for the understanding of the molecular 
recognition events underlying the biological functions of these systems. 
 
A pluridisciplinary approach, in a collaborative work with experimental groups, 
has been carried out for the study of carbohydrate-protein interaction. Molecular 
modelling studies have assisted to NMR experimental methods to unravel the molecular 
recognition features of a biologically relevant trisaccharide (trimannoside) with Pisum 
sativum lectin as a model lectin. This combined study has required the use of synthetic 
fluorinated complex glycan mimics to provide detailed structural and binding 
information for every sugar ring, allowing the elucidation of the interacting ligand 
epitope and the bound conformations. Computational techniques have been proved to 
assist the 
19
F NMR experiments and to provide the necessary 3D perspective for the 
elucidation of this example of molecular recognition of high complexity. 
 
The interaction of a series of glycans with human galectin-3 has been studied, 
pointing out to the subtle differences in the recognition event. By means of combined 
molecular modelling and NMR techniques, we have identified the ligand-receptor 
interactions accounting for the gal-3 recognition of three glycans containing the 
lacdiNAc motif: blood group A type II tetrasaccharide, and two compounds derived 
from the important xenoantigen α-Gal epitope. Our findings have unravelled important 
details at atomic level of the gal-3 recognition. 
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Computational studies of human galectin-1, -3 and -7, focused on the binding 
pocket adjacent to the CRD, have provided structural basis for a fragment-based design 
of novel galectin binders with predicted selectivity and high affinity. In collaboration 
with other groups, selected compounds have been synthesized and preliminary NMR 
and ITC results are very promising. These selective ligands may contribute to the 
understanding of the highly relevant biological functions of galectins, and their role in 
cancer. 
 
A computational model for the interaction of the PDPN epitope  
(Neu5α2-3Galβ1-3(Neu5α2-6)GalNAc) and Maackia amurensis seed lectins isoforms 
has accounted for the protective action of these lectins against cartilage degradation in 
osteoarthritis (OA). The docking of the tetrasaccharide shows the preference of this 
ligand to bind MAH isoform, due to the presence of disialyl-core and the specific Galβ-
1-3GalNAc glycosidic linkage. The increased levels of the α-2,3-SiaT isoforms and the 
corresponding increase in the levels of -2,3-sialylated glycoproteins in osteoarthritic 
chondrocytes may shed mechanistic light on the pathophysiology of OA. The ability of 
MASL to target sialylated glycoproteins such as PDPN, which is also induced during 
OA and rheumatoid arthritis and to protect chondrocytes from insults leading to cartilage 
degradation might offer further possibilities for therapeutic interventions and novel 
arthritis treatments that may include the regulation of sialylation during acute disease 
stages.  
 
GalNAc-T2 has been used as a prototype GT for studying the binding mode of 
less-polar glycomimetics. In particular, from the docking studies it is inferred that the -
phosphate is required for binding to the Mn
+2
, and thus the replacing of the -phosphate 
while keeping the phosphate or alike groups in the  position should maintain or 
improve the binding of these compounds. Finally, the tMD simulation of the complex of 
GalNAc-T2 with UDP-GalNAc has provided new insights on the substrate recognition 
events involved in the preliminary steps of the catalytic cycle of GalNAc-T2. 
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CONCLUSIONES 
 
Se han empleado técnicas de modelado molecular para la elucidación a nivel 
atómico de las interacciones carbohidrato-proteína de varios sistemas con interés 
biológico y terapéutico. En concreto, se han estudiado los siguientes sistemas: galectinas 
humanas -1, -3 y -7, lectina de Pisum sativum, lectina de semillas de Maackia 
amurensis, y la glicosiltransferasa GalNAc-T2. Nuestros estudios han permitido aportar 
nuevas perspectivas para la comprensión de los procesos de reconocimiento molecular 
implicados en las funciones biológicas de estos sistemas.  
 
Se ha llevado a cabo un estudio pluridisciplinar, en colaboración con grupos 
experimentales, abordándose el estudio de los modos de unión de una trimanosida 
trifluorada, con enlaces α1 → 3 y α1 → 6, y sus derivados disacáridos fluorados, con 
una lectina modelo de Pisum sativum, combinando los estudios computacionales con 
datos experimentales de 
19
F-RMN. Para llevar a cabo este estudio, se han empleado 
glicómiméticos fluorados sintéticos para la elucidación de detalles estructurales y de la 
interacción de cada manosa fluorada con la proteína, identificando el epítopo y las 
conformaciones de unión. Este tipo de estudio no hubiera sido posible sin la presencia 
del flúor. Las técnicas computacionales han proporcionado la perspectiva 3D necesaria 
para la elucidación de este ejemplo de reconocimiento molecular de gran complejidad, 
sineod así un soporte importante de los experimentos de 
19
F-RMN. La combinación de 
los datos experimentales de modelado y los datos de RMN indica la coexistencia de dos 
modos de unión diferentes para la trimanosida trifluorada cuando se une a la lectina de 
Pisum sativum. Este ejemplo ilustra la complementariedad entre estas dos técnicas para 
la elucidación de problemas complejos de reconocimiento molecular donde las técnicas 
experimentales no pueden proporcionar una respuesta completa. 
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Se ha abordado un estudio computacional de la unión de varios ligandos de β-
galactósido (lactosa, LacdiNAc y tres glicanos que contienen el motivo LacNAc: 
tetrasacárido del grupo sanguíneo A tipo II, y dos compuestos derivados del importante 
epítopo α-Gal de xenoantigeno) hacia la galectina-3 humana. Los epítopos LacdiNAc y 
α-Gal contienen el motivo LacNAc, que ha sido propuesto como patrón molecular para 
la respuesta inmune mediada por galectina-3. Se han caracterizado las interacciones 
clave necesarias para la unión a la galectina-3, identificando la sutileza de las diferencias 
en el evento de reconocimiento, mediante técnicas combinadas de modelado molecular y 
RMN. Utilizando este enfoque combinado, se han descrito a nivel atómico las 
interacciones ligando-receptor que caracterizan el reconocimiento de la gal-3 por los 
epítopos LacdiNAc y α-Gal. 
 
Se ha realizado el diseño computacional de nuevos ligandos selectivos de 
galectinas y con mejor afinidad teórica. En particular, hemos centrado nuestros estudios 
en las galectinas -1, -3 y -7, involucradas en la adhesión, crecimiento y regulación 
celular, que además participan en varios procesos tumorales. Nuestro diseño 
computacional se ha centrado en el bolsillo de unión adyacente al dominio de 
reconocimiento de carbohidratos. Esto nos han proporcionado una base estructural para 
llevar a cabo un diseño basado en fragmentos de nuevos ligandos de galectina con 
selectividad y alta afinidad. Con esta aproximación, identificamos los mejores 
fragmentos capaces de anclarse a este bolsillo en cada una de las galectinas y diseñamos 
derivados de lactosa incorporando los mejores fragmentos en su estructura. En 
colaboración con otros grupos, se han sintetizado algunos compuestos seleccionados y 
los resultados preliminares de RMN e ITC son muy prometedores. Estos ligandos 
selectivos pueden contribuir a la comprensión de las funciones biológicas de las 
galectinas, altamente relevantes, y su papel en el cáncer. 
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Se ha propuesto un modelo computacional para la interacción del epítopo de 
podoplanina (PDPN) (Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc) con las isoformas de 
lectina de semilla de Maackia amurensis (MASL), explicando la acción protectora de 
estas lectinas en la degradación del cartílago en la osteoartritis (OA). Hemos explorado 
el sitio de unión de las dos especies moleculares de la MASL, la leucoaglutinina de 
Maackia amurensis (MAL) y la hemaglutinina de Maackia amurensis (MAH), y el 
posible reconocimiento por el epítopo de la glicoproteína podoplanina. La capacidad de 
MASL de unirse a glicoproteínas sialiladas como la podoplanina, que se inducen durante 
la osteoartritis y la artritis reumatoide, protege a los condrocitos de insultos que 
conducen a la degradación del cartílago. Este mecanismo puede suponer nuevas formas 
de intervención terapéutica y nuevos tratamientos para la artritis que incluyan la 
regulación de sialilación durante estadios agudos de la enfermedad. En particular, la 
unión del tetrasacárido (Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc) muestra la 
preferencia de este ligando para unirse a la isoforma de la MAH, debido a la presencia 
de dos unidades de acido siálico y a la presencia del enlace glucosídico específico 
Galβ1-3GalNAc. Los resultados experimentales indican que la MASL preserva la 
estructura y la función del cartílago bajo diversos insultos artríticos interfiriendo con la 
función de los receptores transmembrana α-2,3-sialilados, tales como la glicoproteína 
transmembrana podinaplanina de tipo mucina (PDPN). Se propone la interacción directa 
de MASL con PDPN como un mecanismo plausible para esta actividad protectora de la 
lectina, y nuestros estudios computacionales han proporcionado un modelo molecular 
3D para dicha interacción. 
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Se ha estudiado el modo de unión de una serie de miméticos sintéticos de 
nucleósidos como inhibidores de una glicosiltransferasa modelo, la GalNAc-T2. Estos 
análogos de nucleótidos son compuestos menos polares derivados de la uridina que 
contiene sólo el β-fosfato y podrían ser ligandos eficaces para la inhibición de la enzima, 
como se deduce de los datos experimentales. Hemos propuesto un modelo 3D 
computacional para el modo de unión de estos ligandos para proporcionar más 
información sobre el mecanismo del ciclo catalítico de esta familia de enzimas. En 
particular, a partir de los estudios de modelado molecular se deduce que la sustitución de 
uno de los fosfatos (el de la posición β respecto a la desoxirribosa), mantiene la 
capacidad de unión. Los estudios de docking sugieren que estos análogos menos polares 
son posibles ligandos de GalNAc-T2, donde la parte de la uridina desempeña un papel 
principal en el enlace, de acuerdo además con los modos de unión observados en las 
estructuras cristalográficas. El grupo fosfonato y el azúcar establecen interacciones 
adicionales, no encontrándose diferencias al estudiar otros tipos de azúcar. Además, la 
simulación de tMD nos ha dado ha permitido estudiar los cambios en la pose de unión a 
la GT que el UDP-GalNAc sufre en el proceso de cierre/apertura. Las interacciones 
específicas de GalNAc en este proceso de cierre/apertura pueden ser útiles entender el 
ciclo del mecanismo catalítico de esta enzima y para el diseño de ligandos selectivos de 
GT. De hecho, nos han proporcionado una explicación plausible para el papel del grupo 
N-acetilamido en el enlace, que apoya su mayor afinidad a la enzima en comparación 
con la UDP-Gal. 
 
